

JIGNESH K. PATEL, M.D., PhD

CURRICULUM VITAE

April 2nd, 2021

PROFESSIONAL CONTACT INFORMATION

Business Address: Cedars-Sinai Medical Center
8700 Beverly Blvd
Los Angeles, CA 90048

California Heart Center
8670 Wilshire Blvd, 2nd Floor
Beverly Hills, CA 90211

Phone: (310) 248-8300
Fax: (310) 248-8333
Email: Jignesh.Patel@cshs.org

EDUCATION

Undergraduate 1983 – 1986

University of Cambridge, Cambridge, England, UK

Medical Education 1986 – 1989

Guy's Hospital, United Medical & Dental Schools, University of London, UK

Internship 1990

Surgical Internship, Guy's Hospital, London, UK.

Medical Internship, Lewisham Hospital, London, UK

Residency 1993-1995

Internal Medicine Residency Program

The Cleveland Clinic Foundation, Cleveland, Ohio

Fellowship 1996 -2000

Division of Cardiology, Department of Medicine,

UCLA Medical Center, Los Angeles, CA

LICENSURE

California State Medical License #A056000

Ohio (Temporary) #0006199

ECFMG# 0-419-782-8

DEA #BP5256602

General Medical Council of UK #3338843

BOARD CERTIFICATION

NBE, Certification Board of Nuclear Cardiology (2001)

ABIM, Cardiovascular Diseases – (2009 - 2020)

ABIM, Advanced Heart Failure/Transplant Cardiology (2010 -2020)

PROFESSIONAL EXPERIENCE

Present Position:

2015 – Present	Clinical Professor of Medicine, Cedars Sinai
2010 – Present	Director, Heart Transplant Research, Cedars Sinai Heart Institute
2009 – Present	Medical Director, Heart Transplant Program, Cedars Sinai Heart Institute
2009 – Present	Associate Clinical Professor, David Geffen School of Medicine at UCLA

Previous Position:

1990 – 1992	Senior House Officer Northwick Park Hospital and Clinical Research Centre, London, UK
1993	Registrar in Medicine Pulmonology and Internal Medicine, Guy's Hospital, London
2003 – 2009	Associate Medical Director, UCLA Heart Transplant Program

PROFESSIONAL ACTIVITIES

1992	Royal College of Physicians of the United Kingdom
1994	American College of Physicians
1996 – Present	American College of Cardiology
1999	American Society of Transplantation Thoracic Committee Member
1999	Scientific Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association
1999 – 2000	Co-chair, Fellows-in-Training Section, California Chapter, American College of
2000 – 2009	Consultant Cardiologist, Ahmanson-UCLA Cardiomyopathy Center
2000 – Present	International Society of Heart and Lung Transplantation

2001	American Society of Nuclear Cardiology
2003 – 2009	Radiation Safety Officer, University Cardiovascular Medical Group
2015	Abstract Selection Committee ISHLT
2015	Program Committee ISHLT
2016 – 2018	Heart Failure and Transplantation Council Vice-Chair
2017 – Present	Associate Editor, Current Transplantation Reports
2018	Heart Failure and Transplantation Council Chair
2018	Scientific Advisory Board of the International Academy of Cardiology, 23 rd World Congress on Heart Disease, Boston, MA
2018 – Present	ACC Heart Failure and Transplant Section Leadership Council
2018 – Present	Associate Editor, American Journal of Transplantation

CSMC Professional Activities

2011 – Present	Heart Transplant Executive Committee
2016 – Present	Heart Transplant Selection Committee
2017	Chair, Performance Improvement Group, Comprehensive Transplant Center, Cedars-Sinai Medical Center
2017	CS-Link Ambulatory Clinical Content Review
2017 – Present	Chair, Transplant Committee, Comprehensive Transplant Center, Cedars-Sinai Medical Center
2017 – Present	Chair, Heart Transplant M & M committee
2018 – Present	Heart Failure Research Steering Committee
2019 – Present	CS-Link Optimization Team (CCOT) Committee
2020 – Present	OneLegacy Organ Procurement Organization Liaison
2020 – Present	CS-Link (EHR) Clinical Content Committee
2020 – Present	Online Media TCC COP Committee

Other Professional Activities

2017	Journal Reviewer, Journal of Heart and Lung Transplant
2017	Journal Reviewer, American Journal of Transplantation
2018	Manuscript Reviewer, American Medical Association
2020	Manuscript Reviewer, The American College of Cardiology Foundation (ACCF)
2021	Manuscript Reviewer, The American College of Cardiology Foundation (ACCF)

HONORS AND SPECIAL AWARDS

1986	Travel Awards: The Royal Society of Tropical Medicine & Hygiene; The Royal College of Pathologists; The Wellcome Trust
1988	The Richard Ellis Prize in Paediatrics, Guy's Hospital, London
1996	Awardee, Specialty Training and Advanced Research (STAR) Program
1998	Nominee, Fellows Teaching Award, Internal Medicine Residents, UCLA
1999	Chief Cardiology Fellow, UCLA Medical Center
2020	Jon A. Kobashigawa AHF Fellow Teaching Award, Cedars Sinai
2021	Certificate of Excellence for Patient Experience

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:

Active/Ongoing:

ALL IN/NIH 1U01AI136816-01 Madsen (PI) 05/01/2018-4/30/2020

Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab. The primary objective of the study is to compare the efficacy of standard of care triple maintenance immunosuppression plus tocilizumab treatment versus standard of care triple maintenance immunosuppression plus placebo on outcomes as defined by a composite 1 year post-transplant endpoint of a) detection of donor-specific antibodies (DSA), b) acute cellular rejection (ACR), c) antibody mediated rejection (AMR), d) hemodynamic compromise (HDC) rejection in absence of biopsy or histological rejection, e) death, and f) retransplantation.

Role: Center PI

Alexion Inc. Patel (PI) 2014-Present

The DUET Cardiac Trial - The De-novo Use of Eculizumab Alongside Conventional Maintenance Therapy in Presensitized Patients Receiving Cardiac Transplantation: An, Open-Label, Investigator-Initiated Pilot Trial. Investigational pilot trial to determine the safety and efficacy of the de-novo use of eculizumab to prevent symptomatic antibody (AMR \geq 1) and/or cellular mediated rejection (\geq 2 Grade 2R) in highly sensitized cardiac transplantation recipients (PRA $>$ 70%).

One Legacy Foundation/Baylor University Kransdorf (Site PI) 06/01/19-Present

Transplant of Redeemed Organs by Judicious Administration of New Direct Acting Antivirals for Hepatitis-C Heart Recipients (TROJAN-C). This prospective, multi-center, open-label clinical trial will utilize Hepatitis C virus (HCV) - Positive donors for heart transplantation in HCV-negative recipients.

Role: Co-Investigator

Pfizer, Inc.

Patel (Site PI)

3/24/17-3/23/2020

ATTR- EXT - A Phase 3 Multicenter, Randomized, Double-Blind, Extension Study To Evaluate The Safety Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Subjects Diagnosed With Transthyretin Cardiomyopathy (Ttr-Cm)

Genzyme

Kobashigawa (PI)

07/01/2018 – 07/01/2021

A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (ATG): A 12-month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without Thymoglobulin® 1.5 mg/kg/d for 5 consecutive days in heart transplant recipients. The purpose of this study is to definitively establish Thymoglobulin's potential efficacy in preventing cardiac allograft vasculopathy.

Role: Co-Investigator

TransMedics

Esmailian (PI)

09/11/2019 – 09/10/2022

OCS-CAR-121918 - Continued Access Protocol to collect additional evidence to evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation (Heart EXPAND CAP

Role: Co-Investigator

Alnylam Pharmaceuticals

Patel (site PI)

02/01/2020 – 01/31/2022

APOLLO-B - A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Eidos Pharmaceuticals

Patel (site PI)

05/21/2019 – 05/20/2022

Eidos AG10-301/ATTRIBUTE-CM - a prospective, randomized, multicenter, parallel-group study will evaluate the efficacy and safety of AG10 in symptomatic subjects compared to placebo, administered on a background of stable heart failure therapy

Donor Funded

Marban (PI)

10/01/2019 – 09/30/2024

Cardiac Amyloidosis Registry Study ("CARS") - This multi-center effort will represent the largest collection of AL and TTR cardiac amyloidosis to date. (TBD) academic medical centers from the US will compile demographic, hemodynamic and organ-involvement data, as well as treatment strategies for AL and TTR amyloidosis.

Role: Co-Investigator

Completed:

Alnylam Pharmaceuticals

3/13/15-3/12/18

A Study Examining the Prevalence of TTR Mutation in Subjects Suspected of Having Cardiac Amyloidosis. The goal of this project was to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis.

Role: Center PI

Alnylam Pharmaceuticals

9/7/15-9/16/18

A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). The primary objective of the study was to determine the efficacy of ALN-TTRSC in patients with FAC.

Role: Center PI

Pfizer

12/1/14-1/31/19

A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed with Transthyretin Cardiomyopathy (TTR-CM)

Role: Center PI

RESEARCH FOCUS AND INTERESTS:

My research is primarily focused on clinical outcomes of patients after transplantation and cardiac amyloidosis. Our group's main goal is to identify therapies which abrogate the risk of allograft rejection and development of transplant vasculopathy, a chronic form of rejection, in heart transplant recipients.

INVITED LECTURES AND PRESENTATIONS

1. "Cloning of homeobox transcription factors from human endothelial cells, Program Project Group- Atherosclerosis Research Unit UCLA, March 1996
2. "Severe aortic stenosis and myocardial ischemia presenting as an acute abdomen," Clinical Case Conference UCLA, June 1996
3. "Modifying perioperative risk in patients with cardiovascular disease undergoing non-cardiac surgery," UCLA Journal Club, March 1997
4. "Cardiac arrest and myocardial infarction secondary to coronary vasospasm induced by Primatene Mist," Clinical Case Conference UCLA, July 1997
5. "Modifying perioperative risk in patients with cardiovascular disease undergoing non-cardiac surgery," Internal Medicine Residents' Conference UCLA, Nov 1997
6. "Does Chlamydia pneumoniae have a role in the etiology of atherosclerosis? – The Clinical Evidence UCLA Journal Club, March 1998
7. "Thoracic outlet syndrome," Internal Medicine Residents' Conference UCLA, April 1998
8. "Management of Unstable Angina and Non-Q Wave MI," UCLA Journal Club, July 1998
9. "Pericardial Diseases," Internal Medicine Residents' Conference UCLA, Jan 1999

10. "Right Ventricular Infarction" Clinical Case Conference UCLA, April 1999
11. "Drug Therapy: Step-by-Step Protocols" Heart Failure Symposium, UCLA Continuing Medical Education, May 1999
12. "Bacterial Infection and Vascular Calcification - Is there a link?" Program Project Group - Atherosclerosis Research Unit UCLA, Aug 1999
13. "The Cellular Basis of Vascular Calcification: the role of inflammation and infection" STAR Program, UCLA, Nov 1999
14. "Bacterial Lipopolysaccharide Stimulates In vitro Vascular Calcification via Class A Scavenger Receptor" External Review, Program Project Group, Atherosclerosis Research Unit, UCLA, Apr 2000
15. "Vascular Calcification and Bacterial Infection - Is there a link?" Division of Cardiology, UCLA, Oct 2000
16. "Use of Beta-blockers in Congestive Heart Failure" Prairie Medical Group, Los Angeles, Oct 2001
17. "Use of Beta-blockers in Congestive Heart Failure" Lancaster, CA, Jan 2002
18. "Transplant Coronary Artery Disease" UCLA Division of Cardiology, Nov 2002
19. "Current Issues in Cardiac Transplantation" UCLA Cardiology Grand Rounds, Jan 2004
20. "Treatment of Severe Congestive Heart Failure" UCLA Cardiology Update, Snowbird, Utah, Feb 2004
21. "Evidence Based Management of Heart Failure" UCLA Heart Failure Symposium, Las Vegas, NV, Mar 2004
22. "Treatment Options for End-Stage Heart Disease" UCLA Cardiology Update, Snowbird, Utah, Feb 2005
23. "Update on Heart Failure: UCLA Symposium" Pasadena, CA, April 2005
24. "Regional Differences in Congestive Heart Failure" International Society of Heart and Lung Transplantation, Philadelphia, PA, April 2005
25. "Syncope: UCLA Family Medicine Board Review", Los Angeles, CA, May 2005
26. "Heart Failure: Grand Rounds" Antelope Valley Hospital, Palmdale, CA, Sept 2005
27. "Advanced Decompensated Heart Failure" UCLA Cardiology Update, Snowbird, Utah, Feb 2006
28. "New Treatment for Congestive Heart Failure" UCLA Cardiology Update, Snowbird, Utah, Jan 2007
29. "Treatment of Congestive Heart Failure" Antelope Valley Hospital, Cardiology in Primary Care VI, Antelope Valley, CA, March 2007
30. "New Treatments for Congestive Heart Failure and Advances in Heart Transplantation" UCLA Cardiology Update, Snowbird, Utah, Feb 2008
31. "Case Studies in Humoral Rejection" International Society of Heart & Lung Transplantation - Sunrise Symposium, Boston, MA, April 2008
32. "Evidence Based, Guideline Recommended ICD Device Therapy 2008: Does Anyone Get Left Out?" Sudden Cardiac Arrhythmia Symposium, Santa Monica, CA, Jul 2008
33. "Immunosuppression in Heart Transplantation" UCLA Cardiology Update, Oct 2008
34. "Cardiac Transplantation and Assist Devices" Sun City Symposium, Sun City, CA, June 2009
35. "Resistant Hypertension" Venice Family Clinic, Venice, CA, Jul 2009
36. "Humoral Rejection" Krannert Heart Institute, Indiana University, Jul 2009
37. "Advances in Decompensated Heart Failure" Heart Failure and Transplant Symposium, Newport, CA, Oct 2009
38. "Advances in Heart Failure and Cardiac Transplantation" UCLA Cardiology Update, Snowbird, Utah, Jan 2010

39. "Acute Decompensated Heart Failure" Cedars-Sinai Fellows' Conference, Feb 2010
40. "Advances in Immunosuppression in Heart Transplantation" Cedars-Sinai Pulmonary Grand Rounds, Mar 2010
41. "Immunosuppression in Cardiac Transplantation" Pharmacy Conference, Cedars-Sinai, May 2010
42. "Immunosuppression in Cardiac Transplantation" An Expert Update on Diagnosis and Treatment Options, Los Angeles, CA, Oct 2010
43. "Immunosuppression" Core curriculum lecture, Cedars-Sinai Cardiology Fellows, Jan 2011
44. "Treatment Impact on Morbidity and Mortality in Atrial Fibrillation" Henry Mayo-Newhall Memorial Hospital, Valencia, CA, Feb 2011
45. "Recent Advances in Cardiac Transplantation" UCLA Cardiology Update, Snowbird, Utah, Mar 2011
46. "Moderator: Management of Advanced Heart Disease in the Aging Population" Controversies and Advances in the Treatment of Cardiovascular Disease, Cedars-Sinai Heart Institute/ACC CA Chapter, Beverly Hills, CA, Oct 2011
47. "Treatment Impact on Morbidity and Mortality in Atrial Fibrillation" Providence-Tarzana Hospital, Tarzana, CA, Jan 2012
48. "New Approaches in the Management of Acute Heart Failure" May 2012
49. "Immunosuppression Post Transplant" Cedars-Sinai Fellows' Conference, May 2012
50. "New Approaches in the Management of Acute Heart Failure" Optimal Care and New Therapies for Advanced Heart Disease, Riverside, CA, Sep 2012
51. "Contemporary Management Strategies for End Stage Heart Failure" Bakersfield Memorial Hospital Symposium, Bakersfield, CA, Oct 2012
52. "Mechanical Circulatory Support" Kerala Institute of Medical Sciences, Trivandrum, Kerala, India, Nov 2012
53. "How to set-up an advanced HF program" Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India, Nov 2012
54. "Acute Decompensated Heart Failure" Trivandrum Medical College, Trivandrum, Kerala, India, Nov 2012
55. "Changing Concepts in Advanced Heart Failure Management" SCTIMST Heart failure Program, Trivandrum, India, Nov 2012
56. "DeNovo antibody and everolimus in heart transplant" Nagoya, Japan, Dec 2012
57. "Current overview of transplantation" Sendai International Center, Sendai, Japan, Dec 2012
58. "Overview of Heart Transplantation" 31st Annual Scientific Meeting of the Japanese Society for Heart Transplantation, Sendai, Japan, Dec 2012
59. "Maintenance Immunosuppression with Everolimus and de novo antibody production after heart transplantation" 31st Annual Scientific Meeting of the Japanese Society for Heart Transplantation, Sendai, Japan, Dec 2012
60. "Medical Therapy Will Remain the Treatment for the Vast Majority of CHF Patients for the Foreseeable Future" STS/AATS Technology Conference 2013 Los Angeles, CA, Jan 2013
61. "Acute Decompensated Heart Failure Therapy – From Disappointment to Promise" Cedars-Sinai Heart Institute Grand Rounds, Feb 2013
62. "How to Evaluate, Diagnose and Treat Chronic Allograft Dysfunction." ISHLT 33rd Annual Meeting and Scientific Sessions, Montreal, Canada, April 2013
63. "Immunosuppression in Heart Transplantation" Cardiology Fellows' Conference, Cedars-Sinai Heart Institute, April 2013

64. "Tacrolimus-Induced Diabetes Compared to Cyclosporine May Lead to More Diabetic Complications Post Heart Transplant" ATC World Transplant Congress, Seattle, Washington, May 2013
65. "Sensitization before and after Heart Transplantation" ATC World Transplant Congress, Seattle, Washington, May 2013
66. "Current and Future Trends in the Management of End Stage Heart Disease" Association of Los Angeles Physicians of Indian Origin, Beverly Hills, California, Nov 2013
67. What is the Future of Biological Therapies for End Stage Heart Disease? Debate - Whole Organ Engineering, Controversies and Advances in the Treatment of Cardiovascular Disease, Nov 2013, Beverly Hills, CA
68. Managing Heart Failure with Preserved Ejection Fraction (HFpEF), American Association of Heart Failure Nurses, June 2014, Los Angeles, CA
69. Approaches to Desensitization Therapies – What Works? World Transplant Congress July 2014, San Francisco, CA
70. Current Approaches to Advanced Heart Failure and the Emerging Role of Mechanical Circulatory Support, 1st Annual Bakersfield Cardiovascular Symposium, Nov 2014, Bakersfield, CA
71. Heart Failure with Preserved Ejection Fraction – State of the Art. Controversies and Advances in The Treatment of Cardiovascular Disease, Nov 2014, Beverly Hills, CA
72. B Cell Therapeutics in Transplantation, ISHLT April 2015, Nice, France
73. Immunologic Risk Factors: Avoiding Hyperacute Rejection, American Transplant Congress, May 2015, Philadelphia, PA
74. "What Drug Therapies, What Data for Refractory AMR?" ISHLT Annual Meeting, April 2016, Washington, DC
75. "Primary Graft Dysfunction in Heart Transplantation" Success with Failure: An Advanced Heart Disease Symposium, June 2016, Culver City, CA
76. "Rapidly Progressive CAV" Cutting Edge of Organ Transplantation, February 2017, Phoenix, AZ
77. Debate: "Pre-Heart Transplant Conundrum: Desensitization vs. Transplanting Against A Positive Flow Crossmatch" Cutting Edge of Organ Transplantation, February 2017, Phoenix, AZ
78. "Prevention of Complement Activation and Antibody Development: Results from the Duet Trial" Cutting Edge of Organ Transplantation, February 2017, Phoenix, AZ
79. "Approach to the Sensitized MCS Patient: Desensitization and Other Strategies" ISHLT April 2017, San Diego, CA
80. "Cardiac Amyloid: Clinical Trials Past, Present and Future" American Transplant Congress Annual Meeting, May 2017, Chicago, IL
81. "Hepatitis C Donors: Do New Therapies Mean New Options?" American Transplant Congress Annual Meeting, May 2017, Chicago, IL
82. "The Problem of Sensitization" Heart Failure Society of America Annual Scientific Sessions. September 2017, Grapevine, TX.
83. "Progress in the Treatment of Cardiac Amyloidosis Controversies and Advances in The Treatment of Cardiovascular Disease". Oct 2017, Beverly Hills, CA
84. "Cardiac Amyloidosis." Internal Medicine Grand Rounds VA/Sepulveda Medical Center.
85. "Importance of Genetic Testing to Improve Quality of Life in Patients with hereditary transthyretin amyloidosis". Charles R. Drew Medical Society. April 2018, Playa Vista, CA.
86. "Cardiac Amyloidosis". Berdie Justice Lecture Series. May 2018, Cedars-Sinai Medical Center.
87. "Immunosuppressants." Harbor UCLA Cardiology Grand Rounds. January 2019, Torrance, CA.
88. "Circulating Antibodies – What, When, Why to Use Desensitization Therapy." CeOT. February 2019, Phoenix, AZ.

89. "Update on Cardiology." Los Robles Grand Rounds. March 2019, Thousand Oaks, CA.
90. "Top 3 Presentations in LVAD/Transplantation." ACC. March 2019, New Orleans, LA.
91. "Outcomes and ISHLT grading of PGD." Society for Heart Failure and Transplantation. March 2019, New Delhi, Delhi, India.
92. "Treatment of PGD." Society for Heart Failure and Transplantation. March 2019, New Delhi, Delhi, India.
93. "PGD in Heart Transplant." Society for Heart Failure and Transplantation. March 2019, New Delhi, Delhi, India.
94. "The Evolving Long-Term Outcomes of Heart Transplantation in Amyloid Patients." ISHLT. April 2019, Orlando, FL.
95. "Heart Transplantation for Cardiac Amyloidosis – Worthwhile?" ISHLT. April 2019, Orlando, FL.
96. "Cardiac Amyloidosis: Update on Diagnosis and Treatment." Optimal Care and New Therapies for Advanced Heart Disease. September 2019, Las Vegas, Nevada.
97. "Management of Acute Decompensated Heart Failure." Optimal Care and New Therapies for Advanced Heart Disease. September 2019, Las Vegas Nevada.
98. "Pre-Transplant Sensitization – To Treat or Not to Treat." Success with Failure: An Advanced Heart Disease Symposium. February 2020, Marina del Rey
99. "Heart Transplantation: Transplant immunology – immune suppressive strategies." Webinar Series on Basics & Advancements of Heart Transplantation. Indian Association of Cardiovascular – Thoracic Surgeons, Indian Society for Heart and Lung Transplantation, & University of Minnesota. August 2020.
100. "Cell free DNA/RNA and other non invasive prognostic rejection surveillance markers" HN Reliance Hospital, Mumbai, India August 2020, Virtual
101. "Hereditary Transthyretin Amyloidosis: Diagnose a Patient, Change a Life." USC Grand Rounds. August 2020. Virtual.
102. "Recent Advances with Emphasis on ATTR." Heart Failure Seoul 2020, The 42nd Scientific Conference of The Korean Society of Heart Failure. September 2020. Conrad Seoul, Seoul, Korea.
103. "Heart Transplantation for Cardiac Amyloidosis – When It's Too Late for Medical Therapy." ACES Lecture. September 2020. Virtual.
104. "Heart Transplantation" Heart Failure Association of India, October 2020, Virtual
105. "Clinician's Perspective on DSA Surveillance" American Society of Histocompatibility and Immunology Annual Meeting, October 2020, Virtual
106. "Heart Transplant Selection and Workup" Heart Failure Association of India Webinar on Advanced Heart Failure and Transplantation, October 2020, Virtual

PUBLICATIONS

RESEARCH PAPERS (PEER-REVIEWED)

1. Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, **Patel J**, Kobashigawa JA, Laks H; UCLA Heart Transplant Group. Use of hearts transplanted from donors with atraumatic intracranial bleeds. J Heart Lung Transplant. 2002 Jun;21(6):623-8.

2. Horwich TB, **Patel J**, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. *Circulation*. 2003 Aug 19;108(7):833-8.
3. Marelli D, Laks H, Patel B, Kermani R, Marmureanu A, **Patel J**, Kobashigawa J; University of California at Los Angeles Heart Transplant Group. Heart transplantation in patients with diabetes mellitus in the current era. *J Heart Lung Transplant*. 2003 Oct;22(10):1091-7.
4. **Patel J**, Kobashigawa JA. Cardiac transplantation: the alternate list and expansion of the donor pool. *Curr Opin Cardiol*. 2004 Mar;19(2):162-5. Review.
5. **Patel JK**, Kobashigawa JA. Immunosuppression, diagnosis, and treatment of cardiac allograft rejection. *Semin Thorac Cardiovasc Surg*. 2004 Winter;16(4):378-85. Review.
6. Kobashigawa JA, Moriguchi JD, Laks H, Wener L, Hage A, Hamilton MA, Cogert G, Marquez A, Vassilakis ME, **Patel J**, Yeatman L. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. *J Heart Lung Transplant*. 2005 Nov;24(11):1736-40.
7. **Patel JK**, Kobashigawa JA. Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection? *Curr Opin Cardiol*. 2006 Mar;21(2):127-31. Review.
8. Kobashigawa JA, **Patel JK**. Immunosuppression for heart transplantation: where are we now? *Nat Clin Pract Cardiovasc Med*. 2006 Apr;3(4):203-12. Review.
9. **Patel JK**, Kobashigawa JA. Everolimus: an immunosuppressive agent in transplantation. *Expert Opin Pharmacother*. 2006 Jul;7(10):1347-55. Review.
10. **Patel JK**, Kobashigawa JA. Tacrolimus in cardiac transplantation. *Expert Rev Clin Immunol*. 2007 Mar;3(2):131-8.
11. Kobashigawa JA, Laks H, Wu G, **Patel J**, Moriguchi J, Hamilton M, Fonarow G, Fishbein M, Ardehali A. The University of California at Los Angeles heart transplantation experience. *Clin Transpl*. 2005:173-85.
12. **Patel JK**, Kobashigawa JA. Tacrolimus in heart transplant recipients: an overview. *BioDrugs*. 2007;21(3):139-43. Review.
13. Middlekauff HR, Chiu J, Hamilton MA, Fonarow GC, Maclellan WR, Hage A, Moriguchi J, **Patel J**. Cyclooxygenase products sensitize muscle mechanoreceptors in humans with heart failure. *Am J Physiol Heart Circ Physiol*. 2008 Apr;294(4):H1956-62.
14. Marelli D, Kobashigawa J, Hamilton MA, Moriguchi JD, Kermani R, Ardehali A, **Patel J**, Noguchi E, Beygui R, Laks H, Plunkett M, Shemin R, Esmailian F. Long-term outcomes of heart transplantation in older recipients. *J Heart Lung Transplant*. 2008 Aug;27(8):830-4.
15. **Patel J**, Kobashigawa JA. Minimization of immunosuppression: transplant immunology. *Transpl Immunol*. 2008 Nov;20(1-2):48-54.
16. **Patel JK**, Everly MJ, Kittleson M, Kobashigawa JA. Use of bortezomib as adjunctive therapy for desensitization in combined heart and kidney transplantation--a case report. *Clin Transpl*. 2009:347-9.

17. Kobashigawa J, Mehra M, West L, Kerman R, George J, Rose M, Zeevi A, Reinsmoen N, **Patel J**, Reed EF; Consensus Conference Participants. Report from a consensus conference on the sensitized patient awaiting heart transplantation. *J Heart Lung Transplant*. 2009 Mar;28(3):213-25.
18. Kubak BM, Gregson AL, Pegues DA, Leibowitz MR, Carlson M, Marelli D, **Patel J**, Laks H, Kobashigawa JA. Use of hearts transplanted from donors with severe sepsis and infectious deaths. *J Heart Lung Transplant*. 2009 Mar;28(3):260-5.
19. Wu GW, Kobashigawa JA, Fishbein MC, **Patel JK**, Kittleson MM, Reed EF, Kiyosaki KK, Ardehali A. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. *J Heart Lung Transplant*. 2009 May;28(5):417-22.
20. Kobashigawa JA, Kiyosaki KK, **Patel JK**, Kittleson MM, Kubak BM, Davis SN, Kawano MA, Ardehali AA. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. *J Heart Lung Transplant*. 2010 May;29(5):504-8.
21. Oda N, Kato TS, Komamura K, **Patel J**, Kobashigawa JA. Retrospective review of Japanese patients undergoing heart transplantation in Japan compared with those undergoing transplantation in the United States. *J Heart Lung Transplant*. 2010 Sep;29(9):1076-8.
22. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, **Patel J**, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. 2010 Aug;29(8):914-56.
23. Kobashigawa JA, **Patel JK**, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, Moriguchi JD, Reed EF, Ardehali AA. The long-term outcome of treated sensitized patients who undergo heart transplantation. *Clin Transplant*. 2011 Jan-Feb;25(1):E61-7.
24. Lockhart D, Kittleson MM, Velleca A, **Patel JK**, Kobashigawa JA. Homeless donors and heart transplantation outcomes. *J Heart Lung Transplant*. 2011 Mar;30(3):355-6.
25. Liu T, Shehata M, Chang D, **Patel JK**, Kittleson MM, Kobashigawa JA, Chugh SS, Wang X. Prolonged QT and cardiac arrest after heart transplantation: inherited or acquired? *J Electrocardiol*. 2011 May-Jun;44(3):350-2.
26. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, **Patel J**, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suci-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, Zuckermann A; Consensus Conference Participants. Report from a consensus conference on antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant*. 2011 Mar;30(3):252-69.
27. Azarbal B, Poommipanit P, Arbit B, Hage A, **Patel J**, Kittleson M, Kar S, Kaldas FM, Busuttil RW. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. *Liver Transpl*. 2011 Jul;17(7):809-13.

28. Zhang Q, Cecka JM, Gjertson DW, Ge P, Rose ML, **Patel JK**, Ardehali A, Kobashigawa JA, Fishbein MC, Reed EF. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. *Transplantation*. 2011 May 27;91(10):1153-8.
29. **Patel JK**, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. *Surgeon*. 2011 Jun;9(3):160-7.
30. Kittleson MM, Shemin R, **Patel JK**, Ardehali A, Kawano M, Davis S, Moriguchi JD, Kobashigawa JA. Donor-recipient sex mismatch portends poor 10-year outcomes in a single-center experience. *J Heart Lung Transplant*. 2011 Sep;30(9):1018-22.
31. **Patel JK**, Kobashigawa JA. Everolimus for cardiac allograft vasculopathy--every patient, at any time? *Transplantation*. 2011 Jul 27;92(2):127-8.
32. Moriguchi J, Davis S, Jocson R, Esmailian F, Ardehali A, Laks H, Kwon M, Kittleson M, Kobashigawa J, **Patel J**, Marelli D, Plunkett M, Beygui R, Shemin R. Successful use of a pneumatic biventricular assist device as a bridge to transplantation in cardiogenic shock. *J Heart Lung Transplant*. 2011 Oct;30(10):1143-7.
33. **Patel J**, Kobashigawa JA. Quest for lower immunosuppression in cardiac transplantation: an analysis of the TICTAC trial. *Future Cardiol*. 2011 May;7(3):293-7.
34. Kittleson MM, **Patel JK**, Moriguchi JD, Kawano M, Davis S, Hage A, Hamilton MA, Esmailian F, Kobashigawa JA. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. *J Heart Lung Transplant*. 2011 Nov;30(11):1250-6.
35. **Patel JK**, Kobashigawa JA. Cardiology patient page. Heart transplantation. *Circulation*. 2011 Jul 26;124(4):e132-4.
36. **Patel J**, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. *J Heart Lung Transplant*. 2011 Dec;30(12):1320-6.
37. **Patel JK**, Kobashigawa JA. Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury. *Future Cardiol*. 2012 Jul;8(4):623-35.
38. Thajudeen A, Stecker EC, Shehata M, **Patel J**, Wang X, McAnulty JH Jr, Kobashigawa J, Chugh SS. Arrhythmias after heart transplantation: mechanisms and management. *J Am Heart Assoc*. 2012 Apr;1(2):e001461.
39. Wei J, Azarbal B, Singh S, Rafiei M, Cheng R, **Patel J**, Esmailian F, Currier J, Kobashigawa J. Frequency of coronary artery fistulae is increased after orthotopic heart transplantation. *J Heart Lung Transplant*. 2013 Jul;32(7):744-6.
40. Shah AB, **Patel JK**, Rafiei M, Morrissey RP, Kittleson MM, Kobashigawa JA. The impact of mean first-year heart rate on outcomes after heart transplantation: does it make a difference? *Clin Transplant*. 2013 Sep-Oct;27(5):659-65.
41. Perkel D, Czer LS, Morrissey RP, Ruzza A, Rafiei M, Awad M, **Patel J**, Kobashigawa JA. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. *Transplant Proc*. 2013 Jul-Aug;45(6):2384-6. doi: 10.1016/j.transproceed.2013.02.116.
42. Kobashigawa JA, Itagaki BK, Razi RR, **Patel JK**, Chai W, Kawano MA, Goldstein Z, Kittleson MM, Fishbein MC. Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation. *Clin Transplant*. 2013 Nov-Dec;27(6):E679-84.

43. Kransdorf EP, Czer LS, Luthringer DJ, **Patel JK**, Montgomery SP, Velleca A, Mirocha J, Zakowski PC, Zabner R, Gaultier CR, Qvarnstrom Y, Benedict T, Steurer F, Bosserman E, Paddock CD, Rafiei M, Kobashigawa JA. Heart transplantation for Chagas cardiomyopathy in the United States. *Am J Transplant*. 2013 Dec;13(12):3262-8. doi: 10.1111/ajt.12507. Epub 2013 Oct 28.
44. Reinsmoen NL, Lai CH, Mirocha J, Cao K, Ong G, Naim M, Wang Q, Haas M, Rafiei, M, Czer L, **Patel J**, Kobashigawa J. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. *Transplantation*. 2014 Mar 15;97(5):595-601.
45. Rafiei M, Kittleson M, **Patel J**, Osborne A, Chang D, Czer L, Reinsmoen N, Esmailian F, Kobashigawa J. Anti-thymocyte gamma-globulin may prevent antibody production after heart transplantation. *Transplant Proc*. 2014 Dec;46(10):3570-4. doi: 0.1016/j.transproceed.2014.08.042.
46. Cheng R, Hachamovitch R, Kittleson M, **Patel J**, Arabia F, Moriguchi J, Esmailian F, Azarbal B. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. *Ann Thorac Surg*. 2014 Feb;97(2):610-6.
47. Cheng R, Hachamovitch R, Kittleson M, **Patel J**, Arabia F, Moriguchi J, Esmailian F, Azarbal B. Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: a weighted meta-analysis of 170 patients. *J Card Fail*. 2014 Jun;20(6):400-6
48. Kobashigawa J, Zuckermann A, Macdonald P, LePrince P, Esmailian F, Luu M, Mancini D, **Patel J**, Razi R, Reichenspurner H, Russell S, Segovia J, Smedira N, Stehlik J, Wagner F; Consensus Conference participants. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. *J Heart Lung Transplant*. 2014 Apr;33(4):327-40.
49. Cheng R, Azarbal B, Yung A, Chang DH, **Patel JK**, Kobashigawa JA. Elevated immune monitoring early after cardiac transplantation is associated with increased plaque progression by intravascular ultrasound. *Clin Transplant*. 2015 Feb;29(2):103-9. doi: 10.1111/ctr.12489.
50. Kobashigawa J, **Patel J**, Azarbal B, Kittleson M, Chang D, Czer L, Daun T, Luu M, Trento A, Cheng R, Esmailian F. Randomized Pilot Trial of Gene Expression Profiling Versus Heart Biopsy in the First Year After Heart Transplant: *Circ Heart Fail*. 2015 Feb 19. pii: CIRCHEARTFAILURE.114.001658.
51. Elboudwarej O, **Patel JK**, Liou F, Rafiei M, Osborne A, Chai W, Kittleson M, Czer L, Stern L, Esmailian F, Kobashigawa JA. Risk of deep vein thrombosis and pulmonary embolism after heart transplantation: clinical outcomes comparing upper extremity deep vein thrombosis and lower extremity deep vein thrombosis. *Clin Transplant*. 2015 Jul;29(7):629-35. doi: 10.1111/ctr.12566. Epub 2015 Jun 16.
52. **Patel J**, Klapper E, Shafi H, Kobashigawa JA. Extracorporeal photopheresis in heart transplant rejection. *Transfus Apher Sci*. 2015 Apr;52(2):167-70. doi: 10.1016/j.transci.2015.02.004. Epub 2015 Feb 11.
53. Reinsmoen NL, **Patel J**, Mirocha J, Lai CH, Naim M, Ong G, Wang Q, Zhang X, Liou F, Yu Z, Kobashigawa J. Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. *J Heart Lung Transplant*. 2016 Feb;35(2):165-72. doi: 10.1016/j.healun.2015.10.013. Epub 2015 Oct 23. PubMed PMID: 26683810.
54. Azarbal B, Cheng R, Vanichsarn C, **Patel JK**, Czer LS, Chang DH, Kittleson MM, Kobashigawa JA. Induction Therapy With Antithymocyte Globulin in Patients Undergoing Cardiac Transplantation Is Associated With Decreased Coronary Plaque Progression as Assessed by Intravascular Ultrasound. *Circ*

Heart Fail. 2016 Jan;9(1):e002252. doi: 10.1161/CIRCHEARTFAILURE.115.002252. PubMed PMID: 26747860.

55. Dijke EI, Platt JL, Blair P, Clatworthy MR, **Patel JK**, Kfoury AG, Cascalho M. B cells in transplantation. *J Heart Lung Transplant.* 2016 Jun, 35(6):704-10. Doi:10.1016/j.healun.2016.01.1232. Epub 2016 Feb 12. PMID: 26996930.

56. Kobashigawa J, Teuteberg J, Colvin M, Edwards L, Daun T, Luu M, **Patel J**, Vega JD, Meyer D; forum participants. Proceedings of the AST heart allocation meeting at the American Transplant Congress, Philadelphia, Pennsylvania, May 4, 2015. *Clin Transplant.* 2016 May;30(5):641-8. doi: 10.1111/ctr.12717. Epub 2016 Mar 22. PubMed PMID: 27000519.

57. Cheng R, Azarbal B, Yung A, **Patel JK**, Chang DH, Liou F, Makkar R, Kobashigawa JA. Elevated immune monitoring as measured by increased adenosine triphosphate production in activated lymphocytes is associated with accelerated development of cardiac allograft vasculopathy after cardiac transplantation. *J Heart Lung Transplant.* 2016 Mar 31. pii: S1053-2498(16)30069-9. doi: 10.1016/j.healun.2016.03.016. PubMed PMID: 27138702.

58. Cheng R, Azarbal B, Yung A, **Patel JK**, Chang DH, Liou F, Makkar R, Kobashigawa JA. Elevated immune monitoring as measured by increased adenosine triphosphate production in activated lymphocytes is associated with accelerated development of cardiac allograft vasculopathy after cardiac transplantation. *J Heart Lung Transplant.* 2016 Aug;35(8):1018-23. doi: 10.1016/j.healun.2016.03.016. Epub 2016 Mar 31. PMID: 27138702.

59. Kransdorf EP, Fishbein MC, Czer LS, **Patel JK**, Velleca A, Tazelaar HD, Roy RR, Steidley DE, Kobashigawa JA, Luthringer DJ. Pathology of Chronic Chagas Cardiomyopathy in the United States: A Detailed Review of 13 Cardiectomy Cases. *Am J Clin Pathol.* 2016 Aug;146(2):191-8. doi: 10.1093/ajcp/aqw098. Epub 2016 Jul 17. PMID: 27425387.

60. **Patel JK**. Early and late AMR in heart transplantation-Distinct entities? *J Heart Lung Transplant.* 2016 Sep;35(9): 1055-6. doi: 10.1016/j.healun.2016.07.005. Epub 2016 Jul 16. PMID: 27578597.

61. Chan JL, Kobashigawa JA, Reich HJ, Ramzy D, Thottam MM, Yu Z, Aintablian TL, Liou F, **Patel JK**, Kittleson MM, Czer LS, Trento A, Esmailian F. Intermediate outcomes with ex-vivo allograft perfusion for heart transplantation. *J Heart Lung Transplantation.* 2016 2017 Mar;36(3):258-263. doi: 10.1016/j.healun.2016.08.015. Epub 2016 Aug 20. PMID: 27646064.

62. Cheng R, Vanichsarn C, **Patel JK**, Currier J, Chang DH, Kittleson MM, Makkar R, Kobashigawa JA, Azarbal B. Long-term clinical and angiographic outcomes of percutaneous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy. *Catheter Cardiovasc Interv.* 2017 Jul;90(1):48-55. doi: 10.1002/ccd.26830. Epub 2016 Nov 10. PMID: 27862865.

63. Elboudwarej O, Phan D, **Patel JK**, Loui F, Aintablian T, Osborne A, Yu Z, Reinsmoen N, Kobashigawa JA. Corticosteroid wean after heart transplantation-Is there a risk for antibody formation? *Clin Transplant.* 2017 Apr;31(4). doi: 10.1111/ctr.12916. Epub 2017 Feb 20. PMID: 28135788.

64. Kransdorf EP, Kittleson MM, **Patel JK**, Pando MJ, Steidley DE, Kobashigawa JA. Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. *J Heart Lung Transplant.* 2017 Jul;36(7):787-796. doi: 10.1016/j.healun.2017.02.015. Epub 2017 Feb 17. PMID: 28318744.

65. Awad M, Czer LS, Esmailian F, Jordan S, De Roberts MA, Mirocha J, **Patel J**, Chang DH, Kittleson M, Ramzy D, Arabia F, Chung JSJ, Cohen JL, Trento A, Kobashigawa JA. Combined Heart and Kidney Transplantation: A 23-Year Experience. *Transplant Proc.* 2017 March;;49(2) 348-353. Doi: 10.1016/j.transproceed.2016.11.040. PMID: 28219597
66. Ruan V, Czer LS, Awad M, Kittleson M, **Patel J**, Arabia F, Esmailian F, Ramzy D, Chung J, De Roberts M, Trento A, Kobashigawa JA. Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review. *Transplant Proc.* 2017 Mar;49(2) 253-259. Doi: 10.1016/j.transproceed.2016.11.034. Review. PMID: 28219580
67. Chan JL, Kobashigawa JA, Aintablian TL, Li Y, Perry PA, **Patel JK**, Kittleson MM, Czer LS, Zarrini P, Velleca A, Rush J, Arabia FA, Trento A, Esmailian F. Vasoplegia after heart transplantation: outcomes at 1 year+. *Interact Cardiovasc Thorac Surg.* 2017 Apr 27. doi: 10.1093/icvts/ivx081. [Epub ahead of print]. PMID: 28459983.
68. Cheng R, Kransdorf EP, Wei J, **Patel JK**, Kobashigawa JA, Azarbal B. Angiogenesis on Coronary Angiography Is a Marker for Accelerated Cardiac Allograft Vasculopathy as Assessed by Intravascular Ultrasound. *Clin Transplant.* 2017 Aug 8. doi: 10.1111/ctr.13069. [Epub ahead of print]. PMID: 28796501.
69. Leong D, Aintablian T, Kittleson M, Olymbios M, **Patel J**, Chang DH, Kobashigawa J. Prolonged corrected QT interval in the donor heart: Is there a risk? *Clin Transplant.* 2017 Jul;31(7)
70. Chan JL, Kobashigawa JA, Aintablian TL, Dimbil SJ, Perry PA, **Patel JK**, Kittleson MM, Czer LS, Zarrini P, Velleca A, Rush J, Arabia FA, Trento A, Esmailian F. Characterizing Predictors and Severity of Vasoplegia Syndrome After Heart Transplantation. *Ann Thorac Surg.* 2017 Dec 27
71. Kobashigawa J, Khush K, Colvin M, Acker M, Van Bakel A, Eisen H, Naka Y, **Patel J**, Baran DA, Daun T, Luu M, Olymbios M, Rogers J, Jeevanandam V, Esmailian F, Pagani FD, Lima B, Stehlik J. Report From the American Society of Transplantation Conference on Donor Heart Selection in Adult Cardiac Transplantation in the United States. *Am J Transplant.* 2017 Oct;17(10):2559-2566.
72. Kobashigawa J, Colvin, M, Luciano P, Dragun D, Crespo-Leiro M, Delgado J, Olymbios M, Parameshwar J, **Patel J**, Reed E, Reinsmoen N, Rodriguez E, Ross H, Starling R, Tyan D, Urschel S, Zuckermann A. The management of antibodies in heart transplantation: An ISHLT consensus document. *J Heart Lung Transplant.* 2018 Jan 31. pii: S1053-2498(18)31292-0. doi: 10.1016/j.healun.2018.01.1291. [Epub ahead of print].
73. **Patel, J.** Per-operative desensitization-A promising strategy for overcoming the antibody barrier in heart transplantation. *J Heart Lung Transplant.* 2018 May;37(5)577-578.
74. Reich H, Dimbil S, Levine R, Megna D, Mersola S, **Patel J**, Kittleson M, Czer L, Kobashigawa J, Esmailian F. Dual-Organ transplantation in older recipients: outcomes after heart-kidney transplant versus isolated heart transplant in patients aged ≥ 65 years. *Interact Cardiovasc Thorac Surg.* 2018 Jul 3.
75. Sato T, Azarbal B, Cheng R, Esmailian F, **Patel J**, Kittleson M, Czer L, Thottam M, Levine R, Dimbil S, Olymbios M, Anzai T, Hamilton MA, Khayal T, Kobashigawa J. Does ex vivo perfusion lead to more or less intimal thickening in the first-year post-heart transplantation? *Clin Transplant.* 2019:e13648. Epub 2019/06/24. doi: 10.1111/ctr.13648. PubMed PMID: 31230384. 2019 Jun 23.

76. Miller RJH, Manabe O, Tamarappoo BK, Hayes S, Friedman J, Slomka PJ, **Patel J**, Kobashigawa J, Berman DS. Comparative prognostic and diagnostic value of myocardial blood flow and myocardial flow reserve after cardiac transplant. *Journal of Nuclear Medicine*. 2019. Epub 2019/08/28. doi: 10.2967/jnumed.119.229625. PubMed PMID: 31451490.
77. Miller RJH, Thomson L, Levine R, Dimbil SJ, **Patel J**, Kobashigawa JA, Kransdorf E, Li D, Berman DS, Tamarappoo B. Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection. *Clin Transplant*. 2019. Epub 2019/08/31. doi: 10.1111/ctr.13704. PubMed PMID: 31468570
78. Shah KS, **Patel J**. Desensitization in heart transplant recipients: who, when, and how. *Clinical Transplantation*. 2019;33(8). doi: 10.1111/ctr.13639.
79. Sato T, Cheng R, Azarbal B, Kittleson M, **Patel J**, Czer L, Levine R, Dimbil S, Olymbios M, Anzai T, Kransdorf E, Chang DH, Hamilton MA, Esmailian F, Kobashigawa J. Combined heart and kidney transplantation-is there a protective effect against cardiac allograft vasculopathy using intravascular ultrasound? *The Journal of Heart and Lung Transplantation*. 2019;38(9):956-62. Epub 2019/07/16. doi: 10.1016/j.healun.2019.06.012. PubMed PMID: 31301966.
80. Shah KS, **Patel J**. Desensitization in heart transplant recipients: Who, When, and how. *Clin Transplant*. 17 June 2019:e13639. Epub 2019/06/18. doi: 10.1111/ctr.13639. PubMed PMID: 31206862. In Press.
81. Michelle M. Kittleson, Robert M. Cole, **Jignesh Patel**, Danny Ramzy, Elizabeth Passano David H. Chang, Dael R. Geft, Lawrence Czer, Robert Vescio, Joshua Chung, Jon A. Kobashigawa, Francisco Arabia, Fardad Esmailian, Jaime D. Moriguchi. Mechanical circulatory support for cardiac amyloidosis. *Clin Transplant*. 2019 Jul 15:e13663. Epub 2019/07/17. doi: 10.1111/ctr.13663. PubMed PMID: 31309629.
82. Miller RJH, Manabe O, Tamarappoo B, Hayes S, Friedman J, Slomka PJ, **Patel J**, Kobashigawa J, Berman DS. Clarifying the utility of myocardial blood flow and myocardial flow reserve after cardiac transplant. *Journal of Nuclear Medicine*. 2019. Epub 2019/10/12. doi: 10.2967/jnumed.119.236190. PubMed PMID: 31601701.
83. Miller RJ, Kwiecinski J, Shah KS, Eisenberg E, **Patel J**, Kobashigawa JA, Azarbal B, Tamarappoo B, Berman DS, Slomka PJ, Kransdorf E, Dey D. Coronary computed tomographic angiography quantitative plaque analysis improves detection of early cardiac allograft vasculopathy: a pilot study. *American Journal of Transplantation*. 2019. Epub 2019/11/24. doi: 10.1111/ajt.15721. PubMed PMID: 31758640.
84. Bellumkonda L, **Patel J**. Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy. *Clinical Transplantation*. 2020 Jan;34(1). e13769. Epub 2019/12/13. doi: 10.1111/ctr.13769. PubMed PMID: 31829455
85. Cheng R, Dawkins S, Hamilton MA, Makar M, Hussaini A, Azarbal B, **Patel JK**, Kobashigawa JA, Trento A, Makkar RR, Kar S. Percutaneous Mitral Repair for Patients in Cardiogenic Shock Requiring Inotropes and Temporary Mechanical Circulatory Support. *JACC Cardiovasc Interv*. 2019 Dec 9;12(23):2440-2441. doi: 10.1016/j.jcin.2019.05.042. No abstract available. PMID: 31806229.
86. Nelson T, Leung B, Bannykh S, Shah KS, **Patel J**, Dumitrascu OM. Cerebral Amyloid Angiopathy-related inflammation in the immunosuppressed: a case report. *Frontiers in Neurology*. 2019. 10:1283.

Epub 2019/12/24. doi: 10.3389/fneur.2019.01283. PubMed PMID: 31866934; PubMed Central PMCID: PMC 6908508

87. Robert H Miller, Adele Pope, Evan Paul Kransdorf, Michele A Hamilton, **Jignesh Patel**, Sean W Hayes, John Friedman, Louise Thomson, Balaji Tamarappoo, Daniel S Berman, Piotr Slomka. Quantitative Assessment of Myocardial Hypermetabolism and Perfusion for Diagnosis of Cardiac Sarcoidosis. *Journal of The American College of Cardiology*. Volume 75, Issue 11 Supplement 1, March 2020. DOI: 10.1016/S0735-1097(20)32275-0
88. Maya Guglin, Mark J. Zucker, Barry A. Borlaug, Erin Breen, Joseph Cleveland, Maryl R. Johnson, Gurusher S. Panjrath, **Jignesh K. Patel**, Randall C. Starling, Biykem Bozkurt, on behalf of the ACC Heart Failure and Transplant Member Section and Leadership Council. Evaluation for Heart Transplantation and LVAD Implantation. *J Am Coll Cardiol*. 2020 Mar, 75 (12) 1471-1487.
89. Khush KK, **Patel J**, Pinney S, Kao A, Alharethi R, DePasquale E, Ewald G, Berman P, Kanwar M, Hiller D, Yee JP, Woodward RN, Hall S, Kobashigawa J. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. *Am J Transplant*. 2019 Mar 5. doi: 10.1111/ajt.15339. PMID: 30835940.
90. **Jignesh K Patel**. Blood Based Immunological Monitoring After Heart Transplant. Current Status And Future Prospects. *Indian Journal of Thoracic and Cardiovascular*. 02 March 2020. DOI: 10.1007/s12055-020-00928-x.
91. Tamarappoo B, Otaki Y, Manabe O, Hyun M, Cantu S, Arnson Y, Gransar H, Hayes SW, Friedman JD, Thomson L, Slomka P, Dey D, Vescio R, **Patel J**, Berman DS.. Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis. *J Nucl Cardiol*. 2020;27(1):28-37. doi:10.1007/s12350-019-01753-5
92. Loupy A, Coutance G, Bonnet G, **Patel JK**, Jouven X, Kobashigawa J, et al. Identification and characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population Based Study. 4 May 2020. *Circulation*. 2020;141:1954–1967. Doi: 10.1161/CIRCULATIONAHA.119.044924.
93. Robin Mark Shaw, Tara C Hitzeman, Yu Xie, Ronit H Zadikany, Andriana P Nikolova, Rachel Baum, Ana-Maria Caldaruse, Sosse Agvanian, Gil Y Melmed, Dermot T MCGovern, Dael R Geft, David H Chang, Jaime D Moriguchi, Antoine Hage, Babak Azarbal, Lawrence S Czer, Michelle M Kittleson, **Jignesh Patel**, Alan H B Wu, Jon A Kobashigawa, Michele Hamilton, TingTing Hong. cBIN1 Score (CS) Identifies Ambulatory HFREF Patients and Predicts Cardiovascular Events. *Frontiers in Physiology*, section Cardiac Electrophysiology. 25 May 2020. doi: 10.3389/fphys.2020.00503.
94. **Patel JK**. Left ventricular assist systems and strokes: Statins to the rescue? *J Heart Lung Transplant*. 2020 Jun;39(6):593-594. doi: 10.1016/j.healun.2020.03.005. Epub 2020 Mar 17. PMID: 32276808
95. Zhang X, Kransdorf E, Levine R, **Patel JK**, Kobashigawa JA. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients. *Hum Immunol*. 2020 Jul;81(7):330-336. doi: 10.1016/j.humimm.2020.04.003. Epub 2020 Apr 17. PMID: 32307126

RESEARCH PAPERS – PEER REVIEWED (IN PRESS)

Kransdorf E, Chang D, Ro R, Reznik R, Yu R, Gordon O, **Patel J**, Kittleson M, Kobashigawa J. Sympathetic Paraganglioma- Induced Cardiomyopathy Requiring Heart Transplantation. *J Heart Lung Transplant*. (Pending Publication).

Coutance G, Kransdorf E, Bonnet G, Loupy A, Kobashigawa J, **Patel JK**. Statistical performance of sixteen post-transplant risk scores in a contemporary cohort of heart transplant recipients. *Am J Transplant*. 2020 Jul 26. doi: 10.1111/ajt.16217. Online ahead of print. PMID: 32713121

Kobashigawa J, Shah P, Joseph S, Olymbios M, Bhat G, Dhital K, Eisen H, Kransdorf E, **Patel J**, Skorka R, Pinney S, Wilson ME, Hall S; Heart Frailty Workgroup. Frailty in Heart Transplantation: Report from the Heart Workgroup of a Consensus Conference on Frailty. *Am J Transplant*. 2020 Jul 13. doi: 10.1111/ajt.16207. Online ahead of print. PMID: 32659872

Zadikany RH, Cole RM, Chang DH, **Patel JK**, Geft DR, Czer L, Esmailian F, Ramzy D, Moriguchi JD, Kobashigawa JA, Kittleson MM. Total Artificial Heart as Bridge to Cardiac Retransplantation. *ASAIO J*. 2020 Jun 29;10.1097/MAT.0000000000001217. doi: 10.1097/MAT.0000000000001217. Online ahead of print. PMID: 32639257

Esmailian G, Kobashigawa JA, Nishihara K, **Patel JK**, Czer L, Megna D, Emerson D, Ramzy D, Trento A, Chikwe J, Esmailian F. Heart transplantation in the era of the SARS-CoV-2 pandemic: Is it safe and feasible? *Clin Transplant*. 2020 Jul 7:e14029. doi: 10.1111/ctr.14029. Online ahead of print. PMID: 32633819

Vaidya G, Czer LSC, Kobashigawa J, Kittleson M, **Patel J**, Chang D, Kransdorf E, Shikhare A, Tran H, Vo A, Ammerman N, Huang E, Zabner R, Jordan S. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. *Transplant Proc*. 2020 Jun 7:S0041-1345(20)32575-6. doi: 10.1016/j.transproceed.2020.06.003. Online ahead of print. PMID: 32563584

Kransdorf EP, Pando MJ, Stewart D, Lindblad K, Bray R, Murphey C, Kaur N, **Patel JK**, Kim I, Zhang X, Maiers M, Kobashigawa JA, Gragert L. Stem cell donor HLA typing improves CPRA in kidney allocation. *Am J Transplant*. 2020 Jun 18. doi: 10.1111/ajt.16156. Online ahead of print. PMID: 32558252

Jignesh Patel. The Rising Source of Acute Renal Injury After Heart Transplantation. *Transpl Int*. 2020 Jul 28. doi: 10.1111/tri.13708. Online ahead of print. PMID: 32722844

CHAPTERS

1. **Patel JK** and Kobashigawa JA. Allograft Coronary Artery Disease. Franco KL and Verrier ED, eds. *Advanced Therapy in Cardiac Surgery (Second Edition)*. BC Decker, Hamilton ON, 2003: 580-593.
2. Kobashigawa J, Laks H, Wu G, **Patel J**, Moriguchi J, Hamilton M, Fonarow G, Fishbein M, Ardehali A. The University of California at Los Angeles heart transplantation experience. *Clin Transpl*. 2005;173-85.
3. **Patel JK**, Kobashigawa JA, Hamilton M. Cardiac, Lipid, and Atherosclerotic Complications Among Lung and Heart-Lung Recipients. Lynch III JP and Ross DJ, eds. *Lung and Heart-Lung Transplantation*. New York, NY: Taylor & Francis Group, 2006: 881-894.

4. **Patel JK**, Kobashigawa JA. Cardiac Allograft Vasculopathy. Ahsan N Ed. Chronic Allograft Failure: Natural History, Pathogenesis, Diagnosis and Management. Landes Bioscience, Austin, TX, 2007:63-73.
5. **Patel JK**, Kobashigawa JA. Thoracic organ transplantation: laboratory methods. *Methods Mol Biol.* 2013; 1034: 127-43. doi: 10.1007/978-1-62703-493-7_7.
6. **Patel JK**, Kobashigawa JA. Recurrent Disease After Heart Transplantation Textbook of Organ Transplantation Kirk A, Knechtle SJ, Larsen CP, Madsen JC, Pearson TC, Webber SB eds. 2014 Wiley
7. Kittleson MM, **Patel JK**, Kobashigawa JA. Cardiac Transplantation. Hurst's The Heart 14th Edition Volume 2. McGraw Hill. 2017:1746-1764.
8. **Patel JK**, Kobashigawa JA. The Sensitized Patient Awaiting Heart Transplantation. *Clinical Guide to Heart Transplantation.* Springer Intl. Publishing. 2017:57-71.

REVIEWS

1. **Patel J**, Kobashigawa JA. Cardiac transplantation: the alternate list and expansion of the donor pool. *Curr Opin Cardiol.* 2004 Mar;19(2):162-5. Review.
2. **Patel JK**, Kobashigawa JA. Immunosuppression, diagnosis, and treatment of cardiac allograft rejection. *Semin Thorac Cardiovasc Surg.* 2004 Winter;16(4):378-85. Review.
3. **Patel JK**, Kobashigawa JA. Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection? *Curr Opin Cardiol.* 2006 Mar;21(2):127-31. Review.
4. Kobashigawa JA, **Patel JK**. Immunosuppression for heart transplantation: where are we now? *Nat Clin Pract Cardiovasc Med.* 2006 Apr;3(4):203-12. Review.
5. **Patel JK**, Kobashigawa JA. Everolimus: an immunosuppressive agent in transplantation. *Expert Opin Pharmacother.* 2006 Jul;7(10):1347-55. Review.
6. **Patel JK**, Kobashigawa JA. Tacrolimus in cardiac transplantation. *Expert Review Clin Immunol.* 2007 Mar;3(2):131-8.
7. **Patel JK**, Kobashigawa JA. Tacrolimus in heart transplant recipients: an overview. *BioDrugs.* 2007;21(3):139-43. Review.
8. **Patel J**. Vitamin Therapy After Heart Transplantation. *Expert Rev Cardiovasc Ther.* 2015 Oct;13(10):1071-4
9. Wolfson AM, Shah KS, **Patel JK**. Amyloid and the Heart. *Curr Cardiol Rep.* 2019 Dec 3;21(12):164. doi: 10.1007/s11886-019-1230-9. Review. PMID: 31792619

EDITORIALS

1. **Patel J**. In pursuit of renal preservation after heart transplantation: inching closer? *Am J Transplant.* 2014 Sep;14(9):1960-1. doi: 10.1111/ajt.12831. Epub 2014 Aug 6
2. **Patel JK**. The B1-Adrenergic Receptor IgG Subclass 3 Autoantibody in Dilated Cardiomyopathy: Friend or Foe? *J Am Coll Cardiol.* 2017 Feb 28;69(8):978-980. doi: 10.1016/j.jacc.2017.01.008. PMID: 28231951.
3. **Patel JK**. Prioritization for sensitization in heart transplantation-An approach toward greater equity. (Editorial). *J Heart Lung Transplant.* 2017 May;36(5):486-487. doi: 10.1016/j.healun.2017.02.009. Epub 2017 Feb 10. PMID: 28262441.

ABSTRACTS

1. Giesler G, Espejo M, Kubak B, Moriguchi J, **Patel J**, Laks H, Kobashigawa J. Increased Risk of CMV Infection in Heart Transplant Patient on Mycophenolate Mofetil. *J Heart Lung Transplant* 2001; 20: 178.
2. Shivkumar K, Espejo M, Kobashigawa J, Watanabe M, Ikeda M, Chuang J, **Patel J**, Moriguchi J, Hamilton M, Kawata N, Laks H. Sudden Death After Heart Transplantation: The Major Mode of Death. *J Heart Lung Transplant* 2001; 20: 180.
3. Espejo M, Kobashigawa J, Moriguchi J, **Patel J**, Kumar N, Hamilton M, Hage A, Kawata N, Laks H. The Dilemma of Disability After Heart Transplantation. *J Heart Lung Transplant* 2001; 20: 244.
4. Cogert G, Kobashigawa J, Espejo M, **Patel J**, Moriguchi J, Laks H. Plasmapheresis Lowers the Incidence of Transplant Coronary Artery Disease following Hemodynamic Transplant Rejection. AST Chicago, Chicago Sheraton Hotel, May 15, 2001.
5. Subherwal S, Cogert GA, Hamilton M, Wu G, **Patel JK**, Espejo Vassilakis M, Fishbein MC, Kobashigawa JA. Incidence of non-cellular (humoral) rejection unchanged in the 1990 decade despite a decrease in cellular rejection [abstract]. *J Investig Med* 2003;51(1):S115-6.
6. **Patel JP**, Espejo Vassilakis M, Cole B, Kessler L, Kubak B, Kobashigawa JA, Patel JK. Outcomes Following Cardiac Transplantation in Patients Receiving Allografts from Hepatitis C Positive Donors – The UCLA Experience. Presented at American College of Cardiology Scientific Session, Chicago, IL, Apr 2003.
7. Cruz D, Espejo Vassilakis M, Garfinkel A, Moriguchi J, Fonarow G, Fishbein M, Kobashigawa J, **Patel J**. The vagrancy of B-type natriuretic peptide (BNP) levels in orthotopic heart transplant (OHT) recipients. Presented at American College of Cardiology Scientific Session, Chicago, IL, April 2003.
8. Kao J, Fishbein MC, Kobashigawa JA, **Patel JK**, McLellan RC, Burdick M, Belperio J, Strieter RM. Elevated levels of the CXCR3 chemokine ligand ITAC is associated with the development of severe transplant coronary artery disease in humans [abstract]. *J Heart Lung Transplant* 2003;22(1S):S97-98.
9. Cogert GA Subherwal S, Wu G, **Patel JK**, Vassilakis ME, Fishbein MC, Moriguchi J, Laks H, and Kobashigawa JA. Incidence of non-cellular (humoral) rejection unchanged in the 1990 decade despite a decrease in cellular rejection [abstract]. *J Heart Lung Transplant* 2003;22(1S):S119-120.
10. Baird BL, Velleca AW Erickson VS, Woo MA, **Patel JK**, Hamilton MA, Kobashigawa JA, and Dracup KA. Rapid assessment of quality of life in patients with advanced heart failure [abstract]. *J Heart Lung Transplant* 2003;22(1S):S132.
11. Espejo Vassilakis M, Kobashigawa JA, Subherwal S, Fishbein MC, **Patel JK**, Moriguchi J, Go S, Almeda P and Laks H. Scoring of 2.788 endomyocardial biopsies correlate rejection to the development of transplant coronary artery disease after heart transplantation [abstract]. *J Heart Lung Transplant* 2003;22(1S):S139.
12. Cogert GA, Shivkumar K, **Patel JK**, Weiner I, Moriguchi J, Espejo Vassilakis M, Laks H, and Kobashigawa JA. Implantable cardioverter defibrillators in heart transplant patients at risk for sudden death: shocking news? [abstract]. *J Heart Lung Transplant* 2003;22(1S):S178-179.
13. Kobashigawa JA, Cogert GA, Tobis JM, Currier J, Espejo Vassilakis M, **Patel JK**, Moriguchi JD, Laks H. Improved survival of heart transplant patients with severe transplant coronary artery disease in the era of percutaneous coronary intervention and statin therapy. Accepted for presentation at American Transplant Congress, Washington DC, June 2003.

14. Ji S, Cesario D, Valderrabano M, Cote S, Hardie M, Boyle NG, Shannon KM, Espejo-Vassilakis M, Hamilton MA, Hage A, Moriguchi JD, **Patel JK**, Kobashigawa JA, Wiener I, Shivkumar K, UCLA Cardiac Arrhythmia Center, Los Angeles, CA. Mechanistic Basis of Supraventricular Arrhythmias Following Orthotopic Cardiac Transplantation. Accepted for presentation at American Heart Association Conference 2003, Orlando, FL, November 9-11, 2003.
15. Kobashigawa JA, **Patel JK**, Marquez A, Oeser BT, Moriguchi JD, Laks H, University of California, Los Angeles, Los Angeles, CA. The renal benefit of calcinerin inhibitor-free immunosuppression after heart transplantation: Is it safe? [abstract]. *J Am Coll Cardiol* 2004;43(5 SupplA):193A.
16. Kobashigawa JA, Moriguchi JD, **Patel J**, Shaw J, Oeser BT, and Laks H. Five-year results of a randomized single center study of tacrolimus (TAC) vs. neoral cyclosporine (CYA) [abstract]. *J Heart Lung Transplant* 2004;23(2 Suppl 1):S46.
17. Kobashigawa JA, Cogert G, Moriguchi JD, **Patel JK**, Laks H. The highly sensitized patient awaiting heart transplantation: success with combination therapy of plasmapheresis and intravenous gamma globulin [abstract]. *J Heart Lung Transplant* 2004;23(2 Suppl 1):S61.
18. **Patel JK**, Oeser BT, Go S, Rivera BJ, Plesa ML, Moriguchi JD, Kobashigawa JA. Retransplantation – never too old for one? [abstract]. *J Heart Lung Transplant* 2004;23(2 Suppl 1):S72.
19. Kobashigawa JA, Moriguchi JD, Cogert G, Hage A, Hamilton MA, Vassilakis ME, Marquez A, Yeatman L, **Patel J**, Laks H. 10-year results of the pravastatin randomized trial in heart transplant recipients [abstract]. *J Heart Lung Transplant* 2004;23(2 Suppl 1):S115.
20. Kobashigawa JA, **Patel JK**, Cogert G, Almeda NP, Go S, Lee P, Camara R, Velleca A, Laks H. The dark side of corticosteroid weaning after heart transplantation: Is it worth it? *Am J Transplant* 2004;4(8):174
21. Kobashigawa JA, **Patel JK**, Cogert G, Almeda NP, Go S, Lee P, Camara R, Velleca A, Laks H. The dark side of corticosteroid weaning after heart transplantation: Is it worth it? Accepted for presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
22. **Patel JK**, Marquez A, Sue E, Kobashigawa E, Laks H, Kobashigawa JA. The development of left ventricular hypertrophy after heart transplantation: Is this a marker for poor outcome. Accepted for presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
23. **Patel JK**, Go S, Fonarow G, Oeser BT, Laks H, Kobashigawa JA. Heart transplantation for patients greater than 65 years: Are we expecting too much? Accepted for presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
24. **Patel JK**, Nakashima J, Moriguchi JD, Oeser BT, Marquez A, Laks H, Kobashigawa JA. Poor outcome of early development of cardiac allograft vasculopathy after cardiac transplantation. Accepted for presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
25. Mitropoulos FA, Laks H, Kermani R, Marelli D, Ardehali A, Plunkett M, Esmailian F, Odum J, Moriguchi J, Hamilton M, **Patel J**, Kobashigawa J. Use of donor hearts with left ventricular ejection fraction \leq 50% for transplantation. Accepted for presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
26. Nakashima JK, Kobashigawa JA, **Patel JK**, Yamada C, Hamilton M. Patients with refractory hypercholesterolemia have poor outcome after heart transplantation [abstract]. *J Investig Med* 2005;53(1):S83.

27. Seid A, Kobashigawa JA, **Patel JK**, Yamada B, Hamilton M. A multidisciplinary network of social support can positively affect outcome in lower socioeconomic patients (medical/Medicaid insurance) after heart transplantation [abstract]. *J Investig Med* 2005;53(1):S96.
28. Alison-Mayne S, **Patel JK**, Kobashigawa JA, Laks H, Hamilton M. The use of marginal donor hearts in heart transplant patients [abstract]. *J Investig Med* 2005;53(1):S96.
29. Almeda NP, Odim J, Laks H, **Patel JK**, Hamilton M, Kobashigawa JA. Bypassed donor hearts: the long term outcome after heart transplantation [abstract]. *J Investig Med* 2005;53(1):S121-2.
30. Go SE, Kobashigawa JA, **Patel JK**, Hamilton M. Asymptomatic humoral rejection diagnosed on endomyocardial biopsy after heart transplant appears to have clinical significance [abstract]. *J Investig Med* 2005;53(1):S122.
31. Plesa M, **Patel JK**, Marquez A, Nakashima J, Kobashigawa JA. Ezetimibe for hypercholesterolemia in patients after heart transplant [abstract]. *J Investig Med* 2005;53(1):S145.
32. Busuttill AA, Horwich TB, Fonarow GC, **Patel J**, Kobashigawa JA. Anemica is associated with a significant increase in mortality in the orthotopic heart transplant population [abstract]. *J Am Coll Cardiol* 2005 Feb;45(Suppl 1):156A.
33. Kobashigawa JA, **Patel JK**, Marquez A, Oeser BT, Velleca A, Camara R, Laks H. Calcineurin inhibitor-free renal sparing protocol for patients with renal insufficiency after heart transplantation: trouble on the horizon? [abstract]. *J Am Coll Cardiol* 2005 Feb;45(Suppl 1):157A.
34. Kobashigawa JA, Ro Thomas, Fishbein MC, **Patel JK**, Oeser BT, Laks H. Biopsy-proven ISHLT grades 1A, 1B, and 2 rejection in heart transplant patients: should we re-classify them into one mild rejection grade? [abstract]. *J Am Coll Cardiol* 2005 Feb;45(Suppl 1):157A.
35. Kobashigawa JA, **Patel JK**, Furukawa H, Marquez A, Oeser BT, Laks H. Five-year results of a randomized single center study of Tacrolimus vs. Microemulsion Cyclosporine in heart transplant patients. Presented at 3rd International Congress on Immunosuppression, San Diego, CA, Dec 8-11, 2004.
36. Almeda NP, Kobashigawa JA, **Patel JK**, Camara R, Velleca A, and Laks H. Coricosteroid weaning after heart transplantation: A five-year risk assessment. Presented at 3rd International Congress on Immunosuppression, San Diego, CA, Dec 8-11, 2004.
37. Marquez A, Kobashigawa JA, **Patel JK**, Oeser BT, Velleca A, Camara R, Laks H. Cyclosporine/Tacrolimus-free renal sparing protocol for patients with renal insufficiency after heart transplantation: is it safe? Presented at 3rd International Congress on Immunosuppression, San Diego, CA, Dec 8-11, 2004.
38. **Patel JK**, Ro T, Fishbein MC, Oeser BT, Marquez A, Laks H, Kobashigawa JA. Justification of the newly proposed ISHLT biopsy grading scale by combining grades 1A, 1B, and 2 into one mild rejection grade [abstract]. *J Heart Lung Transplant* 2005 Feb;24(2S):S66.
39. Laks H, Mitropoulos F, Odim J, **Patel JK**, Marquez A, Plesa M, Oeser BT, Kobashigawa JA. Long-term outcome of alternate list heart transplant patients [abstract]. *J Heart Lung Transplant* 2005 Feb;24(2S):S70.
40. Odim J, Laks H, Almeda NP, **Patel JK**, Kobashigawa JA. CABG-patched donor hearts: the long term outcome [abstract]. *J Heart Lung Transplant* 2005 Feb;24(2S):S71.
41. Kobashigawa JA, Fishbein MC, **Patel JK**, Oeser BT, Almeda NP, Alison-Mayne S, Seid A, Laks H. Should humoral rejection be included in the new ISHLT biopsy grading scale [abstract]. *J Heart Lung Transplant* 2005 Feb;24(2S):S144.

42. **Patel JK**, Kobashigawa JA, Marquez A, Oeser BT, Velleca A, Camara R, Laks H. Caution using a calcineurin inhibitor-free renal sparing protocol for heart transplant patients with renal dysfunction [abstract]. *J Heart Lung Transplant* 2005 Feb;24(2S):S160.
43. **Patel JK**, Mitropoulos F, Laks H, Moriguchi JD, Wang EZ, Oeser BT, Kobashigawa JA. Nesiritide immediately after heart transplantation: a pilot study [abstract]. *Am J Transplant* 2005;5(Suppl 11):169.
44. Miller S, **Patel JK**, Lee P, Wu GW, Chi L, Fishbein M, Laks H, Kobashigawa JA. Hemodynamic Compromise Predicts Future Cardiac Allograft Vasculopathy and Nonfatal Major Adverse Cardiac Events. *J Investig Med* 2006;54(1):S120.
45. Sarkissian S, Ro T, **Patel JK**, Wu GW, Hamilton MA, Kobashigawa JA. What is the Outcome of International Society for Heart & Lung Transplantation Grade 1A/1B Rejections under Various Immunosuppressive Regimens? *J Investig Med* 2006;54(1):S120.
46. Kawano J, Cruz D, Wu GW, **Patel JK**, Sarkissian S, Vaidya V, Laks H, Kobashigawa JA. Average First-Year Brain Natriuretic Peptide Predicts Poor Outcome after Heart Transplantation. *J Investig Med* 2006;54(1):S149.
47. Wu GW, **Patel JK**, Reed E, Gjertson D, Hamilton MA, Kobashigawa JA. Flow Cytometry-Positive, Cytotoxicity-Negative Donor-Specific Crossmatch: To Transplant or Not to Transplant, That is the Question. *J Investig Med* 2006;54(1):S150.
48. Parikh A, **Patel JK**, Kubak B, Thompson OM, Patel JP, Hamilton MA, Kobashigawa JA. Hepatitis C Donor Hearts in Noninduction Immunosuppressive Regimens Portend Poor Outcome after Heart Transplantation. *J Investig Med* 2006;54(1):S150.
49. **Patel JK**, Seid A, Mansukhani A, Thompson OM, Wu GW, Laks H, Kobashigawa JA. When To list for re-do heart transplant in patients with severe cardiac allograft vasculopathy. *J Heart Lung Transplant*. 2006; 25(2S):100-101.
50. **Patel JK**, Reed E, Gjertson D, Wu GW, Laks H, Kobashigawa JA. Flow-cytometry positive, cytotoxicity-negative donor-specific crossmatch: To transplant or not to transplant, that is the question. *J Heart Lung Transplant*. 2006; 25(2S):108.
51. **Patel JK**, Lai C, Fishbein MC, Go SE, Wu GW, Laks H, Kobashigawa JA. Asymptomatic humoral rejection after heart transplantation: Does it require therapy? *J Heart Lung Transplant*. 2006; 25(2S):109.
52. **Patel JK**, Parikh A, Kubak B, Thompson OM, Patel JP, Laks H, Kobashigawa JA. Hepatitis C donor hearts in non-induction immunosuppressive regimens portend poor outcome after heart transplantation. *J Heart Lung Transplant*. 2006; 25(2S):114.
53. Cruz D, Wu GW, **Patel JK**, Kawano J, Sarkissian S, Thompson OM, Vaidya V, Laks H, Kobashigawa JA. Average first-year BNP predicts poor outcome after heart transplantation. *J Heart Lung Transplant*. 2006; 25(2S):132.
54. Ro T, **Patel JK**, Sarkissian S, Wu GW, Laks H, Kobashigawa JA. What is the outcome of ISHLT grade 1A/1B rejections under various immunosuppressive regimens? *J Heart Lung Transplant*. 2006; 25(2S):134.
55. Smooke S, Dev S, **Patel JK**, Kawano J, Almeda NP, Thompson OM, Wu GW, Laks H, Kobashigawa JA. Pre-transplant glucose intolerance and not diabetes predicts non-fatal major adverse cardiac events after cardiac transplantation. *J Heart Lung Transplant*. 2006; 25(2S):138.
56. Vaidya VS, Cruz D, Wu GW, **Patel JK**, Sarkissian S, Kawano J, Laks H, Kobashigawa JA. Persistently Elevated B-Type Natriuretic Peptide (BNP) Levels after Acute Allograft Rejection in Heart Transplant Recipients Predict Poor Outcomes. *Am J Transplant*. 2006; 6(2S):558.

57. **Patel JK**, Kawano J, Wu GW, Laks H, Kobashigawa JA. Efficacy of Photopheresis of Recurrent/Refractory Humoral and Cellular Rejections in Heart Transplant Patients. *Am J Transplant*. 2006; 6(2S):146-7.
58. **Patel JK**, Miller S, Kawano J, Sarkissian S, Seid A, Wu GW, Laks H, Kobashigawa JA. Intravenous Immunglobulin as Part of Combined Immunotherapy Appears Effective for Late (>30 Days) Complex Rejection after Cardiac Transplantation. *Am J Transplant*. 2006; 6(2S):147.
59. **Patel JK**, Reed E, Gjertson G, Wu GW, Laks H, Kobashigawa JA. Flow-Cytometry Positive, Cytotoxicity-Negative Donor-Specific Crossmatch is Associated with Good Outcome Following Cardiac Transplantation Using Non-Induction Immunosuppressive Regimen. *Am J Transplant*. 2006; 6(2S):775.
60. **Patel JK**, Lai C, Fishbein MC, Go SE, Wu GW, Laks H, Kobashigawa JA. Asymptomatic Humoral Rejection after Heart Transplantation is Associated with the Development of Cardiac Allograft Vasculopathy. *Am J Transplant*. 2006; 6(2S):379-80.
61. **Patel JK**, Lee P, Miller S, Lai C, Fishbein M, Wu GW, Laks H, Kobashigawa JA. Hemodynamic Compromise Rejection Predicts Future Cardiac Allograft Vasculopathy and Non-Fatal Major Adverse Cardiac Events. *Am J Transplant*. 2006; 6(2S):381-2.
62. **Patel JK**, Parikh A, Kubak B, Patel JP, Laks H, Kobashigawa JA. Poor Outcome after Heart Transplantation with Hepatitis C Donor Hearts and Non-Induction Immunosuppressive Regimens. *Am J Transplant*. 2006; 6(2S):382-3.
63. **Patel JK**, Smooke SJ, Kawano J, Almeda NP, Wu GW, Laks H, Kobashigawa JA. The High Incidence of Glucose Intolerance and New-Onset Diabetes after Heart Transplantation is not Affected by Choice of Calcineurin Inhibitor. *Am J Transplant*. 2006; 6(2S):556.
64. Yajnik M, Vaidya VS, **Patel JK**, Cruz D, Wu GW, Kittleson MM, Hamilton MA, Kobashigawa JA. The Validity of B-Type Natriuretic Peptide Blood Levels to Detect Heart Failure in Heart Transplant Patients. *J Investig Med* 2007;55(1):S136.
65. Kawano MA, **Patel JK**, Kittleson MM, Hamilton MA, and Kobashigawa JA. Pharmacologic Myocardial Perfusion Stress Testing to Detect Significant Cardiac Allograft Vasculopathy-Is It Worthwhile? *J Investig Med* 2007;55(1):S137.
66. Seid A, Aye O, **Patel JK**, Chinakarn L, Kittleson MM, Hamilton MA, Kobashigawa JA. Increased Infection Risk of Non-Cardiac Surgeries after Heart Transplantation. *J Investig Med* 2007;55(1):S137.
67. Gokanapudy L, Itagaki BK, Kobashigawa JA, Wu GW, Brubaker W D, Kawano MA, Kittleson MM, Hamilton MA, and **Patel JK**. Re-Transplantation for Heart Failure with Preserved Systolic Function. *J Investig Med* 2007;55(1):S137.
68. Brubaker WD, Itagaki BK, Kobashigawa JA, Wu GW, Kawano MA, Kittleson MM, Hamilton MA, and **Patel JK**. The Stiffer the Heart, the Worse the Outcome after Heart Transplantation. *J Investig Med* 2007;55(1):S137.
69. Chinakarn L, Kawano MA, Song H, **Patel JK**, Hamilton MA, and Kobashigawa JA. Outcome of Combined Kidney and Redo Heart Transplant Recipients from a Single Center. *J Investig Med* 2007;55(1):S137.
70. Itagaki BK, Kobashigawa JA, Wu GW, **Patel JK**, Kawano MA, Kittleson MM, Hamilton MA, and Fishbein MC. Widespread Fibrosis of Myocardial and Adjacent Tissues Causing Restrictive Cardiac Physiology in Patients Needing Re-do Heart Transplant. *J Investig Med* 2007;55(1):S137.

71. Song H, Kittleson MM, Yajnik M, Wu GW, Kobashigawa BI, **Patel JK**, Hamilton MA, and Kobashigawa JA. Naturally Occurring Leukopenia as a Marker for Good Outcome after Cardiac Transplantation. *J Investig Med* 2007;55(1):S158.
72. **Patel JK**, Kawano MA, Wu GW, Kawano JC, Yajnik M, Kittleson MM, Kobashigawa JA. Practically Speaking: The initiation of lower dose mycophenolate mofetil (MMF) 1000 mg bid appears to have similar outcome to 1500 mg bid after heart transplantation. *J Heart Lung Transplant* 2007; 26(2S):S70.
73. Vaidya VA, Yajnik M, **Patel JK**, Cruz D, Wu GW, Kittleson MM, Kobashigawa JA. The validity of BNP blood levels to detect heart failure in heart transplant patients. *J Heart Lung Transplant* 2007;26(2S):S120-1.
74. Itagaki BK, Kobashigawa JA, Wu GW, **Patel JK**, Kawano MA, Kittleson MM, Fishbein MC. Widespread fibrosis of myocardial and adjacent tissues causing restrictive cardiac physiology in patients needing re-do heart transplant. *J Heart Lung Transplant* 2007;26(2S):S138.
75. Itagaki BK, Kobashigawa JA, Wu GW, Brubaker W, Kawano MA, Gokanapudy L, Kittleson MM, **Patel JK**. The stiffer the heart, the worse the outcome after heart transplantation. *J Heart Lung Transplant* 2007;26(2S):S183.
76. **Patel JK**, Kawano JC, Wu GW, Chinakarn L, Kawano MA, Kobashigawa BI, Kittleson MM, Gordon AL, Kagimoto SM, Kobashigawa JA. Recurrent mild rejection in the first year after heart transplantation does not affect outcomes: validation of the revised ISHLT grading system. *J Heart Lung Transplant* 2007;26(2S):S226.
77. Zhang Q, Si K, Ge P, Wu GW, **Patel JK**, Kobashigawa J, Fishbein MC, Reed EF. HLA and MICA: Targets of antibody mediated rejection in heart transplantation. *J Heart Lung Transplant* 2007;26(2S):S106.
78. Shao ES, Chen TE, Wu GW, **Patel JK**, Kobashigawa JA. Cardiac transplantation for giant cell myocarditis: A single center experience. *J Heart Lung Transplant* 2007;26(2S):S154.
79. Kobashigawa JA, Kawano MA, Wu GW, Kawano JC, Yajnik M, Kittleson MM, **Patel JK**. First-year mycophenolate mofetil does reductions: Do they portend poor outcome? *J Heart Lung Transplant* 2007;26(2S):S228.
80. Aye O, **Patel JK**, Seid A, Chinakarn L, Kittleson MM, Kobashigawa JA. Increased infection risk of non-cardiac surgeries after heart transplantation. *J Heart Lung Transplant* 2007;26(2S):S236.
81. **Patel JK**, Kawano MA, Kittleson MM, Kobashigawa JA. Pharmacological myocardial perfusion stress testing to detect significant cardiac allograft vasculopathy- is it worthwhile? *J Heart Lung Transplant* 2007;26(2S): S236-7.
82. Miller SJ, Kobashigawa JA, Kittleson MM, **Patel JK**, Kawano MA, Ardehali A. The use of ECMO/Intra-aortic balloon pump to support hemodynamics in patients with cardiogenic shock due to severe rejection. *J Heart Lung Transplant* 2007;26(2S):S237.
83. Itagaki BK, Kobashigawa JA, Wu GW, Brubaker W, Kawano MA, Gokanapudy L, Kittleson MM, **Patel JK**. Re-transplantation for heart failure with preserved systolic function. *J Heart Lung Transplant* 2007;26(2S):S237-8.
84. Kittleson MM, Song H, Yajnik M, Wu GW, Kobashigawa BI, **Patel JK**, Kobashigawa JA. Naturally occurring leucopenia as a marker for good outcome after cardiac transplantation. *J Heart Lung Transplant* 2007;26(2S):S254-5.
85. **Patel JK**, Kawano MA, Wu GW, Chinakarn L, Song H, Kittleson MM, Kobashigawa JA. Heart Transplantation in Septagenarians: Is It Worth It? *Am J Transplant* 2007;7(S2):406.
86. Kobashigawa J, Kiyosaki K, Kubak B, **Patel J**, Kittleson M, Ardehali A. Surgical Treatment of Heart Failure Transplantation and Arrhythmias I. "Successful Use of Immune Monitoring

- (Cylex) In Heart Transplantation for Rejection and Infection Risk. Scientific Sessions 2007, Orlando, FL, November 4-7, 2007. *Circulation* Oct 2007;116: II-572.
87. Kobashigawa J, **Patel J**, Kawano M, Wu G, Kittleson M, Kiyosaki K, Moriguchi J, Ardehali A. Surgical Treatment of Heart Failure Transplantation and Arrhythmias II. "The Long Term Outcome of Treated Presensitized Patients who Undergo Heart Transplantation: Is It Successful?" Scientific Sessions 2007, Orlando FL, November 4-7, 2007. *Circulation* Oct 2007;116: II-644.
 88. Kobashigawa JA, Reed E, Sue E, **Patel JK**, Kittleson MM, Kawano MA, Kiyosaki KK, Ardehali A. Successfully Treated Pre-transplant Sensitized Patients Have Favorable Post-Transplant Outcomes. *J Heart Lung Transplant* 2008;27(2S):S19.
 89. Itagaki B, **Patel JK**, Kittleson MM, Kawano MA, Ardehali A, Kobashigawa JA. The Innocence of Coronary Spasm after Heart Transplantation. *J Heart Lung Transplant* 2008;27(2S):S23.
 90. **Patel JK**, Simenhoff B, Kittleson MM, Kawano MA, Ardehali A, Kobashigawa JA. Making Sense of Immunosenescence in Older Heart Transplant Recipients. *J Heart Lung Transplant* 2008;27(2S):S33.
 91. Kittleson MM, Song HS, **Patel JK**, Kawano MA, Patel D, Kiyosaki KK, Ardehali A, Kobashigawa JA. End-stage Renal Disease after Heart Transplantation The Benefits of Kidney Transplantation. *J Heart Lung Transplant* 2008;27(2S):S23.
 92. **Patel JK**, Kawano JC, Kittleson MM, Duong U, Ardehali A, Kobashigawa JA. First-Year Statin Resistant Hypercholesterolemia: A Cause for Concern in the Development of Cardiac Allograft Vasculopathy. *J Heart Lung Transplant* 2008;27(2S):S45.
 93. Kittleson MM, Carr SA, **Patel JK**, Kawano MA, Kiyosaki KK, Ankrom AK, Ardehali A, Kobashigawa JA. Everolimus May Have Lower Adverse Effect Profile Compared to Sirolimus in Heart Transplant Patients. *J Heart Lung Transplant* 2008;27(2S):S30.
 94. **Patel JK**, Brown A, Kittleson MM, Kawano JC, Kawano MA, Kiyosaki KK, Ardehali A, Kobashigawa JA. Malignancy Risk in 2007 with Current Immunosuppression Regimens. *J Heart Lung Transplant* 2008;27(2S):S23.
 95. Kobashigawa JA, Kiyosaki KK, **Patel JK**, Kittleson MM, Ardehali A. Success of Immune Monitoring with ImmuKnow (Cylex) to Assess Rejection/Infectious Risk in Heart Transplantation. *J Heart Lung Transplant* 2008;27(2S):S41.
 96. **Patel JK**, Itagaki B, Ankrom A, Kawano MA, Kiyosaki KK, Yajnik M, Abbas A, Kobashigawa JA. Hemodynamic Compromise Rejection: Diagnose and Treat Cardiac Rejection and Vasculopathy Before it is Too Late. *J Heart Lung Transplant* 2008;27(2S):S41.
 97. Kittleson MM, Vaidya AS, **Patel JK**, Kawano MA, Ardehali A, Kobashigawa JA. Long-Term Risks Post Steroid Weaning: Not so Rosy After All. *J Heart Lung Transplant* 2008;27(2S):S23.
 98. Kittleson MM, Kawano JC, **Patel JK**, Kawano MA, Yajnik MV, Kiyosaki KK, Ardehali A, Kobashigawa JA. Hypercholesterolemia in Heart Transplant Patients on Proliferation-Signal Inhibitors: Is Statin Therapy Effective? *J Heart Lung Transplant* 2008;27(2S):S29.
 99. Vaidya VS, Yajnik M, Heidenreich P, Kawano MA, Vaidya AS, **Patel JK**, Kittleson MM, Ankrom AK, Ardehali A, Kobashigawa JA. Comparison of Survival and Costs Between Transplantation and Medical Treatment of End Stage Heart Failure. *J Heart Lung Transplant* 2008;27(2S):S34.
 100. Moriguchi J, Kwon M, Punkett M, Esmailian F, Jocson R, Laks H, Marelli D, Beygui R, Davis S, Ardehali A, **Patel J**, Kobashigawa J. Improved Clinical Outcomes Using Bi-Ventricular Assist Devices as Bridges to Transplant in Critically Ill Patients. *J Heart Lung Transplant* 2008;27(2S):S38.

101. Kittleson MM, Ankrom AK, **Patel JK**, Kawano MA Ardehali A, Kobashigawa JA. Aliskiren: A New Anti-Renin Blood Pressure medication Appears Safe and Effective in Heart Transplant Recipients. *J Heart Lung Transplant* 2008;27(2S):S23.
102. Marelli D, Kobashigawa JA, Hamilton MA, Noguchi E, Moriguchi JD, **Patel JK**, Laks H, Esmailian F, Beygui R, Plunkett MD, Ardehali A. Long Term Outcome of Heart Transplant in the Elderly. *J Heart Lung Transplant* 2008;27(2S):S33.
103. Marelli D, Kobashigawa JA, Moriguchi JD, Shuvayev I, Wong SY, Kahn T, Patel JK, Beygui R, Esmailian F, Laks H, Plunkett MD, Ardehali A. ECMO to Salvage Severe Cardiogenic Shock in Advanced Heart Failure and Transplantation. *J Heart Lung Transplant* 2008; 27(2S):S37.
104. Kittleson MM, **Patel JK**, Kawano, MA Kubak, Ardehali A, Kobashigawa JA. Aggressive Antimicrobial Prophylaxis Decreases Infectious Risk Despite Rejection Therapy after Heart Transplantation. *Am J Transpl* 2008;8(S2):348.
105. K Kiyosaki, J Kobashigawa, **J Patel**, J Patel, A Ankrom, M Kittleson, M Kawano, J Moriguchi, E Shao, A Ardehali. The Benefit of Immune Monitoring (Cylex): A Review of 864 Immune Monitoring Assays in Heart Transplantation. *J Heart Lung Transplant* 2009.
106. K Kiyosaki, J Kobashigawa, E Reed, J Moriguchi, M Kawano, A Ankrom, **J Patel**, M Kittleson, E Shao, A Ardehali. The Outcome of Treatment of 100% PRAs in Heart Failure Patients Awaiting Heart Transplantation. *J Heart Lung Transplant* 2009.
107. K Lo, K Kiyosaki, J Kobashigawa, M Kawano, A Ankrom, M Kittleson, E Shao, J Moriguchi, **J Patel**, A Ardehali. Low Peak Oxygen Consumption by Cardiopulmonary Stress Testing After Heart Transplantation Predicts Poor Outcome. *J Heart Lung Transplant* 2009.
108. B Kim, K Kiyosaki, E Shao, **J Patel**, M Kittleson, M Kawano, A Ankrom, J Moriguchi, A Ardehali, J Kobashigawa. Early Permanent Pacemaker After Heart Transplantation is a Surrogate Marker for Poor Outcome: Possible Immune Mechanisms. *J Heart Lung Transplant* 2009.
109. E Shao, M Kawano, K Kiyosaki, **J Patel**, M Kittleson, J Moriguchi, A Ardehali, J Kobashigawa. Late Rapidly Progressive Cardiac Allograft Vasculopathy is Associated with Poor Outcome. *J Heart Lung Transplant* 2009.
110. **J Patel**, M Kawano, K Kiyosaki, A Ankrom, M Kittleson, J Moriguchi, A Ardehali, J Kobashigawa. When is Too Old, Too Old for Redo Heart Transplantation? *J Heart Lung Transplant* 2009.
111. S Sohrabian, M Kawano, K Kiyosaki, A Ankrom, **J Patel**, J Moriguchi, M Kittleson, A Ardehali, J Kobashigawa. Spare Me the Renal Sparing Protocol - Poor Long Term Outcomes. *J Heart Lung Transplant* 2009.
112. M Kawano, J Kobashigawa, K Kiyosaki, A Ankrom, **J Patel**, M Kittleson, E Reed, A Ardehali. Outcome of Retrospective Positive Donor Specific Crossmatch After Heart Transplantation - Are They Doomed? *J Heart Lung Transplant* 2009.
113. **J Patel**, M Kawano, K Kiyosaki, E Shao, A Ankrom, M Kittleson, J Moriguchi, A Ardehali, J Kobashigawa. Addressing the Myth of Elevated Bilirubin as a Contraindication to Heart Transplantation. *J Heart Lung Transplant* 2009.
114. E Moreno, A Velleca, M Kawano, K Kiyosaki, S Wong, A Ankrom, **J Patel**, M Kittleson, L Ventura, J Moriguchi, A Ardehali, J Kobashigawa. Does High Risk Status Identified by Pre-Transplant Social Worker and Psychiatric Evaluation Predict Outcome After Heart Transplant? *J Heart Lung Transplant* 2009.
115. A Ankrom, **J Patel**, E Shao, S Carr, M Kawano, M Kittleson, K Kiyosaki, J Moriguchi, A Ardehali, J Kobashigawa. Obesity Confers Protection from Cardiac Allograft Vasculopathy. *J Heart Lung Transplant* 2009.

116. E Shao, M Kawano, N Moradzadeh, A Ankrom, K Kiyosaki, **J Patel**, M Kittleson, J Moriguchi, A Ardehali, J Kobashigawa. Right Ventricular Dysfunction Immediately Post Transplant - A Marker for Poor Outcome? *J Heart Lung Transplant* 2009.
117. E Shao, M Kawano, **J Patel**, M Kittleson, A Ankrom, K Kiyosaki, J Moriguchi, A Ardehali, J Kobashigawa. The Problem of Rejection in Redo Heart Transplant Recipients. *J Heart Lung Transplant* 2009.
118. J Patel, E Shao, **J Patel**, M Kawano, K Kiyosaki, A Ankrom, M Kittleson, J Moriguchi, A Ardehali, J Kobashigawa. Pre-Transplant FEV1/FVC but not FEV1 alone by Pulmonary Function Testing Predicts Poor Outcome After Heart Transplantation: The Bane of COPD. *J Heart Lung Transplant* 2009.
119. **J Patel**, B Kubak, M Kawano, A Ankrom, M Yajnik, K Kiyosaki, M Kittleson, J Moriguchi, A Ardehali, J Kobashigawa. The Efficacy of Shorter Duration CMV Prophylaxis After Heart Transplantation. *J Heart Lung Transplant* 2009.
120. Sasaoka T, Kato T, Kobashigawa J, **Patel J** et al. Retrospective Review of Japanese Heart Transplant Recipients Transplanted in Japan and Transplanted at UCLA in the U.S. *J Heart Lung Transplant* 2009.
121. **Patel J**, Kittleson M, Reed E, Aguas G, Kawano M, Davis S, Burch C, Velleca A, Stimpson E, Moriguchi J, Ardehali A, Kobashigawa J. The Importance of Anti-HLA DQ Antibodies as a Risk Factor for the Development of Transplant Coronary Artery Disease (TCAD) After Heart Transplantation. *J Heart Lung Transplant*. 2010; 29(2): S73-S74.
122. Kittleson M, **Patel J**, Reed E, Gjertson D, Kawano M, Davis S, Burch C, Velleca A, Stimpson E, Moriguchi J, Ardehali A, Kobashigawa J. Accommodation after Heart Transplantation: Does it Exist? *J Heart Lung Transplant*. 2010; 29(2): S63.
123. Lai C, **Patel J**, Fishbein M, Kittleson M, Share M, Davis S, Kawano M, Moriguchi J, Ardehali A, Kobashigawa J. C4d in Heart Transplant Biopsies Does Not Appear to Represent Poor Outcome. *J Heart Lung Transplant*. 2010; 29(2): S38.
124. Moreno E, Velleca A, Burch C, **Patel J**, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Pre-Transplant Smoking in Heart Transplant Patients: A Marker for Long Term Outcome? *J Heart Lung Transplant*. 2010; (29)2: S60.
125. Kittleson M, **Patel J**, Moriguchi J, Kawano M, Patel K, Davis S, Hage A, Hamilton M, Ardehali A, Kobashigawa J. Heart Transplant Rejection with Cardiogenic Shock Supported with Extracorporeal Membrane Oxygenation (ECMO): Outcome from a Single Center Experience. *J Heart Lung Transplant*. 2010; 29(2): S91.
126. Velleca A, Burch C, Montgomery S, Lockhart D, **Patel J**, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Threat of Medication Miscommunication in Non-English Speaking Heart Transplant Recipients. *J Heart Lung Transplant*. 2010; 29(2): S125.
127. Kawano M, Kittleson M, Fishbein M, **Patel J**, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Review of 12,703 Endomyocardial Biopsies: The Truth of Quilty Lesions in the Cyclosporine and Tacrolimus Era. *J Heart Lung Transplant*. 2010; 29(2): S73.
128. Kawano M, **Patel J**, Kittleson M, Reed E, Gjertson D, Cecka M, Velleca A, Stimpson E, Burch C, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Incidence and Outcome of Sensitization in Patients Awaiting Re-do Heart Transplantation. *J Heart Lung Transplant*. 2010; 29(2): S123-S124.
129. **Patel J**, Kittleson M, Reed E, Zhang Q, Rajalingam R, Velleca A, Stimpson E, Burch C, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Effectiveness of a Standardized Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies

- (cPRA) in Sensitized Heart Transplant Candidates: Does it Make Sense to Desensitize? *J Heart Lung Transplant.* 2010; 29(2): S103-S104.
130. Kittleson M, **Patel J**, Azarbal B, Moriguchi J, Kawano M, Davis S, Hage A, Ardehali A, Kobashigawa J. First Angioplasty Does Not Appear to Alter Outcome in Heart Transplant Patients with Newly Diagnosed Transplant Coronary Artery Disease. *J Heart Lung Transplant.* 2010; 29(2): S124.
 131. **Patel J**, Kittleson M, Zhang Q, Reed E, Kawano M, Davis S, Cecka M, Burch C, Velleca A, Stimpson E, Moriguchi J, Ardehali A, Kobashigawa J. Are Circulating Antibodies Necessary To Make A Diagnosis Of Antibody-Mediated Rejection? *J Heart Lung Transplant.* 2010; 29(2): S54.
 132. Kittleson M, **Patel J**, Reed E, Zhang Q, Cecka M, Stimpson E, Velleca A, Burch C, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Does MFI Quantitation Of Circulating Antibodies Correlate With Positive Cytotoxicity? *J Heart Lung Transplant.* 2010; 29(2): S152.
 133. Kittleson M, **Patel J**, Moriguchi J, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa J. The Adverse Effects of Sirolimus in Heart Transplant Patients: Is it Worth it? *J Heart Lung Transplant.* 2010; 29(2): S22.
 134. **Patel J**, Kittleson M, Share M, Kawano M, Davis S, Fishbein M, Lai C, Moriguchi J, Ardehali A, Kobashigawa J. Persistent Pulmonary Hypertension In Heart Transplant Patients: Is This A Recipe For Long-Term Failure? *J Heart Lung Transplant.* 2010; 29(2): S92.
 135. **Patel J**, Kittleson M, Kubak B, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Asymptomatic Positive CMV Serology is Associated with Increased Risk for the Development of Transplant Coronary Artery Disease (TCAD): Who Needs Symptoms? *J Heart Lung Transplant.* 2010; 29(2): S124.
 136. **Patel J**, Kittleson M, Kubak B, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Development Of Cytomegalovirus (CMV) Infection During Ongoing Valganciclovir Therapy. *J Heart Lung Transplant.* 2010; (29)2: S66-S67.
 137. Shemin R, **Patel J**, Ardehali A, Kittleson M, Kawano M, Davis S, Moriguchi J, Kobashigawa J. Gender Mismatch in Non-induction/Triple-Drug Regimens: Poor 10-Year Outcomes. *J Heart Lung Transplant.* 2010; 29(2): S102.
 138. Montgomery S, Kawano M, Lockhart D, Velleca A, Burch C, **Patel J**, Davis S, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. Does Race Mismatch Have An Impact On Outcome After Heart Transplantation? *J Heart Lung Transplant.* 2010; 29(2): S124-S125.
 139. **Patel J**, Kittleson M, Azarbal B, Hage A, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Does A Normal Angiogram Further From Heart Transplantation Confer Less Chance To Develop CAV?; Should We Still Do Annual Angiograms Late After Transplantation? *J Heart Lung Transplant.* 2010; 29(2): S53.
 140. Burch C, Amegatcher A, **Patel J**, Kittleson M, Kawano M, Davis S, Goldstein Z, Moriguchi J, Ardehali A, Kobashigawa J. Transition Of Pediatric Heart Transplant Patients To The Adult Heart Transplant Program: Are They Doomed To Be Rejected? *J Heart Lung Transplant.* 2010; 29(2): S33.
 141. Kittleson M, Moriguchi J, Kwon M, Reed E, Davis S, Kawano M, Burch C, Velleca A, Stimpson E, **Patel J**, Ardehali A, Kobashigawa J. Highly Sensitized Patients on VAD Support awaiting Heart Transplant on a Ventricular Assist Device (VAD) Appear to have a Less Robust Immune Response Compared to Non-VAD Patients. *J Heart Lung Transplant.* 2010; 29(2): S120.
 142. Lockhart D, Doering L, Burch C, Montgomery S, Velleca A, **Patel J**, Kittleson M, Davis S, Kawano M, Goldstein Z, Moradzadeh A, Moriguchi J, Ardehali A, Kobashigawa J. Are

- Recipients From Heart Donors Listed as Homeless at Increased Risk for Poor Outcome After Heart Transplantation? *J Heart Lung Transplant.* 2010; 29(2): S39.
143. Kwon M, Moriguchi J, Kittleson M, **Patel J**, Kawano M, Davis S, Reed E, Burch C, Velleca A, Stimpson E, Ardehali A, Kobashigawa J. Lack of Sensitization In Patients Awaiting Heart Transplantation On Heartmate II Axial Flow Assist Devices. *J Heart Lung Transplant.* 2010; 29(2): S183.
 144. Davis S, **Patel J**, Kittleson M, Kawano M, Moriguchi J, Hamilton M, Ardehali A, Kobashigawa J. Potential Immunomodulatory Effects of Granulocyte Colony Stimulating Factor (GCSF) in Heart Transplant Patients. *Am J Transplant.* 2010;10(S4):407.
 145. Kawano M, **Patel J**, Kittleson M, Hamilton M, Hage A, Moradzadeh A, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Effects of Donor Height in Heart Transplant Patients on Triple Drug Immunosuppression. *Am J Transplant.* 2010;10(S4):310.
 146. Kittleson M, **Patel J**, Moriguchi J, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa J. Splenectomy Prior to Heart Transplantation Does Not Affect Risk for Rejection and/or Infection after Heart Transplantation in Patients on Triple Drug Immunosuppression. *Am J Transplant.* 2010;10(S4):407.
 147. Kittleson M, **Patel J**, Kawano M, Davis S, Share M, Moriguchi J, Hamilton M, Ardehali A, Kobashigawa J. Safety and Efficacy of Sildenafil in the 1st Year after Heart Transplantation for Pulmonary Hypertension. *Am J Transplant.* 2010;10(S4):307.
 148. Azarbal B, **Patel J**, Kittleson M, Davis S, Kawano M, Moradzadeh A, Goldstein Z, Moriguchi J, Ardehali A, Kobashigawa J. Treadmill Nuclear Stress Testing Appears Effective to Detect Coronary Ischemia in Heart Transplant Patients with Established Transplant Coronary Artery Disease. *Am J Transplant.* 2010;10(S4):309.
 149. **Patel J**, Kittleson M, Davis S, Kawano M, Moriguchi J, Ardehali A, Kobashigawa J. 10-Year Follow-up of Hepatitis C Donor Hearts in Triple-Drug Immunosuppression: The Final Nail in the Coffin. *Am J Transplant.* 2010;10(S4):120.
 150. **Patel J**, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Are Quilty B Lesions in Heart Transplant Biopsies in Patients on Tacrolimus Immunosuppression Harbingers of Rejection? A Review of 3651 Endomyocardial Biopsies. *Am J Transplant.* 2010;10(S4):404.
 151. **Patel J**, Azaarbal B, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Czer L, Kass R, Kobashigawa J. Coronary Angioplasty/Stents for Cardiac Allograft Vasculopathy Does Not Alter Outcome for Heart Transplant Patients with ISHLT CAV2 or CAV3 Disease. *J Heart Lung Transplant.* 2011; 30(4, Supplement): S11.
 152. **Patel J**, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Azarbal B, Czer L, Kass R, Kobashigawa J. Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac Allograft Vasculopathy. *J Heart Lung Transplant.* 2011; 30(4, Supplement): S12.
 153. **Patel J**, Kittleson M, Kawano M, Goldstein Z, Stimpson E, Rush J, Rafiei M, Reinsmoen N, Reed E, Hamilton M, Trento A, Kobashigawa J. The Effects of Moderate Strength Pre-Transplant Circulating Antibodies on Outcome after Heart Transplantation. *J Heart Lung Transplant.* 2011; 30(4, Supplement): S21.
 154. Kittleson M, **Patel J**, Kawano M, Goldstein Z, Rafiei M, Reinsmoen N, Reed E, Hage A, Schwarz E, Esmailian, Kobashigawa J. Timing of the Development of Donor Specific Antibody after Heart Transplantation Impacts Long-Term Outcome. *J Heart Lung Transplant.* 2011; 30(4, Supplement): S22.

155. Stimpson E, Piponnier L, **Patel J**, Velleca A, Kawano M, Goldstein Z, Rafiei M, Reinsmoen N, Czer L, Esmailian F, Kobashigawa J. Sorting Out the Intricacies of Multiparity Risk on Outcomes after Heart Transplantation. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S27.
156. Lockhart D, Piponnier L, Velleca A, **Patel J**, Kittleson M, Kearney B, Kao T, Johnson M, Kawano M, Goldstein Z, Rafiei M, Kobashigawa J. The Life of the Octogenarian Heart Transplant Patient. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S27.
157. Kobashigawa J, **Patel J**, Kittleson M, Velleca A, Kawano M, Moradzadeh A, Goldstein Z, Rafiei M, Dyo J, Czer L, Esmailian F. Long-Term Benefit of Renal Sparing Protocols Demonstrate the Lack of Need for Calcineurin Inhibitors. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S54.
158. Morrissey RP, Czer L, Kittleson M, **Patel J**, Schwarz E, Jamero G, Kawano M, Rafiei M, Azarbal B, Trento A, Kobashigawa J. Induction vs. Non-Induction in Heart Transplantation: The Controversy Continues. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S56.
159. **Patel J**, Kawano M, Reed E, Goldstein Z, Rafiei M, Reinsmoen N, Azarbal B, Czer L, Trento A, Kobashigawa J. Circulating Antibody after Heart Transplant and Its Association with Poor Outcome: A Prospective Assessment. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S87.
160. **Patel J**, Goldstein Z, Kawano M, Rafiei M, Reinsmoen N, Reed E, Luthringer D, Schwarz E, Trento A, Kobashigawa J. Early Versus Late Antibody-Mediated Rejection: Is There A Difference? *J Heart Lung Transplant*. 2011; 30(4, Supplement): S87.
161. Kittleson M, **Patel J**, Zakowski P, Czer L, Kobashigawa J. Managing the Threat of Donor-Transmitted Amoebic Encephalitis in a Heart Transplant Recipient. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S132.
162. Kittleson M, **Patel J**, Kawano M, Goldstein Z, Rafiei M, Moriguchi J, Reinsmoen N, Reed E, Hage A, Trento A, Kobashigawa J. Pre-Transplant Strength of Circulating Antibody as Expressed in the Calculated Panel Reactive Antibody Score Predicts Antibody-Mediated Rejection after Heart Transplant. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S175.
163. **Patel J**, Moriguchi J, Stimpson E, Reinsmoen N, Reed E, Kawano M, Goldstein Z, Rafiei M, Hamilton M, Schwarz E, Kobashigawa J. Success of Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies in a Large Cohort of Sensitized Heart Transplant Candidates. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S175.
164. **Patel J**, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Barry O, Hamilton M, Schwarz E, Esmailian F, Kobashigawa J. Does Gender Mismatch Increase the Risk of Antibody-Mediated Rejection (AMR) after Heart Transplantation? *J Heart Lung Transplant*. 2011; 30(4, Supplement): S178.
165. Kobashigawa **J**, **Patel J**, Kittleson M, Kawano M, Hage A, Moradzadeh A, Goldstein Z, Rafiei M, Luthringer D, Schwarz E, Esmailian F. Biopsy-Negative Rejection: An Official New ISHLT Rejection Category? *J Heart Lung Transplant*. 2011; 30(4, Supplement): S178.
166. **Patel J**, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Davidoff J, Hage Am Reinsmoen N, Schwarz E, Kass R, Kobashigawa J. Contrary to Popular Belief, Pre-Transplant Blood Transfusions Are Uncommon Sensitizing Events in Patients Awaiting Heart Transplantation. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S181.
167. Kittleson M, **Patel J**, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Moriguchi J, Czer L, Esmailian F, Kobashigawa J. Challenging the ISHLT Guideline Regarding Switch from Mycophenolate to Sirolimus with Standard Dose Calcineurin Inhibitor. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S182.

168. Kittleson M, **Patel J**, Esmailian F, Trento A, Kass R, Kawano M, Goldstein Z, Rafiei M, Czer L, Hamilton M, Kobashigawa J. Primary Graft Dysfunction: Autopsy Data Sheds Light on Pathogenesis. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S194.
169. Kawano M, Kittleson M, **Patel J**, Goldstein Z, Rafiei M, Moradzadeh N, Moradzadeh A, Hage A, Kobashigawa J. Impact of the Number of Blood Pressure Medications on the Outcome of Heart Transplant Recipients. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S197.
170. Coleman B, Piponniau L, **Patel J**, Velleca A, Kawano M, Goldstein Z, Moradzadeh A, Rafiei M, Geskin A, Azarbal B, Kass R, Kobashigawa J. To Be Immunosuppressed, Transplanted, and Black: High Risk for Heart Transplantation. *J Heart Lung Transplant*. 2011; 30(4, Supplement): S219.
171. Kittleson M, **Patel J**, Kawano M, Goldstein Z, Barry O, Schwarz E, Czer L, Kobashigawa J. Does Gender Mismatch Increase the Risk of Antibody-Mediated Rejection? *J Am Coll Cardiol*. 2011; 57: E315
172. **Patel J**, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Barry O, Hamilton M, Schwarz E, Esmailian F, Kobashigawa J. Male Donor to Female Recipient in Heart Transplantation Increases the Risk of Antibody-Mediated Rejection. *Am J Transplant*. 2011; 11(2, Supplement): 237.
173. **Patel J**, Kittleson M, Goldstein Z, Kawano M, Rafiei M, Reed E, Reinsmoen N, Schwarz E, Kass R, Kobashigawa J. Virtual Crossmatch and Desensitization Therapy Has Reduced Time to Transplant for Sensitized Patients. *Am J Transplant*. 2011; 11(2, Supplement): 237.
174. Kobashigawa J, **Patel J**, Kittleson M, Kawano M, Hage A, Moradzadeh A, Goldstein Z, Rafiei M, Luthringer D, Schwarz E, Esmailian F. The Category of Biopsy-Negative Rejection in Heart Transplantation. *Am J Transplant*. 2011; 11(2, Supplement): 238.
175. Kittleson M, **Patel J**, Esmailian F, Trento A, Kass R, Kawano M, Goldstein Z, Rafiei M, Czer L, Hamilton M, Kobashigawa J. Primary Graft Dysfunction and Autopsy Findings. *Am J Transplant*. 2011; 11(2, Supplement): 238.
176. **Patel J**, Azarbal B, Goldstein Z, Rafiei M, Kawano M, Moradzadeh A, Kittleson M, Czer L, Trento A, Kobashigawa J. Screening Nuclear Stress Testing as a Prognostic Marker after Heart Transplantation. *Am J Transplant*. 2011; 11(2, Supplement): 303.
177. Azarbal B, Wei J, Singh S, Currier J, **Patel J**, Hage A, Makkar R, Kobashiagwa J. Frequency of coronary artery fistulae and extracardiac neovascularization after orthotopic heart transplantation. *Circulation*. 2011 Nov 22; 124 (21) S-A14063.
178. Kai B, **Patel J**, Kittleson M, Czer L, Trento A, Esmailian F, Kobashigawa J. Does persistent first-year low of high cardiac index results in poor outcomes after heart transplantation? *J Am Coll Cardiol* 2012; 59(13): E990
179. Perkel D, **Patel J**, Kittleson M, Chang D, Czer L, Esmailian F, Kobashigawa J. CMV infection in the era of tacrolimus/mycophenolate: Is there still an impact to develop cardiac allograft vasculopathy? *J Am Coll Cardiol* 2012; 59(13): E923
180. Tadwalkar R, **Patel J**, Kittleson M, Czer L, Kobashigawa J. Consequences of first-year rejection after heart transplantation: Is the worse yet to come? *J Am Coll Cardiol* 2012; 59(13): E992
181. Chai W, **Patel J**, Kittleson M, Czer L, Rafiei M, Stern L, Esmailian F, Kobashigawa J. Risk for deep vein thrombosis and pulmonary embolism after heart transplantation: Characterization of an old problem. *J Am Coll Cardiol* 2012; 59(13): E922
182. Sue E, **Patel J**, Kittleson M, Czer L, Trento A, Esmailian F, Kobashigawa J. Does strict diabetic control after heart transplantation lead to better outcome? *J Am Coll Cardiol* 2012; 59(13): E930

183. Kobashigawa J, **Patel J**, Rafiei M, Stern L, Kittleson M, Czer L, Esmailian F. Late Response to Desensitization Therapy. *J Heart and Lung Transplant*. 2012; 31(4): S158
184. **Patel J**, Kittleson M, Rafiei M, Stern L, Chang D, Czer L, Trento A, Kobashigawa J. Desensitization Therapy with Immunoglobulin (IVIg) and Rituximab for Patients Awaiting Heart Transplantation. *J Heart and Lung Transplant*. 2012; 31(4): S161
185. Cao K, Lai CH, Flores S, Rafiei M, Mirocha J, Haas M, Ong G, Naim M, Wang Q, Constanza L, **Patel J**, Reinsmoen N, Kobashigawa J. Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor Specific Antibodies (HLA-DSA) Identify Patients at Risk for Immune Complication in Heart Transplant. *J Heart and Lung Transplant*. 2012; 31(4): S163
186. Rafiei M, **Patel J**, Kittleson M, Patel N, Stern L, Azarbal B, Czer L, Trento A, Kobashigawa J. First-Year Rejection and Cylex Scores Suggest the Importance of Acute Events in the Development of Cardiac Allograft Vasculopathy. *J Heart and Lung Transplant*. 2012; 31(4): S168
187. Stern L, **Patel J**, Kittleson M, Rafiei M, Dilibero D, Hage A, Czer L, Kobashigawa J. Use of Generic Immunosuppression: Does it Truly Matter? *J Heart and Lung Transplant*. 2012; 31(4): S203
188. Kearney B, Chai W, **Patel J**, Kittleson M, Rafiei M, Stern L, Czer L, Kobashigawa J. Does Level of Education Affect Outcome After Heart Transplantation? *J Heart and Lung Transplant*. 2012; 31(4): S203-S204
189. **Patel J**, Shiozaki R, Rafiei M, Stern L, Kittleson M, Chang D, Czer L, Esmailian F, Kobashigawa J. Application of Immunosuppression Clinical Trial Results in Reducing the Incidence of Heart Transplant Rejection-Bridging the New Millennium. *J Heart and Lung Transplant*. 2012; 31(4): S24
190. **Patel J**, Kittleson M, Czer L, Rafiei M, Stern L, Patel DP, Hage A, Esmailian F, Kobashigawa J. The Policy of Placing Older Donors into Older Recipients: Is it Worth it? *J Heart and Lung Transplant*. 2012; 31(4): S24-S25
191. Czer L, **Patel J**, Kittleson M, Rafiei M, Stern L, Chang D, Luthringer D, Esmailian F, Kobashigawa J. Consequences of First-Year Rejection after Heart Transplantation: Is the Worse yet to Come? *J Heart and Lung Transplant*. 2012; 31(4): S25
192. **Patel J**, Kittleson M, Czer L, Rafiei M, Stern L, Esmailian F, Reinsmoen N, Kobashigawa J. Are Donor Specific Antibodies Detected after Heart Transplant All Bad? *J Heart and Lung Transplant*. 2012; 31(4): S35
193. **Patel J**, Kittleson M, Rafiei M, Stern L, Patel N, Czer L, Esmailian F, Kobashigawa J. Resurgence of Photopheresis for Recalcitrant Cellular and Antibody-Mediated Cardiac Allograft Rejection. *J Heart and Lung Transplant*. 2012; 31(4): S223
194. Czer L, **Patel J**, Kittleson M, Rafiei M, Stern L, Chang D, Trento A, Kobashigawa J. Combined Heart-Kidney Transplant Compared to Heart Transplant Alone May Reduce Long Term Development of Cardiac Allograft Vasculopathy. *J Heart and Lung Transplant*. 2012; 31(4): S229
195. Moriguchi J, **Patel J**, Kittleson M, Rafiei M, Stern L, Czer L, Trento A, Kobashigawa J. Older Patients with Hemodynamic Compromise Rejection: What Happened to Immunosenescence? *J Heart and Lung Transplant*. 2012; 31(4): S233
196. Czer L, Lee D, **Patel J**, Kittleson M, Rafiei M, Stern L, Hage A, Esmailian F, Trento A, Kobashigawa J. Tricuspid Regurgitation in the First-Year after Heart Transplant: Does it Lead to Gloom and Doom? *J Heart and Lung Transplant*. 2012; 31(4): S233-S234

197. **Patel J**, Kittleson M, Rafiei M, Stern L, Tang Z, Chang D, Luthringer D, Czer L, Trento A, Kobashigawa J. The Natural History of Biopsy Negative Rejection after Heart Transplantation. *J Heart and Lung Transplant*. 2012; 31(4): S235
198. Moriguchi J, **Patel J**, Kittleson M, Rafiei M, Stern L, Chai W, Chang D, Trento A, Czer L, Kobashigawa J. Risk for Deep Vein Thrombosis and Pulmonary Embolism after Heart Transplantation: Characterization of an Old Problem. *J Heart and Lung Transplant*. 2012; 31(4): S235
199. Kobashigawa J, **Patel J**, Kittleson M, Rafiei M, Stern L, Czer L, Reinsmoen N, Esmailian F. Anti-HLA DQ Antibodies: Does Strength of Antibody Result in Subsequent Greater Cardiac Allograft Vasculopathy? *J Heart and Lung Transplant*. 2012; 31(4): S235-S236
200. Kansara P, Kransdorf E, Kittleson M, **Patel J**, Coleman B, Jamero G, Runyan C, Olay C, Jocsos R, Czer L, Trento A, Kass R, Esmailian F, Kobashigawa J, Moriguchi J. Improved Outcomes in “Crash and Burn” Patients through BiVAD Support. *J Heart and Lung Transplant*. 2012; 31(4): S267-S268
201. Coleman B, **Patel J**, Czer L, Mirocha J, Kobashigawa J. Use of Thymoglobulin after Heart Transplantation: Is there a Role in African American Patients? *J Heart and Lung Transplant*. 2012; 31(4): S92-S93
202. Czer L, **Patel J**, Kittleson M, Rafiei M, Stern L, Esmailian F, Kobashigawa J. Infectious Complications of Desensitization Therapy: Is the Cure Worse Than the Disease? *J Heart and Lung Transplant*. 2012; 31(4): S108
203. **Patel J**, Kittleson M, Kansara P, Rafiei M, Stern L, Chang D, Azarbal B, Czer L, Esmailian F, Kobashigawa J. Outcomes Validation of the New ISHLT Cardiac Allograft Vasculopathy Coronary Angiogram Grading Scale. *J Heart and Lung Transplant*. 2012; 31(4): S121
204. Czer L, **Patel J**, Kittleson M, Rafiei M, Stern L, Chang D, Azarbal B, Trento A, Kobashigawa J. Distal Pruning as an Important Factor for Outcome in the New ISHLT Cardiac Allograft Vasculopathy Grading Scale. *J Heart and Lung Transplant*. 2012; 31(4): S121-S122
205. **Patel J**, Kittleson M, Shiozaki R, Rafiei M, Stern L, Azarbal B, Czer L, Esmailian F, Kobashigawa J. First-Year Brain Natriuretic Peptide (BNP) as a Biomarker after Heart Transplant to Predict Severity of Cardiac Allograft Vasculopathy (CAV) as per the new ISHLT CAV Scale. *J Heart and Lung Transplant*. 2012; 31(4): S122
206. **Patel J**, Kittleson M, Czer L, Rafiei M, Stern L, Reinsmoen N, Kobashigawa J. Maintenance Immunosuppression and De Novo Antibody Production after Heart Transplantation: Does the Choice of Drugs Matter? *Am J Transplant*. 2012; 12 (Suppl 3): 73-74
207. **Patel J**, Kittleson M, Czer L, Rafiei M, Stern L, Patel DP, Hage A, Esmailian F, Kobashigawa J. The Policy of Placing Older Donors into Older Recipients: Is it Worth it? *Am J Transplant*. 2012; 12 (Suppl 3): 96
208. **Patel J**, Kittleson M, Czer L, Rafiei M, Stern L, Reinsmoen N, Kobashigawa J. Are Donor-Specific Antibodies Detected after Heart Transplant All Bad? *Am J Transplant*. 2012; 12 (Suppl 3): 121
209. Kobashigawa J, **Patel J**, Rafiei M, Stern L, Kittleson M, Czer L, Reinsmoen N, Esmailian F. Late Response to Desensitization Therapy. *Am J Transplant*. 2012; 12 (Suppl 3): 382
210. Dilibero D, **Patel J**, Kittleson M, Rafiei M, Stern L, Hage A, Czer L, Kobashigawa J. Use of Generic Immunosuppression: Does it Truly Matter? *Am J Transplant*. 2012; 12 (Suppl 3): 384
211. Rafiei M, Czer L, **Patel J**, Kittleson M, Stern L, Chang D, Esmailian F, Kobashigawa J. Combined Heart-Kidney Transplant Compared to Heart Transplant Alone May Reduce Long Term Development of Cardiac Allograft Vasculopathy. *Am J Transplant*. 2012; 12 (Suppl 3): 384

212. Stern L, **Patel J**, Kobashigawa L, Rafiei M, Velleca A, Kittleson M, Czer L, Bairey Merz N, Kobashigawa J. Is Hormone Replacement Therapy (HRT) in Postmenopausal Women Associated with Poor Outcome after Heart Transplantation? *Am J Transplant.* 2012; 12 (Suppl 3): 477
213. Kobashigawa J, **Patel J**, Kittleson M, Rafiei M, Stern L, Czer L, Reinsmoen N, Esmailian F. Anti-HLA DQ Antibodies: Does Strength of Antibody Result in Subsequent Greater Cardiac Allograft Vasculopathy? *Am J Transplant.* 2012; 12 (Suppl 3): 382
214. Moriguchi J, Kittleson M, **Patel J**, Coleman B, Jamero G, Runyan C, Olay C, Jocson R, Chang D, Czer L, Trento A, Esmailian F, Kobashigawa J. Are Sensitized VAD Patients Similar to Sensitized non-VAD Patients in Terms of Outcome? *Am J Transplant.* 2012; 12 (Suppl 3): 120-121
215. Kansara P, Czer L, **Patel J**, Kittleson M, Mirocha J, Moriguchi J, Chang D, De Robertis M, Trento A, Kass R, and Kobashigawa J. Prior Cardiac Surgery is a Predictor of Mortality in the First-Year in Heart Transplant Recipients. *Am J Transplant.* 2012; 12 (Suppl 3): 476
216. Kransdorf E, Czer L, **Patel J**, Zakowski P, Gaultier C, Zabner R, Chang D, Kittleson M, Kobashigawa J. High Prevalence and Reactivation of Chagas Disease in Heart Transplant Recipients. *Am J Transplant.* 2012; 12 (Suppl 3): 477-478
217. Reinsmoen NL, Law C-H, Ong GD, Naim M, Wang Q, Masukawa R, Duong H, **Patel J**, Kobashigawa J. Optimising Transplantation of Broadly Sensitized Heart Patients: Three Antibody Profiling Strategies and Therapeutic Intervention. 24th International Congress of the Transplantation Society. Berlin, Germany. July 15th-19th 2012
218. Dhiantravan V, **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Mycophenolate not Azathioprine with Increased Risk for Skin Cancer after Heart Transplant. *J Am College of Cardiology.* 2013; 61(10) Suppl A: 195
219. Geft D, **Patel J**, Kittleson M, Chang D, Rafiei M, Osborne A, Czer L, Esmailian F, Kobashigawa J. Use of Cylex Immune Monitoring Score to Guide Immunosuppression After Heart Transplantation Reduces Infection Risk. *J Am College of Cardiology.* 2013; 61(10) Suppl A: 196
220. Kansara P, Czer L, **Patel J**, Mirocha J, Kittleson M, De Robertis M, Moriguchi J, Chang D, Ramzy D, Kass R, Esmailian F, Trento A, Kobashigawa J. Early Mortality and Morbidity in Heart Transplant Recipients with Prior History of Cardiac Surgery: Analysis of United Network for Organ Sharing Database. *J Am College of Cardiology.* 2013; 61(10) Suppl A: 196
221. Tadwalkar R, Kittleson M, **Patel J**, Moriguchi J, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Reinsmoen N, Kobashigawa J. Establishing a PRA Threshold to Treat Sensitized Patients Awaiting Heart Transplant in the Era of the Virtual Crossmatch. *J Am College of Cardiology.* 2013; 61(10) Suppl A: 163
222. Song H, Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Ramzy D, Hage A, Czer L, Kobashigawa J. Change in Cylex Scores Predicts Risk for Infection in the First-Year following Heart Transplantation. *J Am College of Cardiology.* 2013; 61(10) Suppl A: 196
223. Moradzadeh A, Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. The Risk of Clostridium Difficile in Heart Transplant Patients on Different Immunosuppression Regimens. *J Am College of Cardiology.* 2013; 61(10) Suppl A: 195
224. Aaronson A, Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Benefit of Tacrolimus/Mycophenolate to Reduce Cardiac Allograft Vasculopathy after Heart Transplantation. *J Am College of Cardiology.* 2013; 61(10) Suppl A: 195

225. Rafiei M, Kittleson M, **Patel J**, Osborne A, Chang D, Czer L, Reinsmoen N, Kobashigawa J. Anti-thymocyte Gammaglobulin May Prevent Antibody Production after Heart Transplantation. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 196
226. **Patel J**, Reinsmoen N, Kobashigawa J. Maintenance Immunosuppression and de novo Antibody Production after Heart Transplantation- Does the Choice of Drugs Matter? *Am Society of Transplant: Cutting Edge of Transplantation*. 2013
227. **Patel J**, Reinsmoen N, Kobashigawa J. The Incidence of Circulating Antibodies at the Time of Pathology Defined Antibody-Mediated Rejection after Heart Transplantation. *Am Society of Transplant: Cutting Edge of Transplantation*. 2013
228. **Patel J**, Reinsmoen N, Kobashigawa J. Pre-Transplant PRA and Risk for Antibody-Mediated Rejection after Heart Transplantation. *Am Society of Transplant: Cutting Edge of Transplantation*. 2013
229. Kobashigawa J, **Patel J**, Reinsmoen N. The Development and Impact of Circulating Antibodies in Non-Sensitized Patients after Heart Transplantation. *Am Society of Transplant: Cutting Edge of Transplantation*. 2013
230. Kobashigawa J, **Patel J**, Reinsmoen N. ATG Induction Improves Outcome for Sensitized Patients Who Have Undergone Heart Transplantation. *Am Society of Transplant: Cutting Edge of Transplantation*. 2013
231. Daun T, **Patel J**, Kittleson M, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, Czer L, Hamilton M, Kobashigawa J. Does Regular exercise after heart transplantation have any benefit? Real life experience. *J Heart and Lung Transplant*. 2013; 32(4): S198
232. Kansara P, **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Trento A, Kobashigawa J. Early Mortality and Morbidity in First 60 Days in Adult Heart Transplant Recipients with Prior History of Cardiac Surgery: Analysis of United Network for Organ Sharing database. *J Heart and Lung Transplant*. 2013; 32(4): S162
233. **Patel J**, Kittleson M, Rafiei M, Osborne A, Aaronson A, Chang D, Azarbal B, Czer L, Moriguchi J, Kobashigawa J. Benefit of Tacrolimus/Mycophenolate to Reduce Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S50
234. Kobashigawa J, Tadwalkar R, Kittleson M, **Patel J**, Moriguchi J, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Reinsmoen N. Establishing a PRA Threshold to treat Sensitized Patients Awaiting Heart Transplant in the Era of the Virtual Crossmatch. *J Heart and Lung Transplant*. 2013; 32(4): S53
235. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Proliferation Signal Inhibitors Reduce Severity of Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S50
236. Kittleson M, **Patel J**, Rafiei M, Osborne A, Jamero G, Chang D, Azarbal B, Czer L, Kobashigawa J. Even Mild Renal Insufficiency is a Risk for Mortality after Heart Transplant. *J Heart and Lung Transplant*. 2013; 32(4): S40
237. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Reinsmoen N, Kobashigawa J. The incidence of circulating antibodies at the time of Pathology Defined Antibody-Mediated Rejection after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S20-2S21
238. Phan A, Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Czer L, Ramzy D, Esmailian F, Kobashigawa J. ATG Induction Improves Outcome for Sensitized Patients Who Have Undergone Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S200

239. Wei J, Azarbal B, Cheng R, Geft D, Rafiei M, **Patel J**, Czer L, Kobashigawa J. Cardiac Allograft Vasculopathy is Less Frequent in Contemporary Heart Transplant Population. *J Heart and Lung Transplant*. 2013; 32(4): S209-S210
240. Morlend R, Kittleson M, **Patel J**, Rafiei M, Osborne A, Hage A, Chang D, Czer L, Moriguchi J, Trento A, Kobashigawa J. Complications on the Heart Transplant Waiting List is Common: Reducing Wait List Time for Sensitized Patients May Avoid Complications. *J Heart and Lung Transplant*. 2013; 32(4): S208
241. Wei J, Singh S, Young A, Rafiei M, Hage A, **Patel J**, Esmailian F, Currier J, Kobashigawa J, Azarbal B. Coronary Artery Fistulae after Orthotopic Heart Transplantation are Associated with Decreased Prevalence of Transplant Coronary Artery Disease. *J Heart and Lung Transplant*. 2013; 32(4): S210-211
242. Kittleson M, **Patel J**, Rafiei M, Osborne A, Shiozaki R, Chang D, Moriguchi J, Czer L, Kobashigawa J. Failed Prednisone Taper Off after heart transplant: Is there a price to be paid? *J Heart and Lung Transplant*. 2013; 32(4): S200
243. Rush J, Kittleson M, **Patel J**, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, Czer L, Kobashigawa J. Men Versus Women: Outcome Differences on Cyclosporine and Tacrolimus. *J Heart and Lung Transplant*. 2013; 32(4): S201
244. Piponniau L, Kittleson M, **Patel J**, Rafiei M, Osborne A, Dhiantravan V, Chang D, Czer L, Hage A, Hamilton M, Moriguchi J, Kobashigawa J. Mycophenolate not Azathioprine is Associated with Increased Risk for Skin Cancer after Heart Transplant. *J Heart and Lung Transplant*. 2013; 32(4): S199
245. Kobashigawa J, **Patel J**, Kittleson M, Chang D, Czer L, Daun T, Trento A, Esmailian F. Results of a Randomized Trial of Allomap vs. Heart Biopsy in the first year after Heart Transplant: Early Invasive Monitoring Attenuation through Gene Expression Trial. *J Heart and Lung Transplant*. 2013; 32(4): S203
246. Velleca A, Kittleson M, **Patel J**, Rafiei M, Osborne A, Ngan A, Hage A, Chang D, Czer L, Kobashigawa J. Tacrolimus- versus Cyclosporine-induced Diabetes Leads to More Diabetic Complications after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S202
247. Stimpson E, **Patel J**, Kittleson M, Rafiei M, Osborne A, Lee F, Chang D, Hage A, Ramzy D, Czer L, Hamilton M, Kobashigawa J. The Obesity Paradox. *J Heart and Lung Transplant*. 2013; 32(4): S212
248. Reinsmoen N, Lai C, Mirocha J, Cao K, Ong G, Naim M, Wang Q, Riega S, Rafiei M, **Patel J**, Kobashigawa J. Increased Negative Impact of Anti-Angiotensin Type 1 Receptor Antibodies Together with de novo Donor HLA Specific Antibodies on Graft Outcome in Heart Transplant Recipients. *J Heart and Lung Transplant*. 2013; 32(4): S113
249. Kransdorf E, Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Czer L, Hage A, Zakowski P, Kobashigawa J. High Rate of Reactivation of Chagas Disease After Heart Transplantation in the United States. *J Heart and Lung Transplant*. 2013; 32(4): S130
250. Kittleson M, **Patel J**, Rafiei M, Osborne A, Moradzadeh A, Chang D, Czer L, Zakowski P, Kobashigawa J. The Development of Clostridium Difficile in Heart Transplant Patients on Different Immunosuppression Regimens. *J Heart and Lung Transplant*. 2013; 32(4): S131
251. Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Ramzy D, Esmailian F, **Patel J**. Cylex Scores May Predict Risk for Infection in the First Year Following Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S74
252. Geft D, **Patel J**, Kittleson M, Chang D, Rafiei M, Osborne A, Hage A, Czer L, Esmailian F, Kobashigawa J. Use of Cylex Immune Monitoring Score to Guide Immunosuppression after Heart Transplantation Reduces Infection Risk. *J Heart and Lung Transplant*. 2013; 32(4): S73

253. Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Ramzy D, Czer L, Reinsmoen N, Kobashigawa J. Pre-Transplant Circulating Antibodies Predict Antibody-Mediated Rejection after Heart Transplant Using the New ISHLT Grading Scale. *J Heart and Lung Transplant*. 2013; 32(4): S87-S88
254. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, Trento A, Kobashigawa J. The Development and Impact of de novo Circulating Antibodies in Non-Sensitized Patients after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S86
255. Thottam M, **Patel J**, Kittleson M, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, Czer L, Hamilton M, Kobashigawa J. Cardiac Rehabilitation after Heart Transplantation Reduces Development of Cardiac Allograft Vasculopathy. *J Heart and Lung Transplant*. 2013; 32(4): S80
256. Kittleson M, **Patel J**, Rafiei M, Osborne A, Yabuno J, Chang D, Azarbal B, Czer L, Hamilton M, Kobashigawa J. Chronic Anemia is Not a Predictor for Poor Outcome after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S254-S255
257. Kittleson M, **Patel J**, Rafiei M, Osborne A, Tittle M, Chang D, Czer L, Esmailian F, Trento A, Kobashigawa J. Longer and Shorter Hospital Stay after Heart Transplant Both Risk Factors for Suboptimal Outcome. *J Heart and Lung Transplant*. 2013; 32(4): S263
258. Coleman B, **Patel J**, Mirocha J, Czer L, Kobashigawa J. Induction Therapy in African American Heart Transplant Recipients: Analysis of the UNOS Database. *J Heart and Lung Transplant*. 2013; 32(4): S134-S135
259. Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, **Patel J**. Comparable Waiting Time for Highly Sensitized Patients Awaiting Heart Transplant Using Desensitization Therapy and the Virtual Crossmatch. *Am J Transplant*. 2013; 13 (suppl 5): 455
260. Kobashigawa J, Watanabe J, Shafi H, **Patel J**, Kittleson M, Jordan S, Klapper E, Toyoda M. Clinical and Mechanistic Outcomes of Photopheresis after Heart Transplantation. *Am J Transplant*. 2013; 13 (suppl 5): 453
261. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Pathology and Clinical Progression of Biopsy Proven pAMR1 After Heart Transplantation. *Am J Transplant*. 2013; 13 (suppl 5): 455
262. Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, **Patel J**. Poor Outcomes In Non-Sensitized Patients Developing de Novo Circulating Antibodies After Heart Transplantation. *Am J Transplant*. 2013; 13 (suppl 5): 70-71
263. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. First Year Mild Renal Insufficiency Associated With Increased Mortality After Heart Transplant. *Am J Transplant*. 2013; 13 (suppl 5): 453
264. Osborne A, **Patel J**, Kittleson M, Rafiei M, Chang D, Czer L, Kobashigawa J. Kidney Dialysis After Heart Transplantation: The Short and Long Term Outcomes. *Am J Transplant*. 2013; 13 (suppl 5): 454
265. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Potential Downfall of Failed Prednisone Wean After Heart Transplant. *Am J Transplant*. 2013; 13 (suppl 5): 457
266. Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. The Role of Cardiac Rehabilitation After Heart Transplantation in the Reduction of Cardiac Allograft Vasculopathy. *Am J Transplant*. 2013; 13 (suppl 5): 452
267. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, Kobashigawa J. The Presence of Circulating Antibodies at The Time of Pathology Defined Antibody-Mediated

- Rejection After Heart Transplant: Are They Out There? *Am J Transplant*. 2013; 13 (suppl 5): 453-454
268. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Tacrolimus-Induced Diabetes Compared to Cyclosporine May Lead to More Diabetic Complications Post Heart Transplant. *Am J Transplant*. 2013; 13 (suppl 5): 94
269. Rafiei M, Kittleson M, **Patel J**, Osborne A, Chang D, Czer L, Kobashigawa J. Persistent Asymptomatic C4d Staining in the First Year After Heart Transplantation is a Marker for Cardiac Allograft Vasculopathy. *Am J Transplant*. 2013; 13 (suppl 5): 71
270. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. ATG Induction for Sensitized Patients Who Have Undergone Heart Transplant: Is it Beneficial? *Am J Transplant*. 2013; 13 (suppl 5): 457
271. **Patel J**, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Severity of Cardiac Allograft Vasculopathy After Heart Transplant Is Reduced With Proliferation Signal Inhibitors. *Am J Transplant*. 2013; 13 (suppl 5): 454
272. Reinsmoen N, Lai C, Mirocha J, Cao K, Naim M, Ong G, Duong H, Riega S, Rafiei M, **Patel J**, Kobashigawa J. Anti-Angiotensin Type 1 Receptor Antibodies Associated With Rejection in Donor HLA Antibody Negative Recipients. *Am J Transplant*. 2013; 13 (suppl 5): 456
273. Kobashigawa J, **Patel J**, Kittleson M, Chang D, Czer L, Daun T, Trento A, Esmalian F. Intravascular Ultrasound (IVUS) Results of a Randomized Trial of Allomap vs. Heart Biopsy in the 1st Year after Heart Transplant. *Am J Transplant*. 2013; 13 (suppl 5): 549
274. Kittleson M, **Patel J**, Rafiei M, Osborne A, Chang D, Azarbal B, Czer L, Esmalian F, Reinsmoen N, Kobashigawa J. Comparison of Maintenance Immunosuppression and de novo Antibody Production in the First-Year After Heart Transplant. *Circulation* 2013; In Press
275. Elboudwarej O, **Patel J**, Osborne A, Liou F, Reinsmoen N, Kobashigawa J. Prednisone Wean After Heart Transplantation – Is There a Risk for Antibody Formation? *Circulation* 2013; In Press
276. Kai B, Reinsmoen N, Yu Z, Liou F, Yabuno J, **Patel J**, Kittleson M, Hamilton M, Chang D, Czer L, Kobashigawa J. Does Anything Work for the Highly Sensitized Patients Awaiting Heart Transplant? *Am Coll Cardiol*. 2014; 63 (12_S)
277. Cheng R, Azarbal B, **Patel J**, Chang D, Kobashigawa J. Elevated Immune Monitoring after Cardiac Transplantation is Associated with Increased Plaque Progression by Intravascular Ultrasound. *Am Coll Cardiol*. 2014; 63 (12_S)
278. Grigorian-Shamajan L, Yu Z, Liou F, **Patel J**, Kittleson M, Azarbal B, Chang D, Czer L, Kobashigawa J. Percutaneous Coronary Intervention versus Medical Therapy for Moderate Coronary Lesions after heart Transplantation: What to do? *Am Coll Cardiol*. 2014; 63 (12_S)
279. Kafi A, **Patel J**, Kittleson M, Yu Z, Liou F, Yabuno J, Kao T, Czer L, Chang DH, Hage A, Ramzy D, Kobashigawa J. Abnormal Pulmonary Function Tests Contraindicate Heart Transplant. *J Heart Lung Transplant*. 2014; 33(4): S141-142
280. Kittleson M, **Patel J**, Yu Z, Liou F, Aquino A, Velleca A, Czer L, Chang DH, Hamilton M, Trento A, Reinsmoen N, Kobashigawa J. Do Redo Heart Transplant Patients Have an Increased Risk of Antibody Development? *J Heart Lung Transplant*. 2014; 33(4): S284
281. Lipson-Altman N, Reinsmoen N, Kittleson M, Luthringer D, **Patel J**, Liou F, Yu Z, Kearny B, Czer L, Chang DH, Ramzy D, Kobashigawa J. Does the Ability for Donor Specific Antibodies to Bind Complement Always Result in C4d Staining in the Endomyocardial Biopsy After Heart Transplant? *J Heart Lung Transplant*. 2014; 33(4): S83

282. Moriguchi J, Arabia F, **Patel J**, Kittleson M, Yu Z, Liou F, Yabuno J, Chang DH, Czer L, Hage A, Ramzy D, Kobashigawa J. Does VAD Placement Reduce Weight in Obese Severe Heart Failure Patients? *J Heart Lung Transplant*. 2014; 33(4): S209
283. Moriguchi J, Arabia F, Jocson R, **Patel J**, Kittleson M, Liou F, Yu Z, Ernsts W, Hamilton M, Chang DH, Czer L, Kobashigawa J. Extracorporeal membrane Oxygenation as a Bridge to Decision for INTERMACS 1 Patients. *J Heart Lung Transplant*. 2014; 33(4): S250-251
284. Stimpson E, Dilibero D, Kittleson M, **Patel J**, Yu Z, Liou F, Yabuno J, Zakowski P, Czer L, Trento A, Esmailian F, Kobashigawa J. Hepatitis B Vaccination Confers an Increased Rate of Transplant for Patients on the Heart Transplant Waiting List. *J Heart Lung Transplant*. 2014; 33(4): S268
285. Yu Z, **Patel J**, Kittleson M, Liou F, Yabuno J, Jamero G, Chang DH, Czer L, Azarbal B, Trento A, Esmailian F, Kobashigawa J. The Risk of Prior Chest Radiation Therapy in Patients Who Undergo Heart Transplantation. *J Heart Lung Transplant*. 2014; 33(4): S170-171
286. Kittleson M, Chehrazi-Raffle A, **Patel J**, Yu Z, Liou F, Johnson M, Stimpson E, Hage A, Chang DH, Czer L, Zakowski P, Kobashigawa J. Toxoplasma Serology Mismatch with Increased Mortality? Clarifying the Literature. *J Heart Lung Transplant*. 2014; 33(4): S179-180
287. Reinsmoen N, Haas M, **Patel J**, Lai C, Naim M, Ong G, Wang Q, Mirocha J, Yu Z, Liou F, Kobashigawa J. Does the Presence of Complement Binding De Novo DSA Distinguish Different Pathology Defined Rejection Patterns in Heart Transplant Recipients? *J Heart Lung Transplant*. 2014; 33(4): S283
288. **Patel J**, Kittleson M, Yu Z, Liou F, Yabuno J, Aggarwal C, Kearny B, Chang DH, Czer L, Esmailian F, Kobashigawa J. Proliferative Signal Inhibitors and Deep Vein Thrombosis: Is There a Connection? *J Heart Lung Transplant*. 2014; 33(4): S276-277
289. Coleman B, Phillips A, Mirocha J, **Patel J**, Arabia F, Kobashigawa J. Antithymocyte Globulin But Not Basiliximab Is Beneficial After Infant Heart Transplantation – Analysis of the UNOS Database. *J Heart Lung Transplant*. 2014; 33(4): S123
290. Coleman B, Phillips A, Mirocha J, **Patel J**, Arabia F, Kobashigawa J. Induction Therapy in African American Infant Heart Transplants: Is There a Benefit? *J Heart Lung Transplant*. 2014; 33(4): S43
291. Cheng R, Azarbal B, **Patel J**, Kittleson M, Kobashigawa J. Early Immune Monitoring After Cardiac Transplantation Predicts Progression of Maximal Intimal Thickness by Intravascular Ultrasound. *J Heart Lung Transplant*. 2014; 33(4): S24
292. Cheng R, Azarbal B, **Patel J**, Wei J, Kobashigawa J. Presence of Coronary Artery Fistulae after Cardiac Transplantation Is Associated with Increased Plaque Progression by Intravascular Ultrasound. *J Heart Lung Transplant*. 2014; 33(4): S284
293. Moriguchi J, Arabia F, Kittleson M, **Patel J**, Yu Z, Liou F, Ernst W, Huie N, Hage A, Chang D, Czer L, Kobashigawa J. Heart Transplantation vs. Ventricular Assist Device as Destination Therapy in Older Patients: Are They Comparable? *Am J Transplant*. 2014; 14(S3): 52.
294. Arabia F, Moriguchi J, Jocson R, Kittleson M, **Patel J**, Yu Z, Liou F, Chang D, Czer L, Ramzy D, Esmailian F, Kobashigawa J. Single Center Experience of Total Artificial Heart as a Bridge to Heart Transplantation. *Am J Transplant*. 2014; 14(S3): 52.
295. Kittleson M, Reinsmoen N, **Patel J**, Liou F, Yu Z, Luu M, Hamilton M, Hage A, Azarbal B, Kobashigawa J. Heart Transplantation across Low Level Donor Specific Antibodies: Is It Bad? *Am J Transplant*. 2014; 14(S3): 53.
296. Watanabe J, Shafi H, **Patel J**, Klapper E, Yu Z, Krivitskiy I, Liou F, Kittleson M, Jordan S, Kobashigawa J, Toyoda M. Extracorporeal Photopheresis (ECP) Improved Allograft Function

- and Significantly Reduced Inflammatory Cytokines in Patients (Pts) With Refractory Heart Allograft Dysfunction. *Am J Transplant.* 2014; 14(S3): 56
297. Kittleson M, **Patel J**, Hamilton M, Yu Z, Liou F, Yabuno J, Azarbal B, Chang D, Geft D, Kobashigawa J. Anti-Thymocyte Globulin Induction to Prevent Renal Dysfunction: Is It Necessary Today? *Am J Transplant.* 2014; 14(S3): 56
 298. Coleman B, Philips A, Mirocha J, **Patel J**, Kobashigawa J. Induction Therapy in Pediatric Heart Transplantation: Is There a Benefit? Globulin Induction to Prevent Renal Dysfunction: Is It Necessary Today? *Am J Transplant.* 2014; 14(S3): 57
 299. Esmailian F, Kobashigawa J, Thottam M, Yu Z, Liou F, **Patel J**, Kittleson M, Czer L, Trento A. Heart in the Box With Good 1-Year Outcome Post Heart Transplantation. *Am J Transplant.* 2014; 14(S3): 58
 300. **Patel J**, Kittleson M, Ramzy D, Yu Z, Liou F, Yabuno J, Arabia F, Moriguchi J, Czer L, Kobashigawa J. Perioperative Bleeding Risk of Anti-Platelet Therapy Prior to Heart Transplant. *Am J Transplant.* 2014; 14(S3): 59
 301. Arbit B, Azarbal B, Vanichsarn C, Chang D, **Patel J**, Kobashigawa J, Makkar R. Long Term Clinical and Angiographic Outcomes with Everolimus-Eluting Stents for Cardiac Allograft Vasculopathy. *J Am Coll Cardiol.* 2014;64(11_S)
 302. Chang R, Yung A, Azarbal B, **Patel J**, Kobashigawa J. Early Stenosis on Intravascular Ultrasound Immediately After Cardiac Transplantation Predicts Downstream Development of Transplant Coronary Artery Disease. *J Am Coll Cardiol.* 2014;64(11_S)
 303. Rush J, Johnson M, Kao T, **Patel J**, Liou F, Yu Z, Luu M, Chang M, Czer L, Trento A, Esmailian F, Kobashigawa J. Risk of High Risk Donors in Heart Transplantation *Am J Transplant.* 2014; 14(S3): 424
 304. Liou F, **Patel J**, M. Kittleson, Yu Z, Luu M, Piponniau L, Luthringer D, Czer L, Chang D, Hamilton M, Esmailian F, Kobashigawa J. Does Heart-Kidney Transplant Truly Confer Protective Benefits Against Rejection? *Am J Transplant.* 2014; 14(S3): 424
 305. Kobashigawa J, **Patel J**, Kittleson M, F Liou, Yu Z, Rush Z, Stimpson E, Hage A, Czer L, Esmailian F. Impact of the 2006 Donor Heart Allocation UNOS Policy Using Median Waitlist Times for Patients Awaiting Heart Transplant. *Am J Transplant.* 2014; 14(S3): 426
 306. Kittleson M, **Patel J**, Liou F, Yu Z, Lipson-Altman N, Parikh A, Velleca A, Chang D, Czer L, Hamilton M, Esmailian F, Kobashigawa J. Beta Blockers to Slow Heart Rate for Sinus Tachycardia After Heart Trans
 307. Aggarwal C, **Patel J**, Kittleson M, Yu Z, Liou F, Murayama K, Rush J, Chang D, Hage A, Trento A, Kobashigawa J. Smaller Donor By Weight May Lead to More Cardiac Allograft Vasculopathy After Heart Transplantation. *Am J Transplant.* 2014; 14(S3): 429
 308. **Patel J**, Kittleson M, Moriguchi J, Liou F, Yu Z, Yabuno J, Azarbal B, Chang D, Czer L, Kobashigawa J. Cyclosporine vs. Tacrolimus: Which Is a Better Match With Everolimus? *Am J Transplant.* 2014; 14(S3): 430
 309. Kawano J, **Patel J**, Kittleson M, Liou F, Wong D, Jamero G, Azarbal B, Chang DH, Czer L, Trento A, Kobashigawa J. Rubidium Positron Emission Tomography and Coronary Flow Reserve Predicts Graft Function after Heart Transplant. *J Heart Lung Transplant.* Vol 34, No 4S, April 2015
 310. Kawano J, Kittleson M, **Patel J**, Azarbal B, Liou F, Siddiqui S, Wong D, Chang DH, Ramzy D, Czer L, Kobashigawa J. Do Abnormal Regadenoson Scans Predict Subsequent Poor Outcome? *J Heart Lung Transplant.* VOL 34, ISSUE 4, S49, APRIL, 2015

311. Kobashigawa J, Kittleson M, Liou F, Shiozaki R, Siddiqui S, Piponniau L, Geft D, Hamilton M, Czer L, Reinsmoen, **Patel J**. The Time Course of Development of Anti-HLA Antibodies Following Heart Transplantation. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
312. **Patel J**, Reinsmoen N, Kittleson M, Dilibero D, Liou F, Chang DH, Hamilton M, Czer L, Esmailian, Kobashigawa J. Plasmapheresis and Bortezomib for Sensitized Patients Awaiting Heart Transplantation – Worth the Effort? *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
313. **Patel J**, Dilibero D, Kittleson M, Sana S, Liou F, Chang DH, Hage A, Czer L, Trento A, Reinsmoen N, Kobashigawa J. Terminal Complement Inhibition for Complement Inhibition for Highly Sensitized Patients Undergoing Heart Transplantation – Doable? *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
314. Esmailian F, **Patel J**, Kittleson M, Kao T, Liou F, Siddiqui S, Azarbal B, Chang DH, Czer L, Trento A, Kobashigawa J. Shorter Cold Ischemic Time in Older Donors Post-Heart Transplant Appears to be Protective. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
315. Coleman B, Guo X, **Patel J**, Reinsmoen N, Jia Y, Kobashigawa J. Genetic Risk Score (GRS) Predicts Worse Survival in African American Heart Transplant. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
316. **Patel J**, Vescio R, Kittleson M, Siddiqui S, Liou F, Yabuno J, Piponniau L, Kearney B, Hamilton M, Czer L, Kobashigawa J. Single Center Experience with Amyloid Patients in the Current Era of Disease Specific Medications. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
317. Kittleson M, **Patel J**, Liou F, Siddiqui S, Chang DH, Hage A, Hamilton M, Czer L, Trento A, Esmailian F, Kobashigawa J. Combined Kidney Transplant in Patients Needing Redo Heart Transplant: Viable Option? *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
318. Kittleson M, **Patel J**, Liou F, Siddiqui, Yabuno J, Chang DH, Ramzy D, Czer L, Esmailian F, Reinsmoen N, Kobashigawa J. Low Level Donor Specific Antibodies at Transplant does not Appear to be Associated with the Development of Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
319. Siddiqui S, Kittleson M, **Patel J**, Liou F, Aintablian T, Chang DH, Hage A, Czer L, Esmailian F, Kobashigawa J. Risk Factors for Hospital Admissions for Rejection Following Heart Transplantation: The Real Story. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
320. Rush J, Kittleson M, **Patel J**, Stimpson E, Kao T, Liou F, Aintablian T, Siddiqui S, Chang DH, Czer L, Esmailian F, Kobashigawa J. Is There a Risk of Cocaine and Methamphetamine Use in Heart Donors? *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
321. Stimpson, Kao T, Kim L, Morrison S, **Patel J**, Kittleson M, Liou F, Siddiqui S, Yabuno J, Czer L, Kobashigawa J. Care after Heart Transplant, No One Better Than Family: Wrong. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
322. Ghafourian K, **Patel J**, Kittleson M, Passano E, Liou F, Siddiqui S, Yabuno J, Geft D, Chang DH, Czer L, Trento A, Kobashigawa J. Does Time on Ventricular Assist Device Compromise Post-Transplant Outcome? *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
323. Kumar P, Liou F, **Patel J**, Czer L, Kobashigawa J, Luthringer D. Recurrence of Amyloid in Endomyocardial Biopsies Following Orthotopic Heart Transplantation. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
324. Liou F, Kittleson M, **Patel J**, Siddiqui S, Luu M, Kearney B, Ramzy D, Chang DH, Czer L, Reinsmoen N, Kobashigawa J. Anti-Human Leukocyte Antigen Antibody Class Affects Outcomes after Heart Transplant. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015

325. Cheng R, Vanichsarn C, Azarbal B, Czer L, Kittleson M, **Patel J**, Kobashigawa J. Rapid Progression of Allograft Coronary Artery Stenosis is Decreased in Patients Who Received Antithymocyte Globulin Induction at the Time of Transplant. *J Heart Lung Transplant*. Vol 34, No 4S, April 2015
326. **Patel J**, Vescio R, Kittleson M, Siddiqui S, Liou F, Yabuno J, Piponniau L, Kearney B, Hamilton M, Czer L, Kobashigawa J. Heart Transplant for Amyloid Patients in the Current Era of Bortezomib. *Am J Transplant*. 2015; 15 (suppl 3).
327. Velleca A, Kittleson M, Perry N, **Patel J**, Liou F, Siddiqui S, Rush J, Ramzy D, Czer L, Chang DH, Kobashigawa J. Increased Length of Stay after Heart Transplant: What are the Risk Factors? *Am J Transplant*. 2015; 15 (suppl 3).
328. Kobashigawa J, Kittleson M, Patel P, Liou F, Siddiqui S, Chang DH, Azarbal B, Ramzy D, Czer L, **Patel J**. Outcome of Renal Sparing Protocol in a Cross-Sectional Analysis after Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
329. Stimpson E, Kao T, Kim L, Morrison S, **Patel J**, Kittleson M, Liou F, Siddiqui S, Yabuno J, Czer L, Kobashigawa J. Social Support after Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
330. Kawano J, Kittleson M, **Patel J**, Azarbal B, Liou F, Siddiqui S, Wong D, Chang DH, Ramzy L, Czer L, Kobashigawa J. Predictive Value of Regadenoson Scans after Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
331. Kobashigawa J, Kittleson M, Liou F, Shiozaki R, Siddiqui S, Piponniau L, Geft D, Hamilton M, Czer L, Reinsmoen N, **Patel J**. Natural History of Anti-Human Leukocyte Antigen Antibodies after Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
332. **Patel J**, Reinsmoen N, Kittleson M, Dilibero D, Liou F, Chang DH, Hamilton M, Czer L, Esmailian, Kobashigawa J. Outcome of Bortezomib/Plasmapheresis for the Sensitized Patient Awaiting Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
333. **Patel J**, Reinsmoen N, Kittleson M, Dilibero D, Liou F, Chang DH, Hamilton M, Czer L, Esmailian, Kobashigawa J. Outcome of Bortezomib/Plasmapheresis for the Sensitized Patient Awaiting Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
334. **Patel J**, Reinsmoen N, Kittleson M, Velleca A, Dilibero D, Liou F, Chang DH, Hage A, Czer L, Esmailian F, Kobashigawa J. Rituximab with Intravenous Immune Globulin in Sensitized Patients Awaiting Heart Transplant: Does it Work? *Am J Transplant*. 2015; 15 (suppl 3).
335. Luu M, Kittleson M, **Patel J**, Liou F, Siddiqui S, Piponniau L, Hage A, Chang DH, Czer L, Trento A, Kobashigawa J. T-Cell Immune Function vs. Gene Expression Profiling for Heart Transplant Rejection. *Am J Transplant*. 2015; 15 (suppl 3).
336. Kittleson M, **Patel J**, Liou F, Siddiqui S, Fong A, Johnson M, Chang DH, Czer L, Esmailian F, Reinsmoen N, Kobashigawa J. The Effects of Donor Specific Anti-Human Leukocyte Antigen Antibodies Late after Heart Transplantation. *Am J Transplant*. 2015; 15 (suppl 3).
337. Kittleson M, **Patel J**, Liou F, Siddiqui S, Yabuno J, Chang DH, Ramzy D, Czer L, Esmailian F, Reinsmoen N, Kobashigawa J. Is There a Protective Value for Low Level Donor Specific Antibodies to Prevent Cardiac Allograft Vasculopathy after Heart Transplant? *Am J Transplant*. 2015; 15 (suppl 3).
338. **Patel J**, Kittleson M, Czer L, Aintablian T, Johl M, Daun T, Kearney B, Chang D, Azarbal B, Hamilton M, Esmailian F, Kobashigawa J. Does ACE Inhibitor Use in Heart Transplantation Decrease the Development of Cardiac Allograft Vasculopathy? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
339. Kobashigawa J, Kittleson M, **Patel J**, Aintablian T, Zarrini P, Lipson A, Kao T, Daun T, Chang D, Trento A, Hage A, Czer L. Thymoglobulin Provides Protection Against Ischemia

- Reperfusion in the Immediate Post-Transplant Period. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
340. Kobashigawa J, **Patel J**, Kittleson M, Czer L, Aintablian T, Yang M, Sana S, Rush J, Stimpson E, Geft D, Ramzy D, Reinsmoen N. When a Prospective Crossmatch Is Warranted in the Virtual Crossmatch (VXM) Era. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
341. Kittleson M, **Patel J**, Czer L, Aintablian T, Rodriguez G, Norland K, Perry N, Chang D, Arabia F, Hamilton M, Azarbal B, Kobashigawa J. The Clinical Application of Non-Invasive Assessment of Coronary Flow Reserve via Rubidium in Heart Transplant Patients. Vol 35, No 4S, April 2016
342. Neyer J, Kittleson M, **Patel J**, Czer L, Aintablian T, Rodriguez G, Jocson R, Runyan C, Chang D, Moriguchi J, Trento A, Kobashigawa J. Desensitization in Total Artificial Heart Patients. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
343. Kittleson M, **Patel J**, Czer L, Passano E, Aintablian T, Runyan C, Henry H, Chang D, Esmailian F, Moriguchi J, Kobashigawa J. Comparison of 6 Month Hospitalizations in Mechanical Circulatory Support Patients vs Heart Transplant Patients. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
344. **Patel J**, Kittleson M, Czer L, Chang D, Aintablian T, Norris E, Velleca A, Rush J, Stimpson E, Hage A, Trento A, Kobashigawa J. Donor Heart Turn Down, Is It Rational? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
345. Kittleson M, **Patel J**, Czer L, Aintablian T, Rush J, Johnson M, Chang D, Ramzy D, Geft D, Kobashigawa J. Are Pediatric Donor Hearts Viable in Adult Recipients? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
346. Kittleson M, **Patel J**, Czer L, Aintablian T, Daun T, Johnson M, Chang D, Trento A, Geft D, Kobashigawa J. Outcome of Patients Proceeding to Heart Transplant with Low Level Donor-Specific Antibodies: How Do They Do? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
347. **Patel J**, Kittleson M, Czer L, Aintablian T, Stimpson E, Daun T, Manayan T, Rodriguez G, Chang D, Ramzy D, Kobashigawa J. Chronic Lung Disease Fev1/Fvc < 70% and Primary Graft Dysfunction; a Marker for Prolonged Intubation Immediately Post-Transplantation. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
348. Kittleson M, Patel J, Czer L, Aintablian T, Rodriguez G, Velleca A, Kearney B, Chang D, Hamilton M, Esmailian F, Zhang X, Reinsmoen N, Kobashigawa J. Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
349. **Patel J**, Kittleson M, Czer L, Aintablian T, Phan D, Leong D, Rush J, Stimpson E, Chang D, Hage A, Trento A, Kobashigawa J. Prolonged Corrected QT Interval in the Donor Heart: Is There a Risk? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
350. **Patel J**, Kittleson M, Czer L, Aintablian T, Sharoff R, Rodriguez G, Kearney B, Perry N, Hage A, Esmailian F, Kobashigawa J. Severity of Hypertension After Heart Transplant: Does it Impact Outcome? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
351. Moriguchi J, Kittleson M, **Patel J**, Czer L, Aintablian T, Jocson R, Runyan C, Chang D, Azarbal B, Arabia F, Kobashigawa J. Removal of Ventricular Assist Device at the Time of Heart Transplant in Sensitized Patients Results in Reduced Antibody Production. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
352. **Patel J**, Kittleson M, Czer L, Aintablian T, Sharoff R, Kim B, Velleca A, Kearney B, Chang D, Azarbal B, Hamilton M, Trento A, Kobashigawa J. Treatment of Sleep Apnea with Heart Transplantation: Does It Help? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016

353. Esmailian F, Perry P, Luu M, **Patel J**, Kittleson M, Czer L, Aintablian T, Zarrini P, Velleca A, Rush J, Arabia F, Kobashigawa J. Vasoplegia After Heart Transplantation: Unraveling the Enigma. *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
354. Luu M, **Patel J**, Kittleson M, Czer L, Aintablian T, Norland K, Perry N, Chang D, Hamilton M, Geft D, Kobashigawa J. Lower Dose Tacrolimus Monotherapy in Heart Transplant Patients: Is It Safe? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
355. Stimpson E, Velleca A, Kao T, Kim L, Kittleson M, **Patel J**, Czer L, Chang D, Hamilton M, Ramzy D, Kobashigawa J. Care Giver Support for Heart Transplant: Does the Type of Provider Matter? *J Heart Lung Transplant*. Vol 35, No 4S, April 2016
356. Phan D, Aintablian T, **Patel J**, Chang D, Kobashigawa J. Longer Brain Death Duration Associated With Increased Acute Cellular Rejection after Heart Transplantation. *J Am Coll Cardiol*. Volume 67, Issue 13 Supplement, April 2016.
357. Leong D, Aintablian T, Kittleson M, **Patel J**, Chang D, Kobashigawa J. Prolonged Donor Heart Corrected QT Interval: Is There a Risk? *J Am Coll Cardiol*. Volume 67, Issue 13 Supplement, April 2016
358. Kobashigawa J, Kittleson M, Czer L, Aintablian T, Passano E, Chang D, Esmailian F, **Patel J**. Gender Mismatch in the UNOS Heart Transplant Database: Not a Factor in Younger Heart Transplant Patients. *Am J Transplant*. 2016; 16 (suppl 3).
359. Neyer J, **Patel J**, Kittleson M, Chang D, Luu M, Aintablian T, Passano E, Czer L, Esmailian F, Kobashigawa J. Heart and Kidney Transplants in Patients with Mechanical Circulatory Support: Who Needs a Kidney? *Am J Transplant*. 2016; 16 (suppl 3).
360. Kittleson M, **Patel J**, Czer L, Velleca A, Aintablian T, Chang D, Esmailian F, Kobashigawa J. Is Donor Methamphetamine Use a Contraindication in Heart Transplantation? *Am J Transplant*. 2016; 16 (suppl 3).
361. Mohan R, **Patel J**, Kittleson M, Chang D, Aintablian T, Czer L, Esmailian F, Kobashigawa J. Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy? *Am J Transplant*. 2016; 16 (suppl 3). *Am J Transplant*. 2016;16 ; In Press.
362. **Patel J**, Kittleson M, Chang D, Aintablian T, Czer L, Trento A, Kobashigawa J. Outcome of the Various Pathology Grades of Antibody-Mediated Rejection After Heart Transplantation. *Am J Transplant*. 2016; 16 (suppl 3).
363. Chang D, **Patel J**, Kittleson M, Aintablian T, Czer L, Ramzy D, Kobashigawa J. Prednisone Wean After Dual Heart and Kidney Transplantation: Is There a Risk? *Am J Transplant*. 2016; 16 (suppl 3).
364. **Patel J**, Kittleson M, Chang D, Aintablian T, Velleca A, Ramzy D, Czer L, Kobashigawa J. The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation. *Am J Transplant*. 2016; 16 (suppl 3).
365. **Jignesh Patel**, MD, PhD, Michelle Kittleson, MD, PhD, Xiaohai Zhang, PhD, Ellen Klapper, MD, Kellee Murayama, BS, Tamar Aintablian, BS, Lawrence Czer, MD, Dael Geft, MD, David H Chang, MD, and Jon Kobashigawa, MD. Photopheresis Post Heart Transplantation: Does it Portend Poor Outcome? Cedars-Sinai, Los Angeles. Abstract # 2701577
366. **Jignesh Patel**, MD, PhD, Michelle Kittleson, MD, PhD, Lawrence Czer, MD, Tamar Aintablian, BS, Tina Kao, BSN, RN, CCTC, Dael Geft, MD, David Chang, MD, Fardad Esmailian, MD, and Jon Kobashigawa, MD. Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development? Cedars-Sinai, Los Angeles. Abstract #2701613
367. **Jignesh Patel**, MD, PhD, Michelle Kittleson, MD, PhD, Babak Azarbal, MD, Tamar Aintablian, BS, Genevieve Rodriguez, BA, Michele Hamilton, MD, Dael Geft, MD, David Chang, MD,

- Lawrence Czer, MD, Alfredo Trento, MD, Jon Kobashigawa, MD. Outcome of heart Transplant Patients with Rapidly Progressive Cardiac Allograft Vasculopathy. Cedars-Sinai, Los Angeles. Abstract #2701689
368. Leong D, Aintablian T, Patel J, Kittleson M, Geft D, Czer L, and Kobashigawa J. Angiographic Dye Prior to Combined Heart-Kidney Donation does not Appear to Harm Donor Kidney Function after Transplant. *J Am Coll Cardiol*. 2017; 69(11): 1430.
369. Cheng R, **Patel J**, Chang D, Kittleson M, Makkar R, Azarbal B, and Kobashigawa J. Percutaneous Coronary Intervention with Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy and the Impact of Diabetes Mellitus on Stent and Target Lesion Patency. *J Am Coll Cardiol*. 2017; 69(11): 96.
370. David Chang, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Michele Hamilton, Dael Geft, Evan Kransdorf, Lawrence Czer, Jon Kobashigawa, Francisco Arabia, and Jaime Moriguchi. Does Socioeconomic Status Impact Outcome following Mechanical Circulatory Support Device Implantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S435–S436.
371. David Chang, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Ryan Levine, Dael Geft, Evan Kransdorf, Lawrence Czer, Alfredo Trento, Fardad Esmailian, and Jon Kobashigawa. Treatment of Primary Graft Dysfunction with Plasmapheresis Improves Outcome. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S147.
372. Rajeev Mohan, Jonathan Neyer, **Jignesh Patel**, Michelle Kittleson, Tamar Aintablian, Ryan Levine, David Chang, Lawrence Czer, Jaime Moriguchi, Jon Kobashigawa, and Francisco Arabia. Pre-Implant Moderate-Severe Fibrosis on Liver Biopsy Predicts Adverse Outcomes After Mechanical Circulatory Support. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S124–S125.
373. Evan Kransdorf, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Angela Velleca, Emily Stimpson, Dael Geft, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Predicted Heart Mass Is the Optimal Metric for Size Matching in Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S113–S114.
374. **Jignesh Patel**, Michelle Kittleson, Tamar Aintablian, Ryan Levine, Michelle Curry, Antoine Hage, Dael Geft, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. Does the New ISHLT Primary Graft Dysfunction (PGD) Grading Scale in Heart Transplantation Predict Outcome? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S146.
375. **Jignesh Patel**, Michelle Kittleson, Robert Vescio, Tamar Aintablian, Rayshma Sharoff, Ryan Levine, Dael Geft, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Transthyretin Amyloid Patients > 70 Years of Age Appear as Good Candidates for Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S387.
376. Sean Sana, **Jignesh Patel**, Michelle Kittleson, Tamar Aintablian, Matthew Rafiei, Daniel Luthringer, Xiaohai Zhang, Nancy Reinsmoen, Lawrence Czer, and Jon Kobashigawa. The Incidence of Donor-Specific Antibody in the Presence of Biopsy-Proven Antibody-Mediated Rejection After Heart Transplantation *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S198.
377. David Chang, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Angela Velleca, Gina Jamero, Evan Kransdorf, Dael Geft, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Is Tacrolimus/Proliferation Signal Inhibitor (PSI) Comparable to Cyclosporine/PSI After Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S303.
378. Jon Kobashigawa, Michelle Kittleson, Tamar Aintablian, Babak Azarbal, Antoine Hage, Evan Kransdorf, Dael Geft, David Chang, Lawrence Czer, Fardad Esmailian, Xiaohai Zhang, Nancy

- Reinsmoen, and **Jignesh Patel**. Only Persistent Donor Specific Antibodies Are Associated with Subsequent Cardiac Allograft Vasculopathy after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S292.
379. **Jignesh Patel**, Michelle Kittleson, Tamar Aintablian, Gabriel Esmailian, Angela Velleca, Antoine Hage, Evan Kransdorf, Dael Geft, David Chang, Lawrence Czer, and Jon Kobashigawa, 2017. Despite FDA Black Box Warning, Proliferation Signal Inhibitor (PSI) in the First Year with Induction Therapy Appears Safe in Heart Transplant Patients. *The Journal of Heart and Lung Transplantation*, 36(4), S303–S304.
380. Jaime Moriguchi, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, James Kwan, Evan Kransdorf, Dael Geft, David Chang, Lawrence Czer, Jon Kobashigawa, and Francisco Arabia. Combined Heart-Kidney Transplant vs Heart Alone Transplant in Patients with Total Artificial Heart: Are they Viable? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S329.
381. David Chang, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Genevieve Rodriguez, Ryan Levine, Dael Geft, Evan Kransdorf, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Coronary Vasospasm after Heart Transplantation: Does it Portend Poor Outcome? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S294.
382. Richard Cheng, Babak Azarbal, David Chang, Tamar Aintablian, Lawrence Czer, **Jignesh Patel**, and Jon Kobashigawa. Angiogenesis on Coronary Angiography Is a Marker for Accelerated Cardiac Allograft Vasculopathy as Assessed by Intravascular Ultrasound. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S294–S295.
383. Jon Kobashigawa, Michelle Kittleson, Tamar Aintablian, David Chang, Dael Geft, Lawrence Czer, Fardad Esmailian, and **Jignesh Patel**. The Outcome of Heart Transplant Patients with Hemodynamic Compromise Rejection in the Current Era. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S288–S289.
384. Dael Geft, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Ryan Levine, Michael Hashimoto, Evan Kransdorf, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. The Story on Extracorporeal Membrane Oxygenation (ECMO) Directly to Mechanical Circulatory Support or to Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S336–S337.
385. Jon Kobashigawa, Nancy Reinsmoen, Xiaohai Zhang, Michelle Kittleson, Tamar Aintablian, Jennifer Krems, Evan Kransdorf, David Chang, Lawrence Czer, Fardad Esmailian, and **Jignesh Patel**. The Risk of Naïve vs Memory Patients Awaiting Heart Transplantation: Does It Make a Difference in Post-Transplant Outcomes? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S287–S288.
386. Jon Kobashigawa, Michelle Kittleson, Sean Sana, Tamar Aintablian, Ryan Levine, Babak Azarbal, Dael Geft, David Chang, Lawrence Czer, Daniel Luthringer, and **Jignesh Patel**. Correlation of the Grades of Antibody-Mediated Rejection to 1-Year IVUS results after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S288.
387. Dominick Megna, Fardad Esmailian, **Jignesh Patel**, Michelle Kittleson, Tamar Aintablian, Emily Stimpson, Evan Kransdorf, Dael Geft, David Chang, Lawrence Czer, and Jon Kobashigawa. Success for Combined Heart and Kidney Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S229.
388. Frank Liou, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Tina Kao, Evan Kransdorf, Dael Geft, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. Donor Heart Diastolic Dysfunction: Do You Take This Heart for Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S43.

389. Michael Johl, **Jignesh Patel**, Michelle Kittleson, Lawrence Czer, Tamar Aintablian, Angela Velleca, Michele Hamilton, Dael Geft, David Chang, Danny Ramzy, and Jon Kobashigawa. ACE Inhibitors or ARBs - Do They Improve Outcome After Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S234–S235.
390. Dael Geft, Michelle Kittleson, **Jignesh Patel**, Tamar Aintablian, Kristen Yabuno, Brenda Kearney, Evan Kransdorf, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Severe Tricuspid Regurgitation After Heart Transplantation: Does It Require Surgical Repair? *The Journal of Heart and Lung Transplantation*, pr2017. 36(4), S223–S224.
391. **Jignesh Patel**, Michelle Kittleson, Tamar Aintablian, James Kwan, Nena Musto, Brenda Kearney, Dael Geft, David Chang, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Donor Heart Turn Down in the Field: What’s Going On? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S44.
392. Kransdorf E, Kittleson M, **Patel J**, Aintablian T, Levine R, Kearney B, Musto N, Hage A, Geft D, Czer L, Esmailian F, Trento A, Kobashigawa J. Risk of Amiodarone and Permanent Pacemaker Placement After Heart Transplantation. *Am J Transplant*. 2017;17 (suppl 3).
393. Leong D, Azarbal B, **Patel J**, Kittleson M, Czer L, Aintablian T, Chang D, Geft D, Kobashigawa J. In the Modern Era, Cytomegalovirus Does Not Appear to Increase Intimal Thickening After Heart Transplantation. *Am J Transplant*. 2017;17 (suppl 3).
394. Kransdorf E, Aintablian T, Kittleson M, **Patel J**, Kobashigawa J. Validation of a Prediction Model for Cardiac Allograft Vasculopathy. *Am J Transplant*. 2017;17 (suppl 3).
395. **Patel J**, Kittleson M, Czer L, Aintablian T, Stimpson E, Azarbal B, Geft D, Chang D, Esmailian F, Kobashigawa J. Post-Transplant Sensitization: Does it Make a Difference in the Development of First-Year Intimal Thickening? *Am J Transplant*. 2017;17 (suppl 3).
396. **Patel J**, Kittleson M, Czer L, Aintablian T, Kao T, Geft D, Chang D, Esmailian F, Kobashigawa J. Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development? *Am J Transplant*. 2017;17 (suppl 3).
397. **Patel J**, Kittleson M, Zhang X, Klapper E, Aintablian T, Murayama K, Czer L, Geft D, Chang D, Kobashigawa J. Photopheresis for Recalcitrant Rejection After Heart Transplantation: Worthwhile? *Am J Transplant*. 2017;17 (suppl 3).
398. **Patel J**, Kittleson M, Czer L, Aintablian T, Sharoff R, Levine R, Velleca A, Ramzy D, Esmailian F, Kobashigawa J. Severe Tricuspid Regurgitation After Heart Transplantation: Does It Require Surgical Repair? *Am J Transplant*. 2017;17 (suppl 3).
399. Rafiei M, Moriguchi J, Kittleson M, **Patel J**, Aintablian T, Passano E, Sharoff R, Kwan J, Kransdorf E, Chang D, Czer L, Kobashigawa J, Arabia F. Does the Model for End Stage Liver Disease (MELD) Score Predict Outcome in Total Artificial Heart Patients? *Am J Transplant*. 2017;17 (suppl 3).
400. E. Kransdorf, **J. Patel**, X. Zhang, M. Pando, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, K. Norland, M. Hamilton, J. Chung, J. A. Kobashigawa. Novel Methods for Assessing Response to Desensitization. *The Journal of Heart and Lung Transplantation* 2018. 37(4), S439.
401. **J. Patel**, M. Kittleson, L. Czer, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, S. Sana, M. Hamilton, F. Esmailian, D. Luthringer, J. A. Kobashigawa. The Risk of pAMR 1H after Heart Transplantation: Is it Bad? *The Journal of Heart and Lung Transplantation* 2018. 37(4), S52.
402. **J. Patel**, M. Johl, M. Kittleson, L. Czer, S. Dimbil, R. Levine, N. Musto, D. H. Chang, M. Hamilton, A. Trento, J. A. Kobashigawa. 5-Year Outcome of Renal Function with Patients on Renal-Sparing Protocol After Heart Transplantation. *The Journal of Heart and Lung Transplantation* 2018. 37(4), S20.

403. M. Kittleson, **J. Patel**, L. Czer, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, J. Davis, M. Hamilton, A. Trento, X. Zhang, J. A. Kobashigawa. The Clinical Impact of Early vs Late HLA Donor-Specific Antibody Development After Heart Transplantation. *The Journal of Heart and Lung Transplantation* 2018. 37(4), S438.
404. **J. Patel**, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, A. Velleca, E. Kransdorf, M. Hamilton, A. Trento, J. A. Kobashigawa.. Epstein-Barr Virus Mismatch (Donor+/Recipient-): Is Cancer the Only Risk? *The Journal of Heart and Lung Transplantation* 2018. 37(4), S355.
405. E. Kransdorf, **J. Patel**, M. Kittleson, D. Chang, S. Dimbil, R. Levine, A. Shen, A. Jain, M. Olymbios, L. Czer, X. Zhang, J. Kobashigawa. What Antigens to Avoid in Heart Transplant to Optimize Outcome via the Virtual Crossmatch. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S264.
406. Dimbil S, Levine R, Azarbal B, **Patel J**, and Kobashigawa J. Does Time on an Intra-Aortic Balloon Pump for Heart Failure Affect Outcome after Transplant? *J Am Coll Cardiol*. 2019; 73(9, supp 1): 980
407. Miller R, Nikolova A, Kwan A, Levine R, Dimbil S, Kobashigawa J, Kransdorf E, **Patel J**, Thomson L, Li D, Berman D, and Tamarappoo B. Multiparametric Cardiac Magnetic Resonance Phenotyping of Patients with a History of Cardiac Transplant Rejection. *J Am Coll Cardiol*. 2019; 73(9, supp 1): 1639.
408. Kransdorf K, Cole Rm Moriguchi J, Chung J, Ramzy D, **Patel J**, Emailian F, and Kobashigawa J. Turn-Down for Donor Age and Size Has Increased For Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S294.
409. **J. Patel**, M. Kittleson, D. Chang, E. Kransdorf, R. Levine, S. Dimbil, R. Sharoff, L. Czer, A. Hage, F. Esmailian, J.A. Kobashigawa. Heightened Immune Response in Heart Transplant Patients Surviving Severe Primary Graft Dysfunction. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S294.
410. R. Levine, **J. Patel**, M. Kittleson, D. Geft, E. Kransdorf, S. Dimbil, E. Passano, S. Sana, L. Czer, A. Hage, D. Ramzy, J.A. Kobashigawa. Does the Model for End-Stage Liver Disease Predict Primary Graft Dysfunction? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S297
411. A. Wolfson, M. Kittleson, **J. Patel**, E. Kransdorf, R. Cole, R. Levine, S. Dimbil, A. Lam. L. Czer, A. Hage, J. Chung, J. Moriguchi, J.A. Kobashigawa. Biopsy-Negative Rejection Late after Heart Transplantation: Impact on Long-Term Outcome. *The Journal of Heart and Lung Transplantation* 2019. 38(4), S287-288.
412. X. Zhang, **J. Patel**, J. Kobashigawa. Effect of Bortezomib Desensitization Therapy on Levels of AT1R Antibody. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S278.
413. J.A. Kobashigawa, **J. Patel**, M. Kittleson, E. Kransdorf, S. Dimbil, R. Levine, G. Esmailian, C. Kawata, L. Czer, M. Hamilton, D. Ramzy, X. Zhang. Non-HLA Antibodies as a Cause for Biopsy Negative Rejection: Is It Worth Testing for Them? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S87.
414. S. Dimbil, M. Kittleson, **J. Patel**, D. Geft, R. Cheng, R. Levine, T. Sato, L. Czer, B. Azarbal, R. Zabner, P. Zakowski, J.A. Kobashigawa. Does Cytomegalovirus Truly Increase Cardiac Allograft Vasculopathy via First-Year Intravascular Ultrasound after Heart Transplant in the Tacrolimus Era? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S283-284.
415. **J. Patel**, M. Kittleson, R. Levine, S. Sana, A. Shen, D. Geft, B. Azarbal, E. Kransdorf, J. Kobashigawa. Heart Transplantation for Cardiac Amyloidosis - Worthwhile? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S215.
416. M. Kittleson, **J. Patel**, D.H. Chang, E. Kransdorf, R. Levine, S. Dimbil, K. Nishihara, T. Kao, L. Czer, A. Hage, J. Chung, J.A. Kobashigawa. Donor Left Ventricular Hypertrophy: Over-Rated

- or Does Donor History of Hypertension Make a Difference for Post-Heart Transplant Outcome? The Journal of Heart and Lung Transplantation, 2019; 38(4): S431.
417. M. Kittleson, **J. Patel**, E. Kransdorf, D. Geft, S. Dimbil, R. Levine, A. Velleca, L. Czer, A. Hage, R. Zabner, P. Zakowski, J. Kobashigawa. Undue Infection Risk from Proliferation Signal Inhibitors When Initiated Later after Heart Transplantation. The Journal of Heart and Lung Transplantation, 2019; 38(4): S311.
418. D.H. Chang, **J. Patel**, M. Kittleson, E. Kransdorf, S. Dimbil, R. Levine, T. Kao, T. Hage, L. Czer, A. Hage, A. Trento, J.A. Kobashigawa. Is There a Benefit of Metformin after Heart Transplantation? The Journal of Heart and Lung Transplantation, 2019; 38(4): S217.
419. L. Czer, M. Kittleson, **J. Patel**, E. Kransdorf, R. Levine, S. Dimbil, R. Sharoff, B. Kearney, D.H. Chang, M. Hamilton, F. Esmailian, J.A. Kobashigawa. 10-Year Outcomes in Heart-Kidney Transplant Patients: Is There a Protective Effect for the Donor Heart? The Journal of Heart and Lung Transplantation, 2019; 38(4): S217.
420. M. Kittleson, **J. Patel**, R. Cole, D. Geft, S. Dimbil, R. Levine, S. Mersola, L. Czer, B. Azarbal, R. Zabner, P. Zakowski, J.A. Kobashigawa. Does Thymoglobulin Induction Lead to Increased CMV Infection after Heart Transplantation in the Current Tacrolimus Era. The Journal of Heart and Lung Transplantation, 2019; 38(4): S310-S311.
421. E. Kransdorf, **J. Patel**, M. Kittleson, D.H. Chang, R. Levine, S. Dimbil, A. Bitterman, A. Velleca, L. Czer, J. Moriguchi, F. Esmailian, J.A. Kobashigawa. Does Antibody-Mediated Rejection in the First-Month after Heart Transplant Lead to Poor Longer-Term Outcome? The Journal of Heart and Lung Transplantation, 2019; 38(4): S292.
422. M. Kittleson, **J. Patel**, D.H. Chang, D. Geft, S. Dimbil, R. Levine, B. Kearney, L. Czer, M. Hamilton, A. Trento, J.A. Kobashigawa. Heart Transplantation in Muscular Dystrophy: Selection is Crucial for Success. The Journal of Heart and Lung Transplantation, 2019; 38(4): S395-S396.
423. **J. Patel**, M. Kittleson, D.H. Chang, R. Cole, R. Levine, S. Dimbil, A. Jain, B. Kearney, L. Czer, A. Hage, F. Esmailian, J.A. Kobashigawa. The Evolving Long-Term Outcome of Heart Transplantation in Amyloid Patients. The Journal of Heart and Lung Transplantation, 2019; 38(4): S216.
424. **J. Patel**, M. Kittleson, D. Chang, E. Kransdorf, R. Levine, S. Dimbil, T. Kao, L. Czer, R. Cole, F. Esmailian, J. Kobashigawa. 5-Year Outcome of Photopheresis in Heart-Transplantation with Refractory/Persistent Rejection. The Journal of Heart and Lung Transplantation, 2019; 38(4): S276.
425. L. Benck, E. Kransdorf, **J. Patel**, D. Malinoski, R. Levine, C. Neimann, J.A. Kobashigawa. Achievement of Donor Management Goals and Primary Graft Dysfunction after Heart Transplant. The Journal of Heart and Lung Transplantation, 2019; 38(4): S268.
426. K. Shah, J.A. Kobashigawa, **J. Patel**, M. Kittleson, D.H. Chan, S. Dimbil, R. Levine, S. Sana, L. Czer, B. Azarbal, F. Esmailian, P. Halloran. Heart Transplant Patients with Histologic Normal and Molecular Microscope Abnormal Biopsies: An Exploratory Analysis. The Journal of Heart and Lung Transplantation, 2019; 38(4): S284-S285.
427. E. Kransdorf, M. Kittleson, **J. Patel**, R. Cole, S. Dimbil, R. Levine, M. Olymbios, T. Kao, L. Czer, B. Azarbal, J. Chung, J.A. Kobashigawa. Mixed Rejection: More Important Than Thought after Heart Transplantation. The Journal of Heart and Lung Transplantation, 2019; 38(4): S388.
428. D.H. Chang, **J. Patel**, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J.A. Kobashigawa. Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant. The Journal of Heart and Lung Transplantation, 2019; 38(4): S210-S211.

429. D.H. Chang, M. Kittleston, **J. Patel**, D. Geft, R. Levine, S. Dimbil, K. Nishihara, T. Kao, L. Czer, A. Trento, J.A. Kobashigawa. Short and Stout Female Donors in Heart Transplantation: Do They Make a Difference? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S270.
430. Velleca A, **Patel J**, Kittleston M, Levine R, Dimbil S, Mersola S, Hamilton M, Esmailian F, Kobashigawa J. Intravenous methamphetamine does not appear to be a contraindication for heart donation in heart transplantation. *American Journal of Transplantation*. 2019. 38(4), S92.
431. Shah K, Levine RJ, Dimbil S, Sana S, Halloran PF, **Patel J**, Chang DH, Kransdorf E, Kittleston M, Kobashigawa A. Prevalence of donor specific antibody in heart transplant recipients with antibody-mediated rejection as compared to abnormal intragraft mRNA transcripts by molecular microscope system. *American Journal of Transplantation*. 2019; 19:773-4.
432. Shah K, Chang DH, **Patel J**, Levine RJ, Dimbil S, Passano E, Kobashigawa JA. Increasing doses of pain medications pre-heart transplant as a risk factor for outcomes after transplant. *American Journal of Transplantation*. 2019; 19:773.
433. **Patel J**, Kransdorf E, Levine R, Dimbil S, Czer L, Kobashigawa JA. Does the type of pre-heart transplant desensitization therapy affect 5-year post-transplant outcomes? *American Journal of Transplantation*. 2019; 19:352
434. **Patel J**, Kittleston M, Chang DH, Levine R, Dimbil S, Czer L, Esmailian F, Kobashigawa JA. 3-year outcome of heart transplantation in patients with amyloidosis. *American Journal of Transplantation*. 2019; 19:775.
435. Olymbios M, Dimbil S, Levine RJ, Esmailian F, **Patel J**, Kobashigawa JA. Risk factors to define an extended criteria donor heart do not appear to have cumulative adverse effects after heart transplantation. *American Journal of Transplantation*. 2019; 19:479.
436. Kransdorf E, **Patel J**, Dimbil S, Levine R, Chang DH, Kobashigawa JA. What is the post-heart transplant risk of infectious complications from pre-transplant desensitization therapy? *American Journal of Transplantation*. 2019; 19:786.
437. Kittleston M, **Patel J**, Chang DH, Kransdorf E, Dimbil S, Levine R, Yabuno K, Czer L, Hamilton M, Esmailian F, Kobashigawa JA. Amiodarone and primary graft dysfunction in heart transplantation: reality or myth? *American Journal of Transplantation*. 2019; 19:774-5.
438. Dimbil S, **Patel J**, Azarbal B, Kittleston M, Levine R, Chang DH, Kobashigawa JA. Outcome of left main stenting after heart transplantation. *American Journal of Transplantation*. 2019; 19:778.
439. Dimbil S, Kittleston M, **Patel J**, Geft D, Cheng R, Levine R, Sato T, Czer L, Zabner R, Zakowski P, Kobashigawa JA, Azarbal B. The use of first-year intravascular ultrasound in the tacrolimus era in heart transplantation. *American Journal of Transplantation*. 2019; 19:780.
440. Lor K, Kransdorf E, **Patel J**, Kittleston M, Chang D, Kobashigawa JA. Anemia and Hemolysis on Dapsone Despite Normal Glucose-6-Phosphate Dehydrogenase Activity in Heart Transplant Recipients. *Am J Transplant*. 2019; 19 (suppl 3).
441. Kittleston M, **Patel J**, Chang DH, Dimbil S, Levine R, Czer L, Kobashigawa JA. Is Muscular dystrophy A contraindication to heart transplantation? *American Journal of Transplantation*. 2019;19:780.
442. Kittleston M, **Patel J**, Kransdorf E, Dimbil S, Levine R, Kobashigawa JA. Outcome of late biopsy-negative rejection after heart transplantation. *American Journal of Transplantation*. 2019; 19:771-2.
443. Kittleston M, **Patel J**, Dimbil S, Levine RJ, Esmailian G, Shen A, Hage T, Kobashigawa JA. Infectious risk of rejection therapy following heart transplantation; can it be avoided? *American Journal of Transplantation*. 2019; 19:783-4.

444. Kobashigawa JA, Starling R, Passano E, Bernhardt P, Azarbal B, Cheng R, Esmailian F, Khush K, Mancini D, **Patel J**, Sato T, Varnous S. Breaking Concepts: 10-year Follow-Up of the Everolimus versus Azathioprine Heart Transplant Multi-National Study. *Am J Transplant*. 2019; 19 (suppl 3).
445. Aguilar J, **Patel J**, Kittleson M, Chang DH, Kransdorf E, Shen Am Nishihara K Czer L, Kobashigawa JA. Outcomes of Hearts Transplanted From >60 Year-old Donors. *J Am Coll Cardiol*. 2020 Mar 24;75(11 S1):814.
446. **J. Patel**, M. Kittleson, D.H. Chang, K. Nishihara, A. Shen, T. Megerdichian, R. Zabner, K. Lor, L. Czer, F. Esmailian, A. Trento and J. Kobashigawa. The Forgotten Hepatitis B Donor in Heart Transplantation. *The Journal of Heart and Lung Transplantation*. Vol 39, No 4S, April 2020.
447. M. Kittleson, **J. Patel**, D. Chang, K. Nishihara, A. Shen, A. Velleca, M. Hamilton, P. Zakowski, L. Czer, F. Esmailian and J. Kobashigawa. Effect of the Shingels Vaccine in Altering Clinical Shingles after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
448. **J. Patel**, M. Kittleson, E. Kransdorf, D. Chang, L. Czer, A. Shen, K. Nishihara, R. Sharoff, M. Hamilton, F. Esmailian and J.A. Kobashigawa. The Natural History of Pre-Existing Donor Specific Antibody and Amnestic Responses after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
449. X. Zhang, R. Levine, **J. Patel**, M. Kittleson, L. Czer, and J. Kobashigawa. Vimentin Antibodies Increased in Patients with AMR in the Absence of HLA Donor Specific Antibodies. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
450. **J. Patel**, M. Kittleson, D.H. Chang, K. Nishihara, A. Shen, S. Mersola, A. Velleca, A. Hage, L. Czer, D. Emerson and J.A. Kobashigawa. Does the Dose of Mycophenolate Mofetil Impact Outcome after Heart Transplantation? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
451. **J. Patel**, M. Kittleson, D. Chang, K. Nishihara, A. Shen, G. Harris, A. Velleca, B. Azarbal, L. Czer, D. Ramzy and J. Kobashigawa. Pre-Transplant Collagen Vascular Disease as a Risk Factor for Increase in Cardiac Allograft Vasculopathy after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
452. **J. Patel**, M. Kittleson, D. Chang, K. Nishihara, A. Shen, G. Harris, A. Velleca, B. Azarbal, L. Czer, D. Ramzy and J. Kobashigawa. Pre-Transplant Collagen Vascular Disease as a Risk Factor for Increase in Cardiac Allograft Vasculopathy after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
453. M. Kittleson, **J. Patel**, D. Chang, K. Nishihara, A. Shen, A. Patel, A. Velleca, B. Azarbal, L. Czer, D. Emerson, A. Trento and J. Kobashigawa. Longer-Term Morbidity/Mortality of Severe Left Ventricular Primary Graft Dysfunction after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
454. J.A. Kobashigawa, M. Kittleson, D.H. Chang, E. Kransdorf, A. Shen, K. Nishihara, G. Jamero, B. Coleman, L. Czer, D. Ramzy, F. Esmailian and **J. Patel**. Post-Heart Transplant Outcomes of Sensitized Patients Who Have Undergone Desensitization Therapy. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
455. V. Nguyen, E. Kransdorf, **J. Patel**, K. Nishihara, R. Levine, C. Sumbi and J. Kobashigawa. Predictors of Delayed Renal Graft Function in Combined Heart and Kidney Transplant Recipients. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
456. **J. Patel**, M. Kittleson, E. Kransdorf, A. Shen, K. Nishihara, G. Jamero, B. Azarbal, A. Hage, L. Czer, D. Megna and J.A. Kobashigawa. Does the Development of Donor Specific Antibody after Heart Transplantation Depend on the Presence or Absence of Corticosteroids as

Maintenance Therapy? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.

457. **J. Patel**, M. Kittleson, D.H. Chang, K. Nishihara, A. Shen, R. Sharoff, A. Velleca, B. Coleman, A. Hage, L. Czer, D. Ramzy and J.A. Kobashigawa. 5-Year Outcome of Patients Weaned off Corticosteroids after Heart Transplantation: Is There a Downside? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
458. M. Kittleson, **J. Patel**, E. Kransdorf, A. Shen, K. Nishihara, S. Rajkumar, A. Velleca, D. Geft, L. Czer, J. Moriguchi and J. Kobashigawa. Desensitization Therapy for Mechanical Circulatory Support Patients with Existing Driveline Infection: Is It Safe with Current Desensitization Therapies? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
459. M. Kittleson, **J. Patel**, E. Kransdorf, A. Shen, K. Nishihara, G. Jamero, S. Sana, A. Hage, D. Geft, L. Czer, F. Esmailian and J.A. Kobashigawa. Is Anti-Thymocyte Globulin for Sensitized Patients Undergoing Heart Transplantation Effective? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
460. A. Aiken, **J. Patel**, E. Kransdorf, A. Shen, K. Nishihara, A. Velleca, R. Cole, M. Hamilton, L. Czer, D. Megna, X. Zhang and J. Kobashigawa. Donor Specific Antibodies after Heart Transplantation: Can They Be Treated? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
461. Nguyen V, Kransdorf E, **Patel J**, Kittleson M, Czer L, Kobashigawa JA Predictors of Renal Graft Failure in Heart/Kidney Transplant Recipients. *J Heart Lung Transplant*. 2020 Apr;39(4):S299-300.
462. M. Kittleson, **J. Patel**, D. Chang, E. Kransdorf, A. Shen, K. Nishihara, D. Melamed, G. Jamero, B. Azarbal, L. Czer, D. Ramzy, A. Trento and J. Kobashigawa. Outcome of Right Ventricular Primary Graft Dysfunction after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
463. Aguilar J, Chang DH, Lin M, Hou J, Huang E, Kittleson M, **Patel J**, Kobashigawa J. JC virus-associated nephropathy in a post-heart and -kidney transplantation patient. *Transpl Infect Dis*. 2020 Jun;22(3):e13288. doi: 10.1111/tid.13288. Epub 2020 Apr 23. PMID: 32282976.
464. Zhang X, Kransdorf E, Levine R, **Patel JK**, Kobashigawa JA. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients. *Hum Immunol*. 2020 Jul;81(7):330-336. doi: 10.1016/j.humimm.2020.04.003. Epub 2020 Apr 17. PMID: 32307126.
465. Nishihara K, **Patel J**, Kittleson M, Chang D, Kransdorf E, Geft D, Shen A, Czer L, Esmailian F, Kobashigawa JA. Do the Characteristics of Donor Specific Antibody Truly Predict Severity of Cardiac Allograft Vasculopathy Late after Transplantation? *Am J Transplant*. 2020; 20 (suppl 3).
466. Kransdorf EP, Pando MJ, Stewart D, Lindblad K, Bray R, Murphey C, Kaur N, **Patel JK**, Kim I, Zhang X, Maiers M, Kobashigawa JA, Gragert L. Stem cell donor HLA typing improves CPRA in kidney allocation. *Am J Transplant*. 2021 Jan;21(1):138-147. doi: 10.1111/ajt.16156. Epub 2020 Jul 13. PMID: 32558252.
467. Kobashigawa JA, Kittleson M, **Patel J**, Chang D, Kransdorf E, Geft D, Nishihara K, Shen A, Czer L, Esmailian F. High-Risk Antibodies Pre-Transplant Impacts Outcome after Heart Transplantation. *Am J Transplant*. 2020; 20 (suppl 3).
468. **Patel KJ**, Kao T, Geft D, Czer L, Esmailian F, Kobashigawa JA, Patel JK. Donor organ evaluation in the era of coronavirus disease 2019: A case of nosocomial infection. *J Heart Lung Transplant*. 2020 Jun;39(6):611-612. doi: 10.1016/j.healun.2020.04.005. Epub 2020 Apr 12. PMID: 32334945; PMCID: PMC7152866.

469. Shen A, **Patel J**, Kittleson M, Chang D, Kransdorf E, Geft D, Nishihara K, Czer L, Esmailian F, Kobashigawa JA. The Frequency of De Novo DSA in the Years Following Heart Transplantation. *Am J Transplant*. 2020; 20 (suppl 3).
470. **Patel J**, Kittleson M, Chang D, Kransdorf E, Geft D, Shen A, Nishihara K, Velleca A, Czer L, Esmailian F, Kobashigawa JA. Is Ischemia Reperfusion Injury Immediately after Heart Transplantation Correlated to Increased Intimal Thickening in the First Year? *Am J Transplant*. 2020; 20 (suppl 3).
471. Kittleson M, **Patel J**, Chang D, Kransdorf E, Geft D, Nishihara K, Shen A, May B, Czer L, Esmailian F, Kobashigawa JA. Is 3-4+ Liver Fibrosis a Contraindication to Heart Transplantation? *Am J Transplant*. 2020; 20 (suppl 3).
472. Coutance G, **Patel J**, Kransdorf E, Levine R, Passano E, Kobashigawa J. Evaluation of the Discrimination of 13 Mortality Risk Scores after Heart Transplantation in a Contemporary UNOS Cohort. *Am J Transplant*. 2020; 20 (suppl 3).
473. Coutance G, Kransdorf E, Bonnet G, Loupy A, Kobashigawa J, **Patel JK**. Statistical performance of 16 posttransplant risk scores in a contemporary cohort of heart transplant recipients. *Am J Transplant*. 2021 Feb;21(2):645-656. doi: 10.1111/ajt.16217. Epub 2020 Sep 5. PMID: 32713121.
474. Vaidya G, Czer LSC, Kobashigawa J, Kittleson M, **Patel J**, Chang D, Kransdorf E, Shikhare A, Tran H, Vo A, Ammerman N, Huang E, Zabner R, Jordan S. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. *Transplant Proc*. 2020 Nov;52(9):2711-2714. doi: 10.1016/j.transproceed.2020.06.003. Epub 2020 Jun 7. PMID: 32563584; PMCID: PMC7275980.
475. Loupy A, Coutance G, Bonnet G, Van Keer J, Raynaud M, Aubert O, Bories MC, Racapé M, Yoo D, Duong Van Huyen JP, Bruneval P, Taupin JL, Lefaucheur C, Varnous S, Leprince P, Guillemain R, Empana JP, Levine R, Naesens M, **Patel JK**, Jouven X, Kobashigawa J. Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study. *Circulation*. 2020 Jun 16;141(24):1954-1967. doi: 10.1161/CIRCULATIONAHA.119.044924. Epub 2020 May 4. PMID: 32363949.
476. Hitzeman TC, Xie Y, Zadikany RH, Nikolova AP, Baum R, Caldaruse AM, Agvanian S, Melmed GY, McGovern DPB, Geft DR, Chang DH, Moriguchi JD, Hage A, Azarbal B, Czer LS, Kittleson MM, **Patel JK**, Wu AHB, Kobashigawa JA, Hamilton M, Hong T, Shaw RM. cBIN1 Score (CS) Identifies Ambulatory HFref Patients and Predicts Cardiovascular Events. *Front Physiol*. 2020 May 25;11:503. doi: 10.3389/fphys.2020.00503. PMID: 32670075; PMCID: PMC7326053.
477. **Patel JK**, Coutance G, Loupy A, Dilibero D, Hamilton M, Kittleson M, Kransdorf E, Azarbal B, Seguchi O, Zhang X, Chang D, Geft D, Czer L, Varnous S, Kobashigawa JA. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. *Am J Transplant*. 2020 Nov 29. doi: 10.1111/ajt.16420. Epub ahead of print. PMID: 33251691.
478. Kittleson M, **Patel J**, Chang D, Kransdorf E, Geft D, Nishihara K, Shen A, Velleca A, Czer L, Esmailian F, Kobashigawa J. Challenging Dogma That Anti-Thymocyte Globulin Induction with Delayed Calcineurin Inhibitor Benefits Patients with Renal Insufficiency Undergoing Heart Transplant. *Am J Transplant*. 2020; 20 (suppl 3).
479. Esmailian G, Kobashigawa JA, Nishihara K, **Patel JK**, Czer L, Megna D, Emerson D, Ramzy D, Trento A, Chikwe J, Esmailian F. Heart transplantation in the era of the SARS-CoV-2 pandemic: Is it safe and feasible? *Clin Transplant*. 2020 Oct;34(10):e14029. doi: 10.1111/ctr.14029. Epub 2020 Jul 24. PMID: 32633819; PMCID: PMC7361065.

480. Kobashigawa J, Shah P, Joseph S, Olymbios M, Bhat G, Dhital K, Eisen H, Kransdorf E, **Patel J**, Skorka R, Pinney S, Wilson ME, Hall S; Heart Frailty Workgroup. Frailty in heart transplantation: Report from the heart workgroup of a consensus conference on frailty. *Am J Transplant*. 2021 Feb;21(2):636-644. doi: 10.1111/ajt.16207. Epub 2020 Aug 29. PMID: 32659872.
481. **Patel J**, Kittleson M, Chang D, Kransdorf E, Geft D, Shen A, Nishihara K, Jamero G, Czer L, Esmailian F, Kobashigawa J. Effects of Donor Heavy Alcohol Use on Post-Heart Transplant Outcomes: Time to Abstain? *Am J Transplant*. 2020; 20 (suppl 3).
482. Setia G, Nishihara K, Singer-Englar T, Zhang X, **Patel J**, Kobashigawa J. Crossing low/moderate-level donor-specific antibodies during heart transplantation. *Clin Transplant*. 2021 Mar;35(3):e14196. doi: 10.1111/ctr.14196. Epub 2020 Dec 30. PMID: 33338283.
483. Coutance G, Raynaud M, **Patel JK**, Kobashigawa JA, Loupy A. Response by Coutance et al to Letter Regarding Article, "Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study". *Circulation*. 2020 Dec 8;142(23):e409-e410. doi: 10.1161/CIRCULATIONAHA.120.050849. Epub 2020 Dec 7. PMID: 33284650.
484. Zhang X, Levine R, **Patel JK**, Kittleson M, Czer L, Kobashigawa JA. Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients. *Hum Immunol*. 2020 Dec;81(12):671-674. doi: 10.1016/j.humimm.2020.09.003. Epub 2020 Oct 9. PMID: 33041085.
485. Stern LK, Velleca A, Nishihara K, Shen A, Zaliznyak M, **Patel J**, Hamilton MA, Ramzy D, Esmailian F, Kobashigawa JA, Kittleson MM. Impact of the United Network for organ sharing 2018 donor heart allocation system on transplant morbidity and mortality. *Clin Transplant*. 2021 Feb;35(2):e14181. doi: 10.1111/ctr.14181. Epub 2021 Jan 15. PMID: 33277716.
486. Chen Q, Moriguchi J, Levine R, Chan J, Dimbil S, **Patel J**, Kittleson M, Megna D, Emerson D, Ramzy D, Trento A, Chikwe J, Kobashigawa J, Esmailian F. Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience. *Transplant Proc*. 2021 Jan-Feb;53(1):329-334. doi: 10.1016/j.transproceed.2020.08.020. Epub 2020 Sep 8. PMID: 32917391.
487. Kobashigawa J, Dadhania DM, Farr M, Tang WHW, Bhimaraj A, Czer L, Hall S, Haririan A, Formica RN, **Patel J**, Skorka R, Fedson S, Srinivas T, Testani J, Yabu JM, Cheng XS; Consensus Conference Participants. Consensus conference on heart-kidney transplantation. *Am J Transplant*. 2021 Feb 2. doi: 10.1111/ajt.16512. Online ahead of print. MID: 33527725
488. Kobashigawa J, Dadhania DM, Farr M, Tang WHW, Bhimaraj A, Czer L, Hall S, Haririan A, Formica RN, **Patel J**, Skorka R, Fedson S, Srinivas T, Testani J, Yabu JM, Cheng XS; Consensus Conference Participants. Consensus conference on heart-kidney transplantation. *Am J Transplant*. 2021 Feb 2. doi: 10.1111/ajt.16512. Epub ahead of print. PMID: 33527725.
489. Ram E, Lavee J, Kassif Y, Peysakhovich Y, Sternik L, Segev A, **Patel J**, Peled Y. Primary heart dysfunction is greater with combined heart and lung compared with isolated heart procurement. *J Thorac Cardiovasc Surg*. 2021 Feb 2:S0022-5223(21)00189-6. doi: 10.1016/j.jtcvs.2021.01.090. Epub ahead of print. PMID: 33691941.
490. Zadikany RH, Cole RM, Chang DH, Patel JK, Geft DR, Czer L, Esmailian F, Ramzy D, Moriguchi JD, Kobashigawa JA, Kittleson MM. Total Artificial Heart as Bridge to Cardiac Retransplantation. *ASAIO J*. 2021 Mar 1;67(3):e77-e79. doi: 10.1097/MAT.0000000000001217. PMID: 33627614
491. Vaidya GN, **Patel JK**, Kittleson M, Chang DH, Kransdorf E, Geft D, Czer L, Vescio R, Esmailian F, Kobashigawa JA. Intermediate-term Outcomes of Heart Transplantation for

Cardiac Amyloidosis in the Current Era. *Clin Transplant*. 2021 Apr 7:e14308. doi: 10.1111/ctr.14308. Epub ahead of print. PMID: 33825224.

492. Zadikany RH, Cole RM, Chang DH, **Patel JK**, Geft DR, Czer L, Esmailian F, Ramzy D, Moriguchi JD, Kobashigawa JA, Kittleson MM. Total Artificial Heart as Bridge to Cardiac Retransplantation. *ASAIO J*. 2021 Mar 1;67(3):e77-e79. doi: 10.1097/MAT.0000000000001217. PMID: 33627614; PMCID: PMC7326319.
493. Aguilar J, Miller RJH (Co-first authors), Otaki Y, Tamarappoo B, Hayes S, Friedman J, Slomka PJ, Thomson L, Kittleson M, **Patel J**, Kobashigawa JA, Berman DS. Clinical Utility Of SPECT In The Heart Transplant Population: Analysis From A Single Large-Volume Center. *Transplantation*, 2021. In press.